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ABSTRACT OF DISSERTATION
DEVELOPMENT OF A NEW ALLELIC DISCRIMINATION REAL-TIME PCR
ASSAY FOR THE DIAGNOSIS OF EQUINE HERPESVIRUS-1 AND
CHARACTERIZATION OF THE VIRULENCE DETERMINANTS OF THE VIRUS
Equine herpesvirus-1 (EHV-1) can cause acute upper respiratory tract disease,
abortion, neonatal death and neurological disease in horses. Rapid, accurate and timely
diagnosis of EHV-1 infection in horses is important to curtail the spread of this pathogen.
It has been reported that the neuropathogenic phenotype of EHV-1 can result from a
single non-synonymous nucleotide substitution at position 2254 (A→G2254) in open
reading frame 30 (ORF30). This was the basis for the development of an allelic
discrimination, real-time PCR assay to distinguish between potential neuropathogenic
and non-neuropathogenic EHV-1 strains. However, PCR analysis of a panel of EHV-1
abortion isolates revealed that other point mutations within ORF30 could produce false
negative results with this previously described assay. Objective one of this dissertation
project was to develop a more sensitive and specific allelic discrimination real-time PCR
assay for the detection of EHV-1. This was achieved by redesigning the primers and
probes targeting ORF30. The new assay was ten times more sensitive than the original
assay, with a lower detection limit of 10 infectious virus particles. Of equal importance to
proper diagnosis is the prevention of EHV-1 infection. None of the commercially
available EHV-1 vaccines provides protection against EHV-1 neurologic disease.
Objective two, therefore, was the in vivo characterization of a cell-passaged EHV-1
neuropathogenic strain, T953, to determine if this virus’s phenotype was attenuated and
could possibly serve as the basis for a vaccine. Two separate groups of 28 BALB/c mice
were inoculated with either the parental strain or passage 135 (T953 P135) of EHV-1
strain T953. The animals were observed for fourteen days, euthanized and their tissues
analyzed for the presence of EHV-1. At the conclusion of the fourteen day observation
period, all of the mice infected with T953 P135 survived and had regained their pre-
inoculation body condition. Also, there were significant differences in virus titer and viral
DNA concentrations between T953 P135 and the parental strain, further confirming the
attenuated phenotype of the virus. Data from this study clearly demonstrate that
sequential cell culture passage of the neuropathogenic T953 strain of EHV-1 results in
attenuation and reduced pathogenicity in young adult BALB/c mice.
KEYWORDS: Equine Herpesvirus Type-1, Neuropathogenic EHV-1, Non-
Neuropathogenic EHV-1, ORF30 Real-Time PCR, Allelic Discrimination Real-Time
PCR, Murine Model
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CHAPTER ONE
Literature Review
1.1 Herpesviridae
1.1.1 Basic Features
Herpesviridae is an extensive family of viruses which infect an array of
vertebrates, including humans and equines, as well as one known invertebrate host, the
oyster.1 Specific pathogens of this family include herpes simplex virus 1, bovine
herpesvirus 2, ostreid herpesvirus 1, varicella-zoster virus and pseudorabies virus.1,2 The
array of diseases linked to Herpesviridae is just as diverse, ranging from Burkitt’s
lymphoma to equine herpesvirus myeloencephalopathy.1,3,4 The basic virion structure of
this family consists of four major elements: 1) core, 2) capsid, 3) tegument, and 4)
envelope (Figure 1.1).1,2 The core consists of a linear, double-stranded DNA genome,
often arranged into two major segments (the unique long and short regions), which
typically contain three origins of replication and are flanked by inverted repeat sequences
(Fig 1.2).1,2 The core is encased within an icosahedral capsid, measuring 100-125 nm in
diameter and composed of capsomers, the number of which varies depending upon the
virus.1,2 Surrounding the capsid is an unstructured layer of proteins called the tegument,
whose functions include virion assembly and termination of host protein synthesis.1,2 The
lipid bilayer envelope encloses the entirety of the virion and its exterior surface is
embedded with a variety of glycoproteins with various functions such as cell-to-cell
spread and complement mediated neutralization.5
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Figure 1.1 Basic virion structure of herpesviruses. This figure depicts the four central
elements of a herpes virion: the lipid envelope embedded with glycoproteins, tegument,
protein capsid, and the core. Within the core is the double-stranded DNA genome of the
virus.
1.1.2 Subfamilies
Members of Herpesviridae are divided into three subfamilies based on their
biological properties: alphaherpesvirinae, betaherpesvirinae, and gammaherpesvirinae.1,2
The characteristics of members of alphaherpesvirinae include their variable host range,
short replication cycle, rapid spread in cell culture, and the ability to establish latent
infections in the sensory ganglia of the central nervous system of their host species.1
Overt vesicular epithelial lesions in the natural host often occur with many members of
this subfamily.2 There are four genera within this subfamily: Simplexvirus,
Varicellovirus, Mardivirus, and Iltovirus.6 Simplexviruses often cross-react serologically
with other members of this genus, and most can establish latent infections in neurons.2
Members include bovine herpesvirus 2 and herpes simplex virus 1. Members of
Varicellovirus are known for latent infections within the sensory nervous system and a
3
Figure 1.2 Herpesvirus genome. The basic composition of the linear genome of Herpes
Simplex Virus 1 consists of a unique long region (UL) and a unique short region (US).
Each region has a terminal repeat (TR) and an internal repeat (IR). The variations in
sequence of the repeats are as follows: TRL is ab, IRL is bc, IRS is ad and TRS is dc.
The locations of the three origins of replication (oriL and oriS) are also depicted. The
genomes of most herpesviruses have a similar organization.
wide range of mammalian hosts.2 Specific members include cervid herpesvirus 1, equine
herpesvirus types 1, 3, 4, 6, 8 and 9.2 Members of Mardivirus affect only birds and
include Marek’s disease virus types 1 and 2.2 Iltovirus has two members, Gallid
herpesvirus 1, which is sometimes referred to as infectious laryngotracheitis virus, and
Psittacid herpesvirus 1 (Pacheco’s disease virus).6,7
Betaherpesvirues have long reproductive cycles, restricted host range, and slow
growth in cell culture.1 Infection by these viruses is often clinically non-apparent in
immune-competent hosts, and latent infections have sometimes been associated with cells
of the monocyte series.2 Three genera compose this subfamily: Cytomegalovirus,
Muromegalovirus, and Roseolovirus.2 Cytomegaloviruses are known for their large
genomes (>200kbp) and enlargement of their host cells.2 African green monkey
cytomegalovirus and human cytomegalovirus are classified in this genus.2
Muromegalovirus currently has two members, mouse and rat cytomegaloviruses, and is
also characterized by large genomes (>200kbp) and enlargement of infected cells.2 The
remaining betaherpesvirus genus, Roseolovirus, also has only two members: human
herpesvirus types 6 and 7.2 These viruses have genomes under 200kbp and are known for
infecting T lymphocytes.2
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The third subfamily, gammaherpesvirinae, has a variable replication cycle,
preference of lymphoid tissue as the site of latent infection, and a specificity for
lymphoblastoid cells during replication.1 Four genera compose this subfamily,
Lymphocryptovirus, Rhadinovirus, Macavirus and Percavirus.6 Members of
Lymphocryptovirus infect only primates and include the Epstein-Barr virus and Gorilla
herpesvirus.2 The host range for Rhadinovirus is more varied, but is still limited to
mammals.2 Latent infections for this genus have been reported in both B and T
lymphocytes.2 Specific pathogens include bovine herpesvirus 4, macacine herpesvirus 5
and human herpesvirus 8.6 Macavirus is primarily composed of genetically similar
pathogens whose primary hosts are either ruminants or pigs.6 Members include
alcelaphine herpesvirus 1, caprine herpesvirus 2 and suid herpesvirus 3.6 Currently, there
are three percaviruses: mustelid herpesvirus 1, equine herpesvirus types 2 and 5.6 Their
classification in this genus is based on their genetic similarities and the lack of paralysis
associated with host infection.6,8 Additional pathogens are under consideration for
inclusion in this genus, mainly, herpesviruses of bats and marine mammals.8,9
1.2 Equine Herpes Viruses
1.2.1 Alphaherpesvirinae
The equine herpesviruses, as mentioned previously, reside within two of the
three major subfamilies of Herpesviridae, alphaherpesvirinae and gammaherpesvirinae
(Table 1.1).10 The alphaherpesviruses consist of equine herpesvirus-1 (EHV-1), EHV-3,
EHV-4, EHV-6, EHV-8 and EHV-9.10 EHV-4 is very similar to EHV-1 and was
considered a subtype of EHV-1 until the 1980s.11,12 The viruses are genetically similar,
sharing 55% to 84% nucelotide homology, depending on the gene.13,14 A high level of
amino acid homology also exists between the two viruses, ranging from 55% to
96%.13,14 EHV-1 and -4 are also known to co-infect the same horse.12 However, EHV-4
primarily causes upper and lower respiratory tract infection, and sporadic, single cases
of abortion.12,15,16 Some occurrences of neurologic disease have also been associated
with EHV-4, but this virus is still not considered a common cause of EHV neurologic
disease.17,18 EHV-3 is the agent responsible for equine coital exanthema, or genital
horse pox, and is transmitted through coitus.19 The virus is highly contagious and can
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reactivate from latency, inducing re-excretion in bodily fluids at 11 month intervals.20
EHV-4 and -3 primarily infect horses, but EHV-8 can infect both donkeys and
horses.21,22 Despite limited information on EHV-8, the virus does cause nonfebrile
rhinitis, nasal discharge and fever.21-23 The genome of a particular strain (isolated in
China) of this pathogen was recently sequenced, demonstrating 80-99% homology
between its nucleotide sequence and EHV-1’s, along with 84-99% homology with
EHV-9.21
In 2000, Taniguchi and Fukushi et al. classified EHV-9 as an equine
herpesvirus.24 EHV-9’s most unique attribute is its host range. Successful experimental
infection has been achieved with goats, hamsters, horses, mice, pigs and marmosets.24-27
Cases of natural infection have been reported in multiple species including Przewalski’s
wild horses, zebras, alpacas, llamas, fallow deer, cattle, gazelles, and a single
documented case of an infected polar bear.26,28-30 Borchers et al have suggested
Burchell’s zebra as the natural reservoir for the virus, but this hypothesis is still under
investigation.28 EHV-9 has certain similarities to EHV-1. The two viruses share 86-95%
nucleotide homology, and EHV-9 is also neuropathogenic in some species.26,30,31 The
virus induces intranuclear inclusions in neurons, but not vasculitis, which is one of the
main pathological lesions of EHV-1 neurologic disease.23,24,26,30
EHV-6, often referred to as asinine herpesvirus 1, is also an alphaherpesvirus
and is tentatively considered a member of Varicellovirus.6,23 The virus can infect horses
and donkeys.6,22,23 EHV-6 is most closely related to EHV-3, and causes skin lesions,
which are similar in appearance to those associated with EHV-3 infection.6,22,23
1.2.2 Gammaherpesvirinae
There are two viruses definitively categorized as gammaherpesviruses – EHV-2
and EHV-5.6,32 They share 60% of their amino acid sequence and frequently co-infect the
same host.32,33 Both were also once referred to as “equine cytomegaloviruses”.1,34 EHV-2
has been associated with respiratory illness, chronic follicular pharyngitis,
keratoconjunctivitis, and poor performance syndrome.35,36 Young horses are particularly
susceptible to EHV-2.35 The pathogen can also cause immune-suppression in the
horse.35,37 EHV-5 is commonly detected in the upper airways and peripheral blood of
6
horses.38-40 Until recently, EHV-5 was considered nonpathogenic; however, current
studies have incriminated it as the causative agent of equine multinodular pulmonary
fibrosis.41,42 Davison et al have tentatively designated EHV-7, often called asinine/mule
herpesvirus 2, as also being a gammaherpesvirus.6,43 The virus is closely related to EHV-
2, EHV-5 and is typically asymptomatic in its natural hosts, mules and donkeys.22,43 In
2008, EHV-7 and -2 were isolated from a donkey with neurological signs.44 A third virus,
zebra herpesvirus 1, was also isolated from the same animal.44 It is unclear which of the
three viruses, or if the combination of these viruses caused the clinical signs.44
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1.3 Equine Herpes Virus Type 1 (EHV-1)
1.3.1 Genome Organization
EHV-1, like other herpes viruses, is a complex infectious agent with a highly
structured genome. The 150.2kbp double-stranded DNA genome possess a unique long
region (UL) of 112,870 base pairs in length, which is composed of sixty-three open
reading frames (ORF) (ORFs 1-63).13,45 Short inverted repeat sequences, both terminal
(TRL) and internal (IRL)repeats, flank the unique long region, and are 32bp in length
(Fig. 1.3).13 The unique short region (US) measures 11,861 base pairs and is composed
of nine ORFs (ORFs 68-76).12,13,45 The US is also flanked by inverted repeats,
measuring 12.7kbp in length.13 The G+C composition is 56.7% and the entire genome
consists of eighty ORFs, seventy-six of which are unique.5,13 Figure 1.4 provides a map
of EHV-1’s genome. Tables 1.2 -1.5 list the gene products for each ORF. Four ORFs
are duplicates, 64-67, and compose both the terminal (TRS) and internal (IRS) repeats of
the unique short region.13 While the roles of these four ORFs are still not clearly
defined, ORF64 is involved with gene expression.12,13 However, Ahn et al. 2011
demonstrated deletion of ORFs 65-67 results in the reduction of virulence in an animal
host and delayed growth in cell culture.12,13,46 Of the 76 unique ORFs, eleven encode for
polypeptides of the capsid and core (ORFs 4, 22, 25, 35, 35.5, 37, 42, 43, 56, 58, 60)
and thirteen for the proteins which compose the tegument (ORFs 8, 1, 12, 13, 14, 19,
23, 24, 40, 46, 48, 51, 55).12,13,47 The ORF37 gene product, UL24, was recently
identified as a putative neuropathogenic factor of EHV-1 in mice.48 The gene products
of eighteen additional ORFs (ORFs 7, 9, 18, 20, 21, 27, 28, 30, 31, 32, 36, 44, 45, 50,
53, 54, 57, 61) contribute to the synthesis and packaging of DNA, such as the DNA
polymerase, origin binding protein, and various DNA packaging proteins.12,13,47 Twelve
ORFs (ORFs 6, 10, 16, 33, 39, 52, 62, 70-74) encode for the various glycoproteins,
whose functions include cell entry, cell-to-cell spread, complement neutralization, and
chemokine binding.47,49-51 The remaining seventeen ORFs with known gene products
are as follows: three regulatory proteins (ORFs 5, 26, 29), three enzymes (ORFs 49, 63,
69), eight membrane/envelope proteins (ORFs 1, 2, 15, 17, 41, 75, 76) and three
proteins of unknown function (ORFs 34, 59, 68).47 Two ORFs, 3 and 47, are as yet
undefined in terms of their gene products.12,13,47
9
Figure 1.3 EHV-1 genome organization. The basic composition of the linear
genome of EHV-1 consists of a unique long region (UL), which is 112.8kbp and a
unique short region (US), which is 11.8kbp. The UL is flanked by a terminal repeat
(TRL) and an internal repeat (IRL), both of which are 32bp long. One origin of
replication (oriL) is located in UL, between ORF39 and 40. US is also flanked
between two repeat sequences (TRS, IRS), which are 12.7kbp in length and are
composed of four ORFs (64-67). Two origins of replication (oriS) are associated
with US, one in IRS and one in TRS. Both origins are located between ORF 64
and 65.
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Figure 1.4 EHV-1 genome arrangement.13 Depicted is the spatial arrangement of EHV-
1’s 80 ORFs. The scale is in kbp, 0-150. Each of the ORFs are colored according to their
gene products.  The duplicate ORFs, 64-67, occur between 115-125kbp and 140-150kbp
regions of the genome. The only area of overlap occurring within the genome is between
ORF35.5 and 35. Since the original publication of this figure, ORF44’s gene product has
been defined as a DNA packaging terminase subunit.12,47 ORF47’s function is still
undefined.12,47 ORF37 gene has been identified as a neurovirulence determinant of EHV-
1 in mice.48 This figure is reprinted with the permission from Telford et al. The DNA
sequence of equine herpesvirus-1, Virol 1992;189:304-316.
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Table 1.2 EHV-1 ORFs 1- 21 and their gene products.
ORF Start Stop Gene Product
1 1298 1906 Membrane protein UL56
2 2562 1945 Membrane protein V1
3 2841 3614 ?
4 4249 3647 Nuclear protein UL55
5 5874 4462 Multifunctional expression regulator
6 7042 6011 Glycoprotein K (gK)
7 10301 7056 DNA helicase-primase
8 10300 11037 Tegument protein UL51
9 12115 11135 Deoxyuridine triphosphatase
10 12084 12386 Glycoprotein N (gN)
11 12549 13463 Tegument protein VP22
12 13595 14944 Transactivating tegument protein VP16
13 15317 17932 Tegument protein VP13/14
14 18083 20326 Tegument protein VP11/12
15 21170 20487 Membrane protein UL45
16 22851 21445 Glycoprotein C (gC)
17 24234 23029 Envelope protein UL43
18 25696 24479 DNA polymerase processivity subunit
19 26262 27755 Tegument host shut-off protein
20 28859 27894 Ribonucleotide reductase subunit 2
21 31276 28904 Ribonucleotide reductase subunit 1
12
Table 1.3 EHV-1 ORFs 22-45 and their gene products.
ORF Start Stop Gene Product
22 32916 31519 Capsid triplex subunit 1
23 33292 36354 Tegument protein UL37
24 36588 46853 Tegument protein
25 47311 46952 Capsid protein
26 48230 47403 Nuclear egress membrane protein
27 48791 48369 DNA packaging protein UL33
28 48763 50625 DNA packaging protein UL32
29 50618 51598 Nuclear egress lamina protein
30 55184 51522 DNA polymerase catalytic subunit
31 55453 59082 Single stranded DNA-binding protein
32 59243 61570 DNA packaging terminase subunit 2
33 61432 64374 Glycoprotein B (gB)
34 64578 65060 ProteinV32
35 67093 65153 Capsid maturation protease
35.5 66142 65153 Capsid scaffold protein
36 68975 67212 DNA packaging protein UL25
37* 69897 69079 Nuclear protein UL24
38 69910 70968 Thymidine kinase
39 71192 73738 Glycoprotein H (gH)
40 76224 74632 Tegument protein UL21
41 76793 77512 Envelope proteinUL20
42 77703 81832 Major capsid protein
43 82083 83027 Capsid triplex subunit 2
44 84320 83148 DNA packaging terminase subunit 1
45 84480 86600 DNA packaging tegument protein UL17
*Neuropathogenicity factor in mice
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Table 1.4 EHV-1 ORFs 46-62 and their gene products.
ORF Start Stop Gene Product
46 86620 87732 Tegument protein UL16
47 88917 87886 ?
48 88947 89900 Tegument protein UL14
49 89369 91153 Tegument serine/threonine protein kinase
50 91135 92832 Deoxyribonuclease
51 92784 93008 Myristylated tegument protein
52 94472 93120 Glycoprotein M (gM)
53 94390 97053 DNA replication origin-binding protein
54 97069 99324 DNA helicase-primase subunit
55 100332 99421 Tegument protein UL7
56 102391 100130 Capsid portal protein
57 102375 105020 DNA helicase-primase subunit
58 105070 105747 Nuclear protein UL4
59 106416 105877 Protein V57
60 107116 106478 Nuclear protein UL3
61 108144 107206 Uracil-DNA glycosylase
62 108843 108147 Glycoprotein L (gL)
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Table 1.5 EHV-1 ORFs 63-76 and their gene products.
ORF Start Stop Gene Product
63 111985 110387 Ubiquitin E3 ligase ICP0
64†
118591
144569
114128
149032
Transcriptional regulator ICP4
(Immediate-early gene)
65†
121368
141792
122249
140911
Regulatory protein ICP22
66†
122862
140298
123572
139588
Virion protein US10
67†
125194
137966
124376
138784
Virion protein V67
68 126275 125019 Virion protein US2
69 126411 127559 Serine/threonine protein kinase US3
70 127681 128916 Glycoprotein G (gG)
71 129097 131490 Glycoprotein J (gJ)
72 131583 132791 Glycoprotein D (gD)
73 132899 134173 Glycoprotein I (gI)
74 134406 136058 Glycoprotein E (gE)
75 136055 136447 Membrane protein US8A
76 136783 137442 Membrane protein US9
Data listed in this table is based on the most recent information available from the
National Center for Biotechnology Information (GenBank # NC_001491.2), along
with the sequence data published in Allen et al. 2004 and Telford et al.
1992.12,13,47
†Duplicate ORFs, which compose the terminal and internal repeats of US.
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1.3.2 Virus Life Cycle
The life cycle of EHV-1, as with most herpes viruses, has two main stages:
lytic and latency.5 During the lytic stage, virus replication and nasal shedding occur,
leading to the infection of new hosts.3 Virus shedding can occur for as long as fifteen
days in naïve horses with a magnitude of 106pfu/nasal swab, or as short as two days
with a magnitude of 102pfu/nasal swab in previously exposed horses.52,53 Transmission
of EHV-1 can occur through contact with virus-shedding horses, contact with an EHV-1
positive aborted fetus, placenta infected with the virus, inhalation of virally laden
secretions, aerosols or fomites.3,53,54
After the introduction of the virus into the horse’s respiratory system, the virus
then infects the epithelial cells of the upper respiratory tract, causing the formation of
multiple erosions in the nasopharyngeal mucosa.55,56 After breaching the epithelium,
EHV-1 spreads to the lamina propria of the nasopharynx, infecting the regional lymph
nodes within twenty-four hours.12 Within the lymph nodes, EHV-1 continues to
replicate, resulting in the discharge of infected leukocytes into the bloodstream, and
establishing viremia.55 CD5+/CD8+ T-lymphocytes are the main cell types of EHV-1
viremia, although EHV-1 replication has also been detected in dendritic cells.57-59 The
viremia allows the migration of EHV-1 to additional infection sites, which typically
leads to one of the following clinical outcomes: abortion, neonatal death due to
pneumonia, lower respiratory tract disease, or equine herpesvirus myeloencephalopathy
(Figure 1.5).60
16
Figure 1.5 Lytic EHV-1 cycle. The lytic phase of EHV-1’s life cycle begins with
transmission of the infectious particle to a new host. The virus replicates with the
upper respiratory tract’s epithelium, spreads to the regional lymph nodes,
establishes viremia by infecting the T-lymphocytes. EHV-1 then migrates to
additional areas of the host, resulting in one of the following conditions: 1)
infection of the endothelial and epithelial cells of the lungs, 2) infection of the
pregnant uterus causing abortion, 3) infection of the foal in utero resulting in the
foal’s death shortly after birth, or 4) infection of endothelial cells that line the
interior surface of blood vessels found within the central nervous system (CNS)
causing myeloencephalopathy. Nasal shedding occurs during the infection of the
upper respiratory tract and can result in the transmission of the virus to additional
hosts.
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Following initial replication in the respiratory tract, EHV-1 can enter a latent
stage rather than continuing to actively infect its host. Latency can occur in the sensory
nerve-cell bodies of the trigeminal ganglia and the lymphocytes, both circulating and
those draining in the lymph nodes (Figure 1.6).61-63 The primary leukocytes latently
infected by EHV-1 are CD5+/CD8+ T-lymphocytes (>80% in venous blood), along with
a small fraction of CD5+/CD8-/CD4- cells (~20% in venous blood).64 Latently infected
lymphocytes contain latency-associated transcripts (ORFs 63 & 64) within the cell.
After the peak of lymphocyte-associated viremia (~10 days post-infection), EHV-1
down regulates from active to restricted transcription, eventually promoting the
dominance of the latent cells over the viremic cells within the lymphocyte
population.62,65 Viremic cells have a transcriptionally active viral genome, the
expression of viral glycoproteins on the cell’s surface and are subject to immune
clearance.66 With latent cells, transcription of the viral genome is restricted, viral
proteins are not expressed, and the cells are resistant to immune clearance.66 Several
questions still remain concerning the precise mechanisms through which EHV-1 enters
latency, including whether there is an actual reduction in the number of viremic cells, or
if they convert to latent cells.65
The reactivation of EHV-1 marks the transition from the latent to lytic stage of
the virus’s life cycle. Reactivation can occur in the field following transport, re-housing,
weaning, infection by EHV-2, or the administration of corticosteroids.62,67,68 Though the
exact molecular events of reactivation still require investigation, the activation of the
immediate-early gene (ORF64) and resuming a lytic pattern of transcription of the viral
genome are key features.68 The appearance of viral glycoproteins on the outer surface of
lymphocytes also occurs with reactivation.62,67 Re-emergence of EHV-1 can occur
within the lymphocytes or in the trigeminal ganglia.61,64,66 Once reactivated, the virus
can migrate to the respiratory epithelium, which often initiates viral shedding within the
nasal mucosa.62,67 However, the host may not show signs of respiratory disease, i.e.
pyrexia and nasal discharge.67 Reactivated EHV-1 can also reestablish cell-associated
viremia, resulting in: infection of the pregnant uterus causing abortion, or infiltration of
the endothelial cells lining the interior surface of blood vessels associated with the
central nervous system causing myeloencephalopathy (Figure 1.6).65 Abortion caused
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by reactivated EHV-1 is not always linked with viremia. In some cases, lymphocytes in
the near vicinity of the pregnant endometrium can transfer infectious virions to the
uterine endothelium, initiating the sequence of events which culminates in
abortion.65,69,70
The occurrence of both the lytic and latent stages serves as the basis for the
two physically, biologically distinct gene pools of the pathogen and is an important
survival mechanism of the virus.12 The first, the latent virus reservoir, is composed
solely of latently infected horses, which lack clinical signs and harbor latently infected
cells resistant to immune clearance. Since EHV-1 cannot be cleared from the horse’s
system and the absence of clinical signs prevents biosecurity measures from being
implemented, the latent reservoir becomes a permanent fixture within the equine
population.12,66 However, the latent virus is only maintained for the duration of the
lifetime of an individual host and, thus the virus must ensure its survival by recruiting
new horses into the pathogen’s infection base.12 The active virus reservoir’s purpose is
the recruitment of new hosts. Unlike the latent reservoir, the active virus gene pool is
more transitory, lasting only until the infection has been cleared by the host’s
system.12,60 This second reservoir must also be periodically replenished, which the
latent reservoir accomplishes. Reactivated virus particles from the latent reservoir are
transmitted from the latent carrier to a new host via nasal shedding.52,67 As mentioned
previously, an important feature of reactivation is that the latent carrier does not always
exhibit clinical signs of respiratory infection, which makes further spread of the
pathogen to other equids readily accomplishable.67 These two reservoirs are interlinked,
each relying on the other for permanence and long-term survival of the virus within the
equine species.
19
Figure 1.6 Clinical outcomes of reactivated EHV-1. Reactivation of the virus
from the T-lymphocytes or trigeminal ganglion neurons causes the re-infection of
the nasal mucosa, leading to viral shedding and ultimately recruiting new hosts
into the virus’s life cycle. Cell-associated viremia can also be re-established,
resulting in either abortion due to infection of the pregnant uterus or
myeloencephalopathy resulting from EHV-1 infection of the vascular endothelial
cells associated with the CNS. Respiratory disease is not commonly linked with
reactivated EHV-1.
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1.4 Outcomes of EHV-1 Infections
1.4.1 EHV-1 Respiratory Disease (Rhinopneumonitis)
The clinical syndromes induced by EHV-1 include respiratory illness, abortion,
neonatal death and neurologic disease. EHV-1 respiratory illness was originally part of a
conglomeration of equine respiratory illnesses known as “equine influenza”, but was
eventually classified as a distinctive respiratory disease called rhinopneumonitis by the
1960s.3,71 Following initial infection of the upper respiratory tract, the pathogen infiltrates
the endothelial and epithelial cells of the lungs.12 Lesions within the respiratory tract vary
based on the age and previous exposure of the host. Older animals tend to have milder
lesions, with multifocal erosions of the nasopharyngeal and nasal mucosa.55,56
Bronchiolitis may also be present, but sparingly, along with interstitial edema and
perivascular cuffing in the lungs.55,56 The lymph nodes associated with the respiratory
tract tend to have mild or nondescript lesions.12 In younger, immunologically naïve
horses, the lesions are more severe and extensive.12,72 Necrosis typically happens in the
mucosa of both the upper and lower respiratory tract, along with the associated lymphoid
follicles.12,72 Multifocal rhinitis lesions are present, varying from necrotizing to
exudative, along with terminal bronchiolitis or alveolitis.12,72
The clinical presentation of EHV-1 respiratory disease occurs within two to
ten days and, again, depends mainly on the age and immunity of the host.12,15 However,
the most common signs are pyrexia, nasal discharge (mucoid progressing to
mucopurulent), anorexia, depression and enlarged lymph nodes (typically
submandibular lymph nodes, but also retropharyngeal nodes).3,12 Coughing often
afflicts the hosts, but the severity and duration are more often determined by external
factors (stable air quality, insufficient rest from training, etc).3,12 EHV-1 lower
respiratory tract disease is typically non-fatal, although complications can arise from
secondary bacterial infections.3,12 In most instances, the horse recovers, but maybe
afflicted with “poor performance syndrome”, which is usually characterized by non-
specific bronchial hypersensitivity and is analogous to chronic obstructive pulmonary
disease.3,12
Therapy for respiratory illness typically involves the use of broad-spectrum
antibiotics to reduce and/or prevent secondary bacterial infections, along with the use of
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fever reducing agents.3,15 According to Ostlund’s survey, proper nursing care, with a
strong emphasis on rest and stress reduction, is critical to recovery from viral
respiratory disease.15 Maxwell et al (2008) and Wong et al (2010) both investigated the
use of antivirals to treat EHV-1 rhinopneumonitis, with a particular emphasis on the use
of acyclovir and valacyclovir.73,74 Meanwhile, Fulton et al (2009) and Brosnahan et al
(2010) centered their research on the use of small-interfering RNAs (siRNAs) as
possible treatments for respiratory infection.105,106 Another possible treatment under
consideration is immunostimulant therapy.  Pearson et al (2007)’s study argues
immunostimulants are best used as a supportive measure for vaccine programs.75-77
1.4.2 EHV-1 Abortion
In 1932, Dimock and Edwards first identified contagious equine abortions were
not all caused by bacterial agents.108 The following year, their research further indicated
that a filterable viral agent was causing equine abortions in Kentucky, and they coined
the term “viral abortion” to refer to the syndrome.109 The following 15 years of research
revealed that EHV-1 was not only the causative agent of this condition, but was
responsible for numerous extensive abortion outbreaks (“abortion storms”) within
Kentucky.3,78,79 The pathogenesis of EHV-1 abortion is similar to EHV-1 respiratory
disease, with a few variations. After inhalation of the infectious virus, the mare develops
a lymphocyte-associated viremia within four to ten days.12 The virus then infects the
endothelial cells of the endometrium, in particular the arterioles, inducing multifocal
vasculitis, and thrombosis, typically resulting in the necrosis of the affected tissues.80-83
The pervasiveness of these lesions is dependent upon the level of viremia, the level of
immunity of the host, and the strain of the virus. In 1994, Mumford et al inoculated
horses with highly virulent strains of EHV-1, such as Ab4, and demonstrated Ab4
induced higher rates of abortion than less virulent strains such as V592.84
While high-titer viremia and virus strain are critical to the occurrence of EHV-
1 induced abortion, host factors also play an important role. Abortion typically occurs
within the last four months of gestation and it is suspected that the release of
prostaglandin may also play a role in this process.12 The presence of virus-neutralizing
antibody, resulting from prior exposure to the virus, appears to decrease the likelihood
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of EHV-1 abortion, even when the animal is infected with a virulent strain, such as
Army 183.84,85 Smith et al’s 2003 study considered cases of abortion, stillbirth and
neonatal death from 1988-97.  This study demonstrated that vaccination and reduction
of stress decreased the occurrence of EHV-1 abortion.86 However, Smith et al also
noted vaccination does not protect against reactivation of latent EHV-1.86
The primary clinical sign of EHV-1 abortion is the explosive, sudden expulsion
of the fetus, often still enveloped within the fetal membranes.12,80 Such “events” are
normally isolated within a herd of broodmares; however, multiple cases of abortion, or
“storms”, affecting whole herds can also occur.15 The pregnant mare does not typically
exhibit signs of respiratory illness prior to abortion.12,80 The aborted fetus is normally
EHV-1 positive, but in situations where severe vascular lesions are widespread within the
endometrium, the fetus may be aborted before transplacental spread of the virus occurs,
resulting in an EHV-1 negative fetus, but a virus positive placenta.12 Examination of the
EHV-1 positive, aborted fetal tissues reveals necrosis in the lungs, liver, spleen, adrenal
glands, along with pneumonitis, and lymphoid depletion of lympho-reticular tissues
throughout the body.12,86,87
Because of the lack of clinical signs prior to abortion, treatment is not possible.
A mare that has experienced an abortion characteristically does not require any treatment
following the event, unless she has suffered damage to her reproductive tract.15 The
reproductive potential of such a mare is usually unaltered and she can conceive again,
following at least a one month period of abstention from breeding to ensure containment
of the virus.12,15 Although EHV-1 abortion does not typically occur successively in the
same mare, future re-infection and abortion may still occur.12,88
1.4.3 EHV-1 Neonatal Viral Pneumonitis
Infection of a pregnant mare does not always result in abortion. In cases where
the endometrial thrombosis is minimal or EHV-1 is completely cleared from the uterus,
the foal can be carried to term and be born without EHV-1 infection.89 In other instances
where the mare becomes infected near the end of gestation, the result is the parturition of
an EHV-1 positive foal.3,90-92 Such foals have congested, consolidated lungs, with
extensive evidence of an acute, necrotizing bronchiolitis, interstitial pneumonia, and
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collapsed alveoli.3,92 Pulmonary and hepatic lesions are also present, along with necrotic
hepatocytes in the liver.92
Clinical signs in neonatal EHV-1 foals typically include failure to nurse,
lethargy, hypoxia, pyrexia, extreme respiratory distress, and intractable diarrhea.90-92
Such foals often die within several days of birth due to extreme cellular damage in
multiple organ systems.3,91,92 Fatalities resulting from secondary bacterial infections, such
as pneumonia, are also common.3,15 In 1993, Ostlund argued that antiviral treatment for
EHV-1 neonatal infection is of questionable value.15 Instead, this survey and Allen et al’s
2004 survey both recommended supportive veterinary care, but with caveat that such care
would not alter the fatal outcome for an EHV-1 infected foal.12,15
1.4.4 Equine Herpesvirus Myeloencephalopathy (EHM)
In addition to respiratory and abortigenic infections, EHV-1 is also a known
cause of neurologic disease. While EHV-1 has been speculatively connected to infectious
paralysis in horses dating back to the 1880s, only in 1966 did Dr. Finn Saxegaard
conclusively link the pathogen with neurological disease.93,94 Over the intervening years,
extensive research has been carried out to unravel the intricacies of equine herpesvirus
myeloencephalopathy (EHM), including characterization of clinical signs along with its
pathogenesis.3 Following initial infection of the horse, pathogen-induced viremia results
in the infection of endothelial cells that line the interior surface of blood vessels found
within the central nervous system (Figure 1.8).60 This infection in turn causes an intense
inflammatory response within the blood vessels and extends into the surrounding nervous
tissue, triggering additional detrimental effects.12,95 These secondary effects include
tissue swelling, tissue anoxia from thrombus-occluded vessels, and infiltration of
inflammatory lymphocytes that release tissue-damaging cytokines such as tumor necrosis
factor (Figure 1.7).12,95 The overall result is that the surrounding nervous tissue suffers
acute cell damage and death.95
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Figure 1.7 Spinal lesions and vasculitis associated with EHM.65,96 Infection of the
endothelial cells of the CNS’s blood vessels can cause vasculitis, which can in turn
induce secondary effects, such as thrombo-ischaemic necrosis and hemorrhages in the
brain and spinal cord. Image B shows the macroscopic hemorrhagic lesions present in
the spinal cord of a horse which suffered from EHM. Image D depicts thromob-
occlusive vasculitis with immunoperoxidase-positive endothelial cells in the spinal
cord. Image used with permission from: Little PB, Thorsen J. Disseminated necrotizing
myeloencephalitis: a herpes-associated neurological disease of horses, Vet Pathol
1976;13:161-171.
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The clinical manifestations of EHV-1 are typically divided into two broad
categories: neuropathogenic (equine herpesvirus myeloencephalopathy; EHM) and non-
neuropathogenic (abortion, respiratory disease and neonatal death). According to
Nugent et al, these two main phenotypic differences of EHV-1 arise from the genetic
composition of the virus. The genetic signature typically associated with
neuropathogenic strains of EHV-1 is found within open reading frame 30 (ORF30),
which codes for the catalytic subunit of the viral DNA polymerase.97 A single point
mutation at position 2254 within the DNA polymerase gene exchanges adenine (A2254)
for guanine (G2254), which in turn causes the replacement of neutral asparagine with
negatively-charged aspartic acid.97 EHV-1’s polymerase, like that of other
alphaherpesviruses, has two identical protein subunits, each of which contains two
catalytic pockets.98 One pocket serves as the site for polymerase activity of the enzyme
and the other is the site for 3’-5’ exonuclease activity.98 The point mutation associated
with EHV-1 neuropathogenic strains occurs on the exterior surface of the polymerase
catalytic site in a linear filament of amino acids lacking secondary structure (Figure
1.8).97,98 The switch from no charge to a negative charge anchors the filament to a
positively charged histidine of a small α-helix loop, which is adjacent to the polymerase
catalytic site.97,98 The charge attraction between the amino acids induces a
conformational change within the viral polymerase, increasing the replicative capacity
of the virus and producing significantly higher viral loads.97,99-101 Current research
argues this increase is the source for the development of neurologic signs in horses
infected with neuropathogenic EHV-1.
A number of studies have been conducted, involving both cases of natural or
experimental EHV-1 infection, which substantiate the correlation between EHM and the
G2254 genotype.
70,97,102-105 Statistical analysis performed on a panel of 176 EHV-1
isolates determined that the association between EHM and the G2254 genotype was 162
times greater than the correlation of EHV-1 neurologic disease and the A2254
genotype.103 However, this same study also found that 24% of the horses with
neurologic signs were with infected the A2254 genotype.
103 Additionally, a study
published in 2010 revealed instances of the A2254 genotype associated with EHM and
the G2254 genotype were
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Figure 1.8 DNA polymerase of an alphaherpesvirus.98 X-ray crystallographic image of
DNA polymerase of an alphaherpesvirus, illustrating the location of the polymerase
catalytic pocket and its proximity to the mutation associated with neuropathogenic strains
of EHV-1. Negatively charged aspartic acid (D) anchors the filament to positively
charged histidine (H) of a small α-helix loop, which is adjacent to the polymerase
catalytic site.97,98 The charge attraction between the amino acids induces a conformational
change within the viral polymerase.97,99-101 Reused from my Master’s thesis, Tracing the
origin of the recent rise in neuropathogenic EHV-1, Department of Veterinary Science.
Lexington: University of Kentucky, 2007;41.
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isolated from animals with no neurologic signs.104 Studies like that of Pronost et al.
indicate viral genotype influences the occurrence of EHM and non-neuropathogenic
EHV-1 disease, but additional data are necessary in order to fully identify all of the
relevant factors (host, environmental, and genetic) resulting in the clinical
manifestations of EHV-1.
For the past several years, greater emphasis has been placed on researching the
causes of EHM and developing improved diagnostic tools for the proper identification
of EHV-1 neuropathogenic strains from field samples, along with the development of
vaccines and improved drug therapies.70,106-114 This elevated emphasis on
neuropathogenic EHV-1 is primarily due to the increase of EHM outbreaks and the
decline of outbreaks of non-neuropathogenic EHV-1. A twenty-four year retrospective
study carried out in France found that EHV-1 induced abortions accounted for ~15% of
the infectious causes of abortion.87 Equine disease monitoring in Central Kentucky
noted a decline in EHV-1 abortion over a fifty-one year period, despite a threefold
increase in the number of broodmares.115 In contrast, the frequency of EHM outbreaks
has increased significantly since 2000.60,70,116,117 In the United States and the United
Kingdom, the number of outbreaks has increased from one reported occurrence in the
1970s to thirty-two outbreaks between the years 2001-2005.118 The case-fatality rate
linked with EHM also appears to be increasing within the United States, ranging from
20% in some outbreaks to as high as 50% in others (Figure 1.9).45 In 2005, significant
EHM outbreaks occurred in Canada, South Africa, Switzerland, and Ireland.45,119,120 In
April 2011, an EHM outbreak began at a national cutting event in Utah and spread to
nine additional states (Arizona, California, Colorado, Idaho, New Mexico, Nevada,
Oklahoma, Oregon, Washington) as well as Western Canada.121 The overall case
fatality rate for this outbreak was 39%. As I completed work on this research, three
additional outbreaks occurred in November 2012, in Utah, Minnesota, and a racetrack
in Illinois.122-124 The complete data on the number of animals affected by EHM, along
with the fatality rates are not yet available. The likelihood of EHM outbreaks occurring
in the future is considered high given the growing horse population, increasing number
of competitions, larger show circuits of longer duration, and the increased number of
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large-scale boarding facilities.125 All of these factors aid neurologic EHV-1 by
providing rapid exposure to large numbers of horses within a short time period.
Figure 1.9 Fatality rates for EHM outbreaks within the United States. The fatality rate
is the percentage of animals with EHM, those which developed neurologic signs, and
died (or were euthanized) from the infection. The rates displayed here are based on the
data collected from reported EHM outbreaks within the six states listed during specific
years. The 38% fatality rate of the Utah 2011 outbreak is based on the number of
confirmed EHM – related deaths resulting from primary exposure at the Ogden, Utah
event. Secondary and tertiary exposures which occurred in different states are not
reflected in this fatality rate.
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Clinical presentation of EHM commences with nasal discharge and pyrexia
approximately four to fourteen days before the onset of neurological signs, which include
the following: muscle weakness in the limbs, ataxia, dragging of the hind toes, loss of
muscle tone in the bladder, complete or partial paralysis of the limbs, inability to rise
from a lying or sitting position, and loss of sensation and sensory reflexes beginning at
the skin of the rump, legs, tail, or perineal area.3 The primary location of the virus and the
extent of the cellular damage it inflicts on the central nervous system determines the
nature and severity of clinical signs.3 For instance, damage to the lower motor neurons
present within the gray matter of the spinal cord causes the animal to exhibit flaccid
muscle paralysis.12,126 In contrast, damage inflicted on the upper motor neurons of the
white matter of the spinal cord results in a rigid or spastic paralysis.12,126 If the sensory
neurons are affected, the result is a loss of sensation, occasionally resulting in an altered
gait.3,12 The severity of the change in gait and which limbs are affected is again
dependent upon the location of the viral infection.3,12
The survival of the host depends on whether or not the animal becomes and
remains recumbent.12 Horses that are completely non-recumbent typically have a
favorable prognosis for recovery with either some residual signs present or without any.3
However, if the animals are incapable of standing after more than two to three days of
being laterally recumbent, euthanasia is normally recommended.3 Natural death due to
EHM results from bowel atony, pneumonia, pulmonary congestion, intussusceptions, or
rupture of the urinary bladder.3
Supportive treatment of EHM typically includes the use of corticosteroids,
because of the occurrence of vasculitis within the nervous tissue.127,128 However,
treatment with such anti-inflammatory drugs can sometimes cause prolonged infection,
immunosuppression, or corticosteroid-associated laminitis, and large doses of the drug
have been known to cause reactivation of the latent virus.127,129 The use of corticosteroids
has also been known to promote spinal hemorrhage, making treatment with this drug a
risky endeavor.130 Non-steroidal anti-inflammatory drugs, such as flunixin meglumine,
are used mainly to alleviate the discomfort of the patient, but they do not appear to inhibit
the activity of the virus.129 Antiviral therapy is not a viable option for treating EHM since
by the time clinical signs of neurologic disease manifest themselves, the virus has already
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ceased replicating.130 However, acyclovir has been used in some outbreaks, but a recent
study suggests that the therapeutic value of the drug is somewhat limited.131 Supportive
care is applied in cases of EHM especially when the horse is completely
recumbent.12,95,127,130 Twenty-four hour care is often needed in such cases to prevent
secondary ailments such as urinary scalding, pressure sores, and colic.95,130
The survival of the host depends on whether or not the animal becomes and
remains recumbent.12 Horses that are completely non-recumbent typically have a
favorable prognosis for recovery with either some residual signs still present or without
any.3 However, if the animals are incapable of standing after more than two to three days
of being laterally recumbent, euthanasia is normally recommended.3 Natural death due to
EHM results from bowel atony, pneumonia, pulmonary congestion, intussusceptions, or
rupture of the urinary bladder.3
Supportive treatment of EHM typically includes the use of corticosteroids, due
to the occurrence of vasculitis within the nervous tissue.127,128 However, the treatment
with such anti-inflammatory drugs can sometimes cause prolonged infection,
immunosuppression, or corticosteroid-associated laminitis, and large doses of the drug
have been known to cause reactivation of the latent virus.127,129 The use of corticosteroids
has also been known to promote spinal hemorrhage, making treatment with this drug a
risky endeavor.130 Non-steroidal anti-inflammatory drugs, such as flunixin meglumine,
mainly alleviate the discomfort of the patient, but they do not appear to inhibit the
activity of the virus.129 Antiviral therapy is not a viable option for treating EHM since by
the time clinical signs of neurologic disease manifest themselves, the virus has already
ceased replicating.130 However, the use of acyclovir has been applied in some outbreaks,
but Bentz et al.’s 2006 study suggests the therapeutic value of the drug is negligible.131 In
severe cases of EHM, in which the horse is completely recumbent, supportive care is
more critical in treatment than current drug therapies.12,95,127,130 Twenty-four hour care is
often necessary in such cases to prevent secondary ailments such as urinary scalding,
pressure sores, and colic.95,130
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1.5 Diagnosis of EHV-1 Infection
1.5.1 Introduction
Regardless of viral genotype, proper diagnosis of EHV-1 is critical to both the
treatment of the individual and curtailing further dissemination of the virus.  A physical
examination along with recording of clinical signs is the first step in diagnosis. During
the course of the physical exam, nasal secretions and whole blood are typically collected
for use in diagnostic testing. Clinical presentation of EHV-1 respiratory disease is very
similar to the clinical signs of other equine viral respiratory pathogens, such as EHV-4,
equine rhinitis virus A, equine influenza virus, and equine adenovirus.132 Additionally,
abortion and neurologic disease can be caused by infectious agents other than EHV-1,
such as equine arteritis virus, West Nile virus, and Saccocystis neurona.133 Therefore,
diagnostic testing is crucial to correctly identifying the suspected cause of disease. A
variety of methods  are available for EHV-1 diagnosis, some of which are very laborious
(virus isolation, ELISA, virus neutralization, histopathology, and immunohistochemical
examination), while others are more rapid and well-suited for epidemics and routine
diagnosis (complement fixation, direct immunofluorescent staining, polymerase chain
reaction).12,129
1.5.2 Virus Isolation
Virus isolation involves the inoculation of a confluent monolayer of cells using
clinical samples obtained from the suspect horse. The optimal procedure for isolating the
virus includes collecting two sample types: peripheral blood leukocytes obtained from a
buffy coat prepared from unclotted blood and nasal secretions collected using a
nasopharyngeal swab.134 With whole blood, the sample should be collected in either
citrate or heparin anticoagulant, not EDTA (ethylene diaminetetra-acetic acid) which can
cause the destruction of cell cultures.134 Proper collection of nasal secretions should be
with either gauze attached to a 50cm length of flexible steel wire encased in latex tubing
or a guarded uterine swab.134 Regardless of the selected device, the swab should be
placed in cold viral transport medium prior to analysis. Cerebrospinal fluid can also be
used for virus isolation, but is not typically collected since isolation is problematic.129,135
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Besides sample type and handling, a crucial aspect of EHV-1 cell culture isolation
is the cell culture type. Various equine-derived cell cultures can be used to isolate EHV-
1: fetal kidney cells, lung cells, dermal fibroblasts and endothelial cells. The main
disadvantage to using equine cell culture is other equid viruses, specifically EHV-4, can
grow in such cultures. To isolate EHV-1, specific cell types should be used, most
commonly rabbit kidney cells (RK-13), but baby hamster kidney, Madin-Darby bovine
kidney, and pig kidney are also suitable choices.134 After selecting the cell type and the
cells are confluent, the monolayer is then inoculated with the prepared sample and
incubated for four to seven days at 37°C in a 5% CO2 environment. Subsequently, the
cell culture is examined for the appearance of cytopathic effect (CPE), as evidenced by
increased refractility, focal rounding, and detachment of the cells from the monolayer.
1.5.3 Serology
I) Complement Fixation
Serum antibody levels can be evaluated using ELISA, virus neutralization, or
complement fixation (CF) tests. Complement fixation assays utilize the interaction
between the antigen-antibody complex and complement, specifically the complex’s
tendency to bind complement. Heating the test serum inactivates endogenous
complement and serial dilutions are then prepared from the serum and combined with
titrated EHV-1 antigen. Guinea pig complement is added and the reaction mixture is
incubated for ~18 hours.136,137 Sheep erythrocytes, often sensitized with hemolysin, are
added to the reaction mixture and then incubated again.136,137 The test outcome is based
on signs of lysis of the erythrocytes. If the erythrocytes are intact, the sample is positive
for EHV-1 antibodies. If the erythrocytes are lysed, then the sample is negative. Antibody
titer is calculated based on the level of hemolysis observed in the serial serum dilutions.
CF assays typically use serum, although cerebrospinal fluid is sometimes used,
but these results are negligible given the lack of consistency with the presence of EHV-1
antibodies in this particular fluid.138 Primarily, the CF assay is most useful in the
diagnosis of EHV-1 respiratory and neurologic disease.134 This technique is an excellent
means of determining recent EHV-1 infection since the CF antibodies to the virus
become undetectable within sixty days of exposure.12,129,135 CF testing is particularly
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recommended for rapid screening of ataxic horses.12,135 However, previous vaccination of
the animal may interfere with the interpretation of the CF results.12 Additionally, cross-
reactivity between EHV-1 and EHV-4 is commonly encountered with this assay; but this
problem can be minimized by using an EHV-1 antigen stock.129,134,139,140
II) Virus Neutralization
Virus neutralization (VN), unlike the CF test, does not require a monolayer of
cells in order to calculate the end-point titer of EHV-1 antibodies. For this assay, test
serum from the suspect animal is combined with serum-free medium and dilutions of an
EHV-1 stock of known titer in designated wells of a flat-bottom 96-well microtitre plate.
A cell suspension is then added to each well and the plate incubated at 37°C in an
atmosphere of 5% CO2. The plate is examined for CPE, stained, and the neutralization
titer calculated. The incubation period ranges between three to five days, depending on
particular laboratory protocols.134,141
This assay employs RK-13 cells because EHV-4 does not replicate in this cell
type.  The VN test usually employs serum, but cerebrospinal fluid is also an option.141
Paired samples must be obtained in order to enable correct interpretation of the results.
The first sample (acute phase) should be collected as early as possible following the onset
of clinical signs and the second (convalescent phase) should be taken two to four weeks
later.134,141 This method is normally applied when diagnosing EHV-1 rhinopneumonitis
due to the variations in antibody levels between the acute and convalescent phases
associated with this disease.134 With EHV-1 abortion and EHM, antibody titers are
typically at their maximal levels when the acute phase sample is collected.134
III) ELISA
The enzyme-linked immunosorbent assay, or ELISA, can also be designed to
detect viral antigen or antibodies for a specific infectious agent. For quantifying
antibodies, EHV-1 antigen binds to a solid support, such as the plastic surface of a
microtitre plate. The serum sample is then incubated with the antigen, followed by the
addition of anti-horse antibody with a conjugate attached to it. The mixture is incubated
again, washed, and a substrate is added to induce a color reaction. If EHV-1 specific
antibodies are present, then a color change will occur, but if none are present, then the
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color remains unchanged. A spectrophotometer reading of the absorbance of the reaction
determines the quantities of antibodies present.
The length of time to complete this assay varies from two to three hours
depending on the protocol used.142,143 Earlier ELISA assays, like other serologic assays,
did not distinguish between EHV-1 and EHV-4.129,134 However, in recent years advances
have been made to develop EHV-1 specific ELISA assays. Specificity of these assays
relies on the structural differences of certain glycoproteins between EHV-1 and EHV-4,
mainly glycoproteins G and D.142,144-146 Additionally, these assays can be used to
diagnose EHV-1 abortion, respiratory, and neurologic disease.129,134,147
1.5.4 Immunofluorescent Staining
Direct immunofluorescent (IF) staining is normally performed on post-mortem
tissue samples. Freshly gharvested samples of lung, liver, thymus and spleen are frozen,
and then sectioned on a cryostat.134 The sections are mounted on slides, fixed with
acetone, and then incubated with a dilution of swine antibody specific for EHV-1 which
is conjugated with fluorescent cells.134 The sections are examined for the presence of
EHV-1 antigen, confirmed by the appearance of fluorescence. IF staining is typically
done to diagnose cases of abortion or neonatal death due to EHV-1 infection.134,148
1.5.5 Immunohistochemistry
Enzyme immunohistochemical staining is most often done with
immunoperoxidase on paraffin-embedded tissue sections. The technique is typically
utilized to diagnosis EHV-1 abortion and EHM post-mortem.72,149,150
Immunohistochemical staining is also useful for evaluating the morphology of EHV-1
associated lesions.
1.5.6 Histopathology
The third technique used for post-mortem diagnosis of EHV-1 is
histopathology. This procedure utilizes formalin-fixed, paraffin embedded tissue sections
to diagnose of EHV-1 abortion or neurologic disease.129,134 Diagnosis relies on the
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presence of characteristic lesions in specific tissues such as thrombotic vasculitis of small
blood vessels in the brain or spinal cord for EHM and herpetic intranuclear inclusion
bodies in the bronchiolar epithelium of an aborted fetus for EHV-1 abortion.134
1.5.7 Polymerase Chain Reaction (PCR)
I) Introduction
The polymerase chain reaction (PCR) is the synthesis and amplification of a
specific nucleotide sequence present in small quantities within a biological sample. This
reaction has three main phases: denaturation, annealing, and extension.151-153 For
denaturation, the temperature of the sample is raised to 95°C to linearize the DNA double
helix and separate the two strands. The next phase, annealing, involves hybridization of
sequence specific sense and anti-sense primers to target regions within the strands of
DNA. For the final phase, extension, a DNA polymerase attaches to the 3´ end of the
primers and synthesizes new strands of DNA, complementary to the original strands. The
three phases compose a single cycle and with each increase in cycle number, the amount
of the PCR product (newly synthesized double stranded DNA) doubles (Figure 1.10).151
The DNA polymerases utilized in PCR typically are derived from thermophilic bacteria
and include the following enzymes: Taq (from Thermus aquaticus), Pfu® (Pyrococcus
furiosis), and Tth (Thermus thermophilus).154 Each of these commercially available
enzymes has a unique property, which is useful for certain types of PCR assays: Taq has
exonuclease activity, Pfu® can synthesis DNA at low temperature (<50°C) and Tth has
reverse transcription activity.151,154 Appropriate amounts of deoxyribonucleoside
triphosphates (dNTPs), along with a buffer and salts, are added with the polymerase to
ensure optimal extension of the primers. The main objective, for routine diagnostic
purposes and disease outbreaks, is to identify the infectious agent by amplifying the
amount of viral DNA present in the sample.
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Figure 1.10 The polymerase chain reaction. The original DNA template is denatured
by the application of heat. In the presence of a DNA polymerase and dNTPs, the
PCR primers are annealed to a target sequence and new DNA is synthesized. The
first cycle produces a product of indeterminate length, but the second cycle produces a
discrete “short product”, which accumulates exponentially with each additional cycle.
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The PCR assay has certain advantages over other methods of diagnosing EHV-1
infection. This technique can be used to analyze both peri- and post-mortem samples
from a suspect horse.155-157 The assay can be performed on multiple specimen types:
whole blood, serum, nasal swabs, sperm, cerebrospinal fluid and un-fixed tissues.158-162
Infectious virus does not have to be present in the sample in order to obtain a positive
result, viral DNA alone is sufficient. However, the application of a DNA extraction
method is normally recommended for the removal of cellular containments from the viral
DNA.163 The assay’s primers can be specific not only for EHV-1, but also for particular
strains of the virus.63,70,106,164
Besides genotyping, PCR assays can also quantify the amount of viral DNA
present along with determining if the animal in question is a latent carrier.62,64,156
Completion of the assay takes approximately two hours, depending on the particular
technique being used. The three principle types of PCR assay used in EHV-1 detection
are conventional, reverse-transcription (RT) and real-time PCR (rPCR). Each assay type
distinguishes EHV-1 infection from other viral infections, but there are key differences
between the assays.
II) Conventional PCR
Conventional PCR, or standard PCR, combines PCR with a detection assay.
Following the completion of the extension phase, the final DNA amplicon requires
visualization, which can be achieved through different methods. Southern blotting and
Southern hybridization with labeled oligonucleotides probe are two possible
methods.165,166 With PCR-ELISA, the amplicon adhers to a solid phase utilizing biotin or
digoxigenin-labelled primers and oligonucleotide probes.167 An enzyme-labelled avidin,
or anti-digoxigenin reporter molecule then detects the amplicon.167 For a number of
years, gel electrophoresis of the amplicon, followed by staining and irradiation with
ultraviolet light has allowed visualization of PCR products.151 Etidium bromide has been
frequently used for gel staining, but due to the mutagenic quality of this substance, other
dyes which are non-mutagenic (partially or completely) have been developed as safer
alternatives: SYBR® Safe, GelRedTM, and GelGreenTM.168 In some instances, gel
electrophoresis is a screening process, with the results then being confirmed using
ELISA, Southern blotting, or chemiluminescence techniques.153
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Conventional PCR allows the detection of the infectious agent and
quantification of the amount of virus present by the co-amplification of an internal
standard.167,169 Additionally, using a nested format increases the sensitivity of the
standard PCR. Nested PCR utilizes two sets of primers: the first amplifies a sequence
within the target DNA and the second set (the nested primers) amplifies a target sequence
within the PCR product produced by the first set of primers (Figure 1.11).170 The result is
a final amplicon with little to no contamination from non-specifically amplified PCR
products from alternative primer target sequences.170 However, the nested technique takes
additional processing time because two separate runs of PCR must be performed with this
procedure.
III) Reverse-Transcriptase PCR
Reverse-Transcription PCR (RT-PCR) begins with the conversion of RNA into
complementary DNA (cDNA), followed by PCR amplification of the cDNA (Figure
1.12). RT-PCR can sometimes require a separate visualization step using either gel
electrophoresis or Southern hybridization, but real-time visualization of PCR products is
also possible.66,171-173 This method has various applications including, but not limited to,
detection of RNA viruses, detection of single nucleotide polymorphisms, quantification
of viral load, along with detection and analysis of mRNA.174-178
This type of PCR is not normally used to detect lytic infections of EHV-1 since
the pathogen is a DNA virus. Most often, this process is for detecting and quantifying
latent EHV-1 in tissues and whole blood.66,171 As with conventional PCR, the sensitivity
of the RT-PCR can also be increased by converting it to a semi-nested, nested or three-
step nested process.179 However, because of the complexity and time consumption of this
assay, RT-PCR is mostly used in a research setting rather than in routine diagnosis.
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Figure 1.11 Nested PCR. During the first run of PCR, the DNA sample is denatured
and primers anneal to a target sequence within test sample. The PCR products from
the first run are then denatured and a second set of primers (the nested primers) anneal
to a target sequence within the PCR products. The result is final amplicon with little
to no contamination from non-specifically amplified PCR products from alternative
primer target sequences.170
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Figure 1.12 Reverse-Transcription PCR.180 RNA is reverse-transcribed into
complementary DNA (cDNA) through the use of a reverse-transcriptase and a sequence
specific primer. The cDNA is then amplified by PCR. This figure was designed by
Jpark623 and originally published by Wikipedia in 2012.
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IV) Real-Time
Real-time PCR (rPCR) does not require a separate process for visualization.
Instead, during its amplification, a fluorescent reporter molecule allows for the detection
of the PCR product.181-183 As the reaction progresses, the level of fluorescence produced
increases in proportion to the amount of amplicon being generated.181-183 The result is
depicted as a plot of PCR cycle number versus the accumulated level of fluorescence
generated throughout the course of the assay.70,106,151 A rPCR assay has three distinct
phases: baseline, exponential, and plateau.184 The baseline phase marks the beginning of
PCR and the fluorescent signal is at background level.184 When observing a plot of a
rPCR assay, the graph line for the baseline phase has a flat line appearance (Figure 1.13).
During the exponential phase, the fluorescent signal increases above background in
proportion to the amount of PCR product and the graph line begins to arc (Figure 1.13).
The cycle number at which the level of fluorescence is above background is the cycle
threshold, or CT value.
183,185,186 This value is relative to the amount of target sequence
present in the test sample. The smaller the amount of the target sequence at the start of
the reaction, the more cycles are required for the fluorescent signal to exceed the
background level of fluorescence.183,185,186 The CT value gauges the amount of viral DNA
present, along with determining the efficiency of the rPCR assay. The plateau phase
occurs when the substrates are exhausted, and the fluorescent signal ceases to increase.184
The graph line of a positive sample, as shown in Figure 1.13, will have baseline and
exponential phases. The plateau phase does not have to occur in order for the sample to
be positive. A negative sample’s graph line will not progress beyond the baseline phase
(Figure 1.13).
Detection of the PCR amplification product in real time requires the use of
fluorescent dyes which specifically hybridize to double-stranded DNA. Different
methods to fluorescently tag amplicons include molecular beacon probes, hydrolysis
probes, hybridization probes, intercalating dyes and scorpion probes.187,188 Two of the
most common methods are the use of SYBR® Green (an intercalating dye) and the Taq-
Man® system.187 With SYBR® Green, the dye incorporates into the minor of double-
stranded DNA, which enhances its fluorescence.187,189,190 As the PCR reaction progresses,
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Figure 1.13 Phases of rPCR. The baseline phase marks the beginning of PCR and
the fluorescent signal is at background level.184 The graph line for the baseline phase
has a flat line appearance as can be seen with the negative sample. The red line is
image is the threshold level between the baseline phase and the exponential phase.
The second phase of PCR, the exponential phase, occurs when the fluorescent signal
increases above background in proportion to the amount of PCR product and the
graph line begins to arc. The plateau phase, the beginnings of which can be with the
positive sample in this image, occurs when the substrates are exhausted, and the
fluorescent signal ceases to increase.
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the fluorescent emission of SYBR® Green increases with the amount of double-stranded
DNA. The advantage of this method is this particular dye works with any set of primers
for any target sequence at a low cost.187 However, SYBR® Green binds to any double-
stranded product present in the reaction, which includes non-specific PCR products
(amplicons which do not contain the target sequence) and primers/dimers.191 Therefore,
melting curve analysis at the end of the PCR reaction is required to distinguish between
the desired PCR amplicon and the unwanted non-specific PCR products.191
The Taq-Man® system utilizes a dual-labeled oligonucleotide hydrolysis probe
and a Taq-Man® DNA polymerase. A Taq-Man® probe is a sequence specific
oligonucleotide probe with a reporter fluorescent dye at the 5´end and a quencher dye at
3´end (Figure 1.14). The polymerase used with this system has 5´-3´exonuclease
activity.192 In the course of the PCR reaction, if the probe does not bind to the test sample
DNA, then the fluorescence emitted by the reporter is absorbed by the quencher, which
produces a steady state in the level of fluorescence.192-194 If the target sequence is present
in the DNA sample, then the polymerase hydrolyzes the probe and thus cleaves the
reporter dye from the probe. The separation from the 3´ quencher dye allows the emission
of fluorescence from the reporter dye to increase (Figure 1.14). Specifically, the level of
fluorescence increases cycle by cycle and is directly proportional to the amount of PCR
amplicon being produced.192-194 The main advantage of the Taq-Man® system is the
fluorescence only increases when the desired PCR amplicon is being formed.
Taq-Man® rPCR has several uses in EHV-1 diagnosis. One application involves
specifying the fluorescent probe for a particular segment of one of EHV-1’s ORFs, such
as a sequence within ORF33.156,164,195 The EHV-1 specific probe not only permits the
differentiation between EHV-1 and other equine viruses, but also allows the
quantification of viral DNA within a certain host. Quantitative rPCR can be absolute or
relative. Absolute quantitative rPCR (AQ-rPCR) determines the amount of the target
DNA present within an unknown sample by comparison with a standard curve, generated
by serially diluted standards of a known concentration of the target DNA.183,184,196,197
Relative quantitative rPCR (RQ-rPCR) determines the concentration of the target DNA
by comparing the change in CT values between samples as measured by an endogenous
standard (internal calibrator) or external standard (external calibrator).183,184,196,197
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Figure 1.14 Taq-Man® rPCR.198 Hydrolysis of the Taq-Man® probe by the DNA
polymerase causes the cleavage of the reporter molecule from the probe. The separation
from the 3´ quencher dye allows the emission of fluorescence from the reporter dye to
increase. As the concentration of PCR amplicon increases cycle by cycle, so does the
level of fluorescence. This figure was designed by Applied Biosystems and published on
the Asuragen.com website in 2012.
The test samples are normally analyzed in triplicate to allow for sample to sample
variation. If using an internal calibrator, then the amount of target DNA present in the test
samples is calculated as a relative fold difference between a test sample and the internal
calibrator (relative quantity of DNA = 2-ΔΔCT).
156,183,184 If using an external calibrator,
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then serial dilutions prepared from the stock DNA generate a standard curve. The DNA
concentration of each test sample is determined using the standard curve and then
expressed relative to the external calibrator (the concentration of the target DNA in the
test sample is divided by the concentration of the target DNA in the external
calibrator).183,184 Regardless of the selected method, quantitative rPCR assesses how
much viral DNA is present in the sample and this data determines the level of exposure to
a particular pathogen. If the concentration of EHV-1 DNA is low in a nasopharyngeal
swab, then the horse may have been recently exposed to the virus. If high concentrations
of EHV-1 DNA are present in the peripheral blood, then the horse has an active viral
infection.
Besides quantifying the amount of virus present, Taq-Man® rPCR can also
identify various strains of EHV-1 by using strain-specific fluorescent probes.70,103,106 This
technique, referred to as allelic discrimination rPCR (AD-rPCR), uses a pair of uniquely
labeled Taq-Man® probes, each specific for a certain sequence variant at a single
nucleotide polymorphism site within the target DNA region.106,199,200 One probe is labeled
with one type of fluorescent molecule, for instance a VIC label, and the second is labeled
with a different fluorescent reporter, such as FAM. Most often, employing only a pair of
different reporter molecules is optimal because of the interference that occurs when three
or more fluorescent reporters are used.151,201 The sequence of the sample DNA
determines the type of fluorescence produced. This method measures the type and level
of fluorescence associated with the hybridization of the two Taq-Man® probes, thereby
determining the genotype of the test sample.151,199,200 In regards to EHV-1 diagnosis, AD-
rPCR permits the rapid differentiation between non-neuropathogenic and
neuropathogenic strains of the virus, which in turn allows the correct course of treatment
to be pursued.
1.6 Prevention of EHV-1 Infection
1.6.1 Management
While a cure for EHV-1 does not currently exist, prevention of disease
outbreaks and infection of individual animals is possible. Prevention has two major
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aspects, management and vaccination. Both aspects are crucial to curtailing the spread of
EHV-1. Furthermore, Barrandeguy et al. (2002), Kydd et al. (2006), and Lunn et al.
(2009) assert that the concurrent use of both methods is responsible for the 75% decline
in EHV-1 abortion storms within the United States.202-204 Herd, or farm, management is
mainly focused on reducing the possibility of an EHV-1 epidemic.12,95 Proper
management procedures typically include the following: segregation, isolation,
subdivision and stress reduction. Segregation involves dividing the horse population on a
farm into distinct categories with specific areas designated for each group: weanlings,
yearlings, new arrivals and transients.3,12,95,205 Isolation entails quarantining new arrivals
for at least three weeks prior to introduction to the rest of the population.95,205 Subdivision
refers to dividing the pregnant mares into small, physically separated foaling groups for
the entire extent of gestation.95,205 Stress reduction necessitates the avoidance or
minimization of any action that causes physiological stress.95,205 This includes numerous
situations, some of which can be controlled by the farm manager and others which
cannot: disruption of social structures, inclement weather, prolonged transport, heavy
parasite load, poor nutrition, relocation, abrupt weaning techniques, and infection with
other pathogens.3,95,205
If an EHV-1 outbreak does occur, prevention of further transmission of the
virus is of upmost importance. Pathogen containment occurs through disinfection,
isolation, submission and hygiene procedures. Any areas in the farm contaminated with
tissues, fluids or secretions from infected animals should be disinfected.3,95,205 Isolation
requires the physical separation of the infected horse, or horses, from all other animals at
the facility. Submission refers to the collection and submission of clinical samples (whole
blood, aborted fetal tissues, nasopharyngeal swab) to a diagnostic laboratory for
analysis.3,95,205 Lastly, standard hygienic procedures (creation of sanitary barriers, use of
protective outer clothing, disinfection and removal of bedding, etc) should also be
implemented.3,95,205
1.6.2 Vaccination
The second aspect of prevention, vaccination, seeks to protect the individual
from viral infection. While there are various commercial EHV-1 vaccines available (more
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than a dozen at last count), none should be used as the sole means of prevention.203
During recovery from EHV-1 infection, most horses develop immunity to the virus,
which lasts for approximately 3-6 months.52,140,206,207 This immunity consists of virus
neutralizing (VN) antibodies, CD4+ T-lymphocyte activity, CD8+ cytotoxic T-
lymphocyte precursors specific for EHV-1, reactive natural killer lymphocyte responses,
and EHV-1 specific antibody-dependent, cell-mediated cytotoxic activity.89
In regards to EHV-1 vaccines, the immune response elicited depends on the
vaccine in use. Live virus vaccines appear to stimulate cytotoxic T-lymphocyte (CTL)
responses and mucosal antibody production, often leading to a reduction in cell
associated viremia.203,206,208 The administration of modified live vaccines evokes mucosal
antibody production and serum VN antibodies in the host, along with the accompanying
reduction in nasal shedding and viremia.203,208 Inactivated vaccines stimulate of VN
antibodies, reduce viremia and nasal shedding, and provoke a T-helper 1
response.203,208,209 While the Pneumabort-K® vaccine type does not usually evoke CTL
responses, Goehring et al (2010) and Bannai et al (2012) demonstrated this vaccine
stimulates an IFN-γ response.208,210 Regardless of the type of vaccine, none of those
currently commercially available completely protects against EHV-1 infection and none
prevent latent infection, reactivation from latency, or EHM.203 Administering an EHV-1
vaccine in a series of three doses enhances its performance.208
While none of the commercially available vaccines provides protection against
EHM, experimental recombinant EHV-1 vaccines demonstrated partial protection against
Ab4, a neuropathogenic strain of EHV-1.211 Minke et al. (2006) engineered four vaccines
using EHV-1 DNA plasmids and a canarypox virus as a vector.211 The resulting vaccines
were capable of suppressing initial virus replication in the upper respiratory tract, along
with stimulating CTL responses.211 However, none of these vaccines reduced cell-
associated viremia.211 Therefore, additional investigation is still necessary to produce a
recombinant vaccine which can induce more comprehensive protection against EHV-1
infection.
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1.7 Rationale
As discussed above, equine herpes viruses are a serious concern for all aspects
of veterinarian medicine. EHV-1 causes a variety of clinical syndromes, many of which
can have fatal outcomes. Equine herpesvirus myeloencephalopathy (EHM), in particular,
can have a devastating impact not only on a single host, but also on a broader scale. The
spring 2011 EHM outbreak in Utah spread to twelve additional states and caused thirteen
deaths out of thirty-three reported cases of EHM.121 A November 2012 EHM outbreak at
an Illinois racetrack caused the cancelation of racing events for seven days in an effort to
contain the virus. The quarantine of this racetrack may not be lifted until January 2013.124
These incidents highlight the ongoing threat EHM presents to the horse industry.
Vital to the containment of EHM outbreaks is a rapid, accurate diagnosis of
EHV-1 infection. Such a necessity is satisfied by real-time PCR (rPCR).  The late Dr.
George Allen developed an allelic discrimination rPCR assay which can distinguish
between the neuropathogenic and non-neuropathogenic genotypes of EHV-1.106
Following the publication of the Allen assay in 2007, research and diagnostic laboratories
in Kentucky and California reported a lack of adequate sensitivity and the generation of
false dual positives using this assay.212,213 Furthermore, false negative results are
produced in this assay by the presence of additional nucleotide substitutions within the
binding region of the Taq-Man® probes.70
Rapid detection of EHV-1 provides clinicians with the necessary information to
properly manage an infected animal and determine what biosecurity measures should be
implemented to contain or prevent an epidemic. An assay with increased sensitivity and
able to detect the smallest possible amount of EHV-1 DNA would permit detection of the
virus in its earliest stages of infection. This would allow isolation of a single infected
animal to occur sooner, reducing the risk of an epidemic. Therefore, the first objective of
this dissertation was to design an allelic discrimination rPCR assay, which can
distinguish between the two known genotypes of EHV-1 with greater sensitivity and
specificity than the original Allen allelic discrimination rPCR assay.70
Of equal importance to accurate diagnosis is the prevention of EHV-1 infection.
Improved management practices have reduced the occurrence of EHV-1 abortion
epidemics. Furthermore, as observed with the three most recent outbreaks in November
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2012, the application of quarantine and the confinement of affected animals to the initial
outbreak site can reduce the severity and scope of an EHM epidemic. Vaccination is also
significant in preventing EHV-1 infection. Immunologically naïve horses can be
protected from severe EHV-1 infections and the occurrence of abortion can also be
reduced in pregnant mares with the proper administration of vaccines.
None of the commercially available EHV-1 vaccines provides protection against
EHM. Minke et al’s 2006 study demonstrated recombinant DNA vaccines could provide
partial immunity against a neurologic strain of the virus.211 This study also revealed these
DNA recombinant vaccines could inhibit initial viral replication, but were incapable of
reducing cell-associated viremia.211
An EHM vaccine would equip clinicians with the means to protect horses from
neurologic disease, regardless of age or previous exposure. Such a vaccine would also
significantly reduce the occurrence of EHM epidemics and the loss of life associated with
them.  Therefore, the second objective of this dissertation was the in vivo characterization
of a cell-passaged EHV-1 neuropathogenic strain, T953, to determine if this virus’s
phenotype was attenuated and could possibly serve as the basis for an EHM vaccine.
The overall purpose of the research in this dissertation is the improved diagnosis
and prevention of EHM. To achieve this, two study objectives were pursued. The first
was the design of a new EHV-1 allelic discrimination rPCR assay, which could
distinguish between the two known genotypes of EHV-1 with greater sensitivity and
specificity. Such an assay could have an immediate impact on EHM outbreaks by
increasing the speed and accuracy of detecting neuropathogenic EHV-1. The
development and evaluation of this new assay is discussed in Chapters 2 and 3. Chapter 2
describes the generation of false negative results and the impact of additional point
mutations on the Allen rPCR assay. Chapter 3 discusses the design and validation of the
new EHV-1 rPCR assay.
Objective two focused on the in vivo characterization of cell-passaged EHV-1
strain T953 to assess its phenotype. Such an assessment ought to determine if this
particular virus strain is a viable candidate for EHM vaccine development, which would
eventually aid in the prevention of EHM outbreaks. The in vivo characterization of cell-
passaged T953 is depicted in Chapters 4 and 5. Chapter 4 focuses on the evaluation of
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four different mouse strains as a possible alternative host for T953. Chapter 5 describes
the comparison of the original, unaltered T953 strain to cell-passaged T953 in BALB/c
mice. Chapter 6 summarizes the conclusions of this dissertation, along with the possible
applications of this research and future studies.
Copyright© Kathryn Laura Smith 2013
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CHAPTER TWO
Identification of Seven EHV Isolates from Sporadic Abortions and the Genotypic
Characterization of Two EHV-1 Isolates
2.1 Introduction
Equine herpesvirus-1 (EHV-1) infections cause significant economic losses to
equine industries worldwide as a result of abortion, respiratory illness, and neurologic
disease in all breeds of horses. Although almost all strains of EHV-1 can induce abortion
in pregnant mares, only certain strains have the potential to cause neurologic disease.97
Equine disease monitoring in Central Kentucky over the past fifty-one years (1957-2008)
has confirmed the frequency of EHV-1 induced abortions has declined, even though the
number of broodmares has increased threefold (Powell, 2008). The majority of such
abortions in recent years have been single, sporadic events on individual farms among
populations of mares that are routinely vaccinated against disease. In contrast, cases of
EHV-1 induced neurologic disease have increased significantly in number since the year
2000.60,116,117,214 Within the United States and the United Kingdom, the number of
reported outbreaks has risen from one occurrence in the early 1970s to thirty-two during
the years 2001–2005.118,214 The associated case-fatality rate may also be increasing within
the United States, ranging from 20% in some instances, to as high as 50% in others.45
Additionally, in 2005 significant outbreaks occurred in Canada, South Africa,
Switzerland, Ireland and other European nations.45,120
Nugent et al. proposed that a single nucleotide substitution within open reading
frame 30 (ORF30) is associated with the occurrence of EHV-1 neurologic disease.97 The
exchange of adenine for guanine at position 2254 (ORF30; A2254→G2254) results in an
asparagine (N) to aspartic acid (D) substitution at amino acid position 752 (N752→D752).97
In 2007, the late Dr. George Allen investigated thirty-two outbreaks of EHV-1 neurologic
disease which occurred in the United Kingdom and the United States between the years
2001 to 2006.80 His results argued that in thirty of the thirty-two outbreaks the G2254
genotype was the causative agent.106 The ability of EHV-1 strains possessing G2254 to
induce neurological symptoms has also been proven through experimental infection of
horses.102 Neuropathogenic EHV-1 strains are also able to replicate more efficiently and
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achieve 10-fold higher levels of leukocyte-associated viremia than observed in horses
infected with non-neuropathogenic strains of EHV-1.99,102,105 The identification of this
unique single nucleotide polymorphism (SNP) in ORF30 allowed for the development of
a real-time PCR assay to discriminate between non-neuropathogenic and
neuropathogenic strains of the virus (real-time Taq-Man® allelic discrimination
PCR).106,116
EHV-1 establishes a life-long latent infection in a high percentage of animals
following exposure to the virus.12,155 Reactivation of the latent virus results in virus
shedding for a limited period of time and the opportunity for transmission of the pathogen
to susceptible, in-contact horses. Outbreaks of neurologic disease are initiated by viral
reactivation and nasal shedding of neuropathogenic strains of EHV-1 by latently infected
carriers.215 The latently infected host is typically asymptomatic, although mares which
harbor EHV-1 can abort their foals without any prior symptoms. While the primary site
of latency is the lymph nodes associated with the respiratory tract, latent virus has also
been detected in circulating lymphocytes and the sensory nerve-cell bodies of the
trigeminal ganglia.61,62,66 Where sporadic cases of abortion have been studied, the
genotype of the strain of EHV-1 isolated from the aborted fetal tissues was found to be
identical to the latent virus present in the mare that aborted.65,155 In light of this
observation, it was felt that archived EHV-1 isolates, derived from fetal tissues and
recovered from sporadic equine abortions, would be an excellent source of material to
study the distribution of both neuropathogenic and non-neuropathogenic strains of EHV-
1 over an extended period of time (1950-2006), within the latent population of the virus.
Prior to 2010 publication of my thesis research, no previously recorded studies
focused on identification of neuropathogenic strains of EHV-1 from sporadic cases of
equine abortion. We hypothesized the neuropathogenic strain of EHV-1 was associated
with sporadic cases of equine herpesvirus abortion prior to the 1960’s, and the proportion
of EHV-1 abortion isolates which possess the neuropathogenic genotype has increased in
recent years in comparison to previous decades in Central Kentucky. We tested this
hypothesis using a real-time Taq-Man® allelic discrimination PCR assay to analyze a
panel of 426 archived EHV-1 isolates recovered from tissues of foals aborted by Central
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Kentucky’s Thoroughbred broodmare population during the past 46 foaling seasons, from
1950 through 2006.
The resulting PCR data demonstrated a marked increase in the occurrence of
viruses with the neuropathogenic genotype (G2254). However, 7 of the 426 isolates could
not be genotyped using the allelic discrimination real-time PCR assay. Therefore, to
ascertain their genetic identity, these seven non-reactive isolates were subjected to
conventional PCR amplification and DNA sequencing.
2.2 Materials and Methods
2.2.1 Cells
Confluent monolayers of fetal equine dermis (KyED) cells were maintained in
850-cm2 tissue culture roller bottles in Eagle’s Minimal Essential Medium (EMEM;
Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (10% FBS) and
gentamicin reagent solution (50-µg/ml; Invitrogen) as previously described.216-218 In the
present study, the KyED cells were used between passages 7 and 10.
2.2.2 Viral Isolates and Generation of Virus Stock
Archived field isolates of EHV-1 have been obtained from sporadic cases of
abortion in Central Kentucky (Bourbon, Clark, Fayette, Franklin, Jessamine, Madison,
Scott and Woodford counties), stored either as lyophilized or wet frozen (-70°C) tissue
culture fluid (TCF) stocks, were available for analysis. To ascertain if there was a time-
related genetic shift in the latent EHV-1 reservoir, it was considered necessary to
examine EHV-1 isolates from different decades, starting with the year 1950. Only
isolates derived from fetal tissues of sporadic cases of abortion from Thoroughbred
broodmares were included in this study. According to their case histories, none of the
mares exhibited any clinical signs of respiratory or neurologic disease prior to aborting.
The seven non-reactive isolates were from the 1970s, 1980s, and 1990s. Their
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laboratory identifications were as follows: 1974D, 1974E, 1982C, 1997A, 1997B,
1997F, 1997G.1
To generate working virus stocks, confluent monolayers of fetal equine dermis
(KyED) cells in 850-cm2 tissue culture roller bottles were inoculated with individual
isolates and each bottle incubated at 37ºC until 100% cytopathic effect (CPE) was
evident. The TCF from each roller bottle was harvested and centrifuged at 12,000 g for
15 min at 4ºC. The supernatant was harvested and filtered using a 0.45 µm membrane
filter to remove any remaining cellular debris. The filtered supernatant was subjected to a
further cycle of centrifugation for one hour at 48,000 g at 4ºC to pellet the virus.
Supernatants were decanted, and the viral pellets in each tube were resuspended in 700µl
of Tris-EDTA buffer (TE; 1.0 M Tris-HCl, (pH 8.0), 0.1 M EDTA: Sigma-Aldrich, St.
Louis, MO) and stored at -80ºC.
2.2.3 Isolation of Viral DNA
The purified virus was treated with Proteinase-K (20 mg/ml in TE buffer
containing 50% glycerol (pH 8.0): Invitrogen, Carlsbad, CA), and the viral DNA was
isolated by phenol chloroform extraction as previously described.216 The isolated viral
DNA was resuspended in 700µl of TE buffer (pH 8.0) and stored at -20°C.
2.2.4 Allelic Discrimination Real-Time PCR Assay
A duplexed real-time Taq-Man® PCR assay was performed in 96-well plates for
the allelic discrimination of the A2254 and G2254 EHV-1 strains, using an ABI 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA). The primers and probes,
as well as the reaction conditions, were identical to those described by the late Dr.
George Allen.106 The sequences for both the A2254 and G2254 probes are given in Table 2.1.
For each reaction, 2.5µl of a viral DNA dilution (5ng per reaction) was combined with
22.5µl of submaster mix, which consisted of the following: 12.5µl of Taq-Man®
Universal PCR Master Mix (Applied Biosystems), 0.625µl of primer/probe mix (40X;
1 Laboratory identification numbers for these isolates were as follows: 1) 1974D =T186, 2) 1974E = T188,
3)1982C = E276, 4) 1997A = 13637, 5) 1997B = 4733 6) 1997F = 28381, 7) 1997G = 14305.
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EHV1_ORF30_2254: Applied Biosystems), and 9.375µl of nuclease free water. The
nucleotide sequences of the real-time primers and probes are listed in Table 2.1.
Table 2.1 Primers and probes for allelic discrimination EHV-1 real-time PCR.106
Primer/ probe Sequence (5' to 3')
Nucleotide
Position
Amplification primers
EHV-1 ORF30 - Forward
CCA CCC TGG CGC TCG
2204 -
2218
EHV-1 ORF30 - Reverse AGC CAG TCG CGC AGC AAG ATG
2328 -
2348
TaqMan® detection probes
EHV-1 ORF30 A2254 VIC-CAT CCG TCA ACT ACT C-MGB†-
NFQ‡
2246 –
2261
EHV-1 ORF30 G2254 6-FAM-TCG GTC GAC TAC TC-MGB†-
NFQ‡
2248 –
2261
Within the sequences of the two TaqMan probes, MGB† designates the minor groove
binder and NFQ‡ the nonfluorescent quencher.
The following thermocycling conditions were used with a 9600 emulation mode, per the
manufacturer’s recommendations: initial denaturation at 95°C for 10 min, followed by 35
cycles at 95°C for 15 sec and 65°C for 1 min. Each PCR run included a control without
DNA (22.5µl of submaster mix plus 2.5µl of nuclease-free water), and two additional
controls with DNA from known A2254 or G2254 EHV-1 isolates. Prior to the
commencement of analysis of the DNA samples from the 426 unknown viral isolates, the
validity of this real-time Taq-Man® allelic discrimination PCR assay was confirmed by
the analysis of fourteen EHV-1 isolates of known A2254 and G2254 genotype.
Post-run analysis for detection and genotype identification of EHV-1 DNA
present in each test sample was performed using ABI 7500 SDS allelic discrimination
analysis software (version 1.3.1.). Amplification in real time of each genotype of EHV-1
DNA present in the test sample wells was represented by the software as a plot of PCR
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cycle number versus the accumulated level of fluorescence (Rn) from each of the Taq-
Man® reporter probes.
2.2.5 PCR Amplification and Sequencing of the Seven Equine Herpes Virus
Isolates
EHV-1, EHV-3, and EHV-4, as well as EHV-2 and EHV-5, specific PCR
assays were performed using a HotStartTaq® DNA polymerase kit (Qiagen, Valencia,
CA). Briefly, 50µl of PCR mixture for each reaction contained 5µl of 10X PCR buffer,
2µl of 25mM MgCl2, 1µl of 10mM dNTP mix, 0.3µl of HotStart DNA Polymerase,
38.3µl of RNase free water, 0.5µl of the forward primer, 0.5µl of the reverse primer
(200mM of each primer), and 2.5µl of the template DNA. The DNA from each isolate
was combined with seven different primer pairs, whose sequences are reported in Table
2.2.165,219 Using an Eppendorf thermal cycler, the amplification parameters were set as
follows:  95°C for 15 min, followed by 35 cycles at 94°C for 30 sec, 60°C for 30 sec, and
72°C for 1 min, and a final extension phase of 72°C for 10 min. The PCR products were
analyzed on a 1% agarose gel and gel purified using a QIAquick gel extraction kit
(Qiagen). Both sense and anti-sense strands were sequenced with the PRISM Ready
Reaction DyeDeoxy Terminator cycle sequencing kit (MWG Operon, Huntsville, AL).
Sequence data were analyzed with the CodonCode (Codon Code Corp., Dedham, MA)
and Vector NTI (Invitrogen) software.
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Table 2.2 Primer pairs specific for EHV-1, EHV-2, EHV-3, EHV-4 and EHV-5.
Virus
Type
Primer Pair Sequence
Product
Size
EHV1
ORF39
gH2055P b 5' AAGAGGAGCACGTGTTGGAT   3' 637bp
gH2688N b 5'   TTGAAGGACGAATAGGACGC   3'
gH2339N b 5'   AGTAGGTCAGGCCGATGCTT   3' 288bp
EHV2
ORF8
gB33717P a 5'   CAGTGTCTGCCAAGTTGATA  3' 445bp
gB34158N a 5'   ATGGTCTCGATGTCAAACAC   3'
EHV3
gG792P a 5' GCGCTCTCTCGGCCTTGCCAG 3'
521bp
gG1309N a 5'   GGCGTCTCGAAAAGCGAGAG   3'
EHV4
ORF33
gB63539P b 5'   CTGCTGTCATTATGCAGGGA   3'
510bp
gB64045N b 5'   CGTCTTCTCGAAGACGGGTA   3'
gB63859N b 5'   CGCTAGTGTCATCATCGTCG   3' 324bp
EHV5 gB1928P
a 5' ATGAACCTGACAGATGTGCC   3'
294bp
gB2218N a 5'   CACGTTCACTATCACGTCGC   3'
Each of these primer sets is specific for one of the five known types of EHV. The
primer sets were used to identify the type of equine herpesvirus for each of the seven
negative isolates. a:Dynon K, Varrasso A, Ficorilli N, et al., Aust Vet J 2001;79:695-
702. b: Varrasso A, Dynon K, Ficorilli N, et al., Aust Vet J 2001;79:563-569.
2.3 Results
Three of the seven DNA samples (1997B, 1997F, 1997G) gave a positive result
with both sets of EHV-4 gB gene (encoded by ORF33) specific primer pairs: a 510bp
product was produced with the first set of primers and a 324bp product was produced
with the second set (Figure 2.1). Sequence analysis further confirmed that these three
isolates were EHV-4. DNA extracted from 1982C gave a 445bp product with the EHV-2
gB gene (ORF8) specific primers as well as a 324bp product with the EHV-4 gB gene
specific primers (Figure 2.1). Sequencing of individual gel purified PCR products further
confirmed the authenticity of the PCR products, suggesting dual EHV-2 and EHV-4
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infection of this particular fetus. The remaining three isolates, 1974D, 1974E and 1997A,
reacted positively with both sets of EHV-1 gH gene (ORF39) specific primers (Fig 2.1).
The sequence analysis of these PCR products further confirmed their authenticity as
EHV-1.
Figure 2.1 PCR amplification of nucleic acid extracted from the seven Taq-Man® real-
time allelic discrimination PCR negative samples. DNA from the seven Taq-Man® real-
time allelic discrimination PCR negative samples was analyzed by conventional PCR
with the EHV1-5 type specific primers. The first lane contains a 100bp DNA ladder. The
EHV type is indicated at the top of the gel image and the virus isolates are identified at
the bottom.  All PCR products were sequenced to validate their authenticity.
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Figure 2.2 Sequence alignment results. The sequence alignments of 1974D and 1974E
with both rPCR probes. With the A2254 probe, two point mutations were present in the
probe binding region (nt# 2248-2261) of both isolates. However, only one point mutation
was observed within the binding region for the G2254 probe.
To investigate whether the lack of reactivity in the allelic discrimination assay
was due to nucleotide mismatches in the primer and/or probe binding sites of 1974D,
1974E and 1997A, we PCR amplified and sequenced a 509bp product from ORF30
which includes these target regions. The 509bp product targets nucleotide numbers 1901-
2410 based on the published genomes of EHV-1 strains V592 (GenBank accession
#AY464052) and Ab4 (GenBank accession#AY665713). V592 is a non-neuropathogenic
strain of EHV-1 and Ab4 is neuropathogenic strain, the use of both provided a wider
spectrum of comparison for the study isolates. A summation of the PCR results (standard
and real-time), along with the sequencing data, for all three isolates is given in Table 2.3.
Comparative nucleotide sequence analysis of ORF30 from 1974D and 1974E found an
additional nucleotide substitution (A2258→C2258) within the real-time probe binding site
that was sufficient to compromise the allelic discrimination assay and give rise to a non-
reactive result (Fig 2.2). The substitution at nucleotide position 2258 resulted in a
tyrosine (Y) to serine (S) amino acid substitution (Y753→S753) within the viral DNA
A2254 Probe
2258
1974D
1974E
Consensus
2258
1974D
1974E
Consensus
G2254 Probe
2254
2254
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polymerase. Therefore, both of these EHV-1 isolates from 1974 contain D752 and S753
amino acid substitutions in the viral DNA polymerase. The PCR amplification and
sequencing of the same region of the 1997A isolate revealed that it was an A2254 EHV-1
isolate and did not contain any additional nucleotide substitutions in the primer/probe
binding regions. Therefore, DNA from 1997A was retested in the allelic discrimination
assay and shown to react with the A2254 probe when the PCR cycle number was increased
from the standard 35 to 50. In summary, the data from these three EHV-1 field isolates
clearly demonstrate that the current assay conditions used in the real-time Taq-Man®
allelic discrimination assay may produce false negative results.
Table 2.3 PCR and sequencing data for 1974D, 1974E, and 1997A.
Isolate
Allelic-Discrimination
Real-Time PCR
(EHV-1 ORF30)
Sequencing
Standard
PCR
(EHV-1
ORF39)
Cycles 35 Cycles 50
Real-Time
PCR Primer
Binding
Region
Real-Time
PCR Probe
Binding
Region
1974D + - -
No
Mismatches
C2258
1974E + - -
No
Mismatches
C2258
1997A + - +
No
Mismatches
No
Mismatches
Sequence mismatches were found in the probe binding regions of both 1974D and 1974E
at nucleotide position 2258: cytosine was present instead of adenine. No mismatches
were found anywhere in 1997A. The sample was retested increasing the cycle number to
50, which produced a positive result.
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2.4 Discussion
Of the seven samples that failed to react in the allelic discrimination assay, three
(1997B, 1997F, 1997G) were subsequently shown by PCR sequencing to be EHV-4 and
not EHV-1, indicting they had been incorrectly identified during initial diagnostic testing.
PCR sequencing also revealed that a fourth sample had been initially misdiagnosed as
EHV-1. This fourth sample, isolated in 1982 (1982C), did not react in the EHV-1 specific
allelic discrimination assay because it contained a mixture of EHV-4 and EHV-2 viruses.
This interesting finding warrants further investigation albeit due to the infrequent
association of EHV-2 with equine abortions and the possible role of this virus in the
pathogenesis of EHV-1 and EHV-4 infections by facilitating reactivation and/or
transactivation.33,36,63,68 In contrast to the four instances where there was likely initial
misdiagnosis of the viral strain involved, the three remaining samples (1974D, 1974E,
1997A) that failed to react in the allelic discrimination assay were identified as EHV-1 by
sequence analysis. Therefore, they were retested and the DNA from one sample (1997A)
reacted with the A2254 probe when the PCR cycle number was increased from 35 to 50.
This is consistent with previous reports that the Taq-Man® allelic discrimination PCR
assay, as originally described, can produce false negative results and has a sensitivity of
96.3% when compared with alternative nucleic acid detection methods.12 However, the
most significant finding occurred with the final two non-reactive EHV-1 isolates, 1974D
and 1974E. In addition to the A2254→G2254 substitution, they possessed an A to C
transposition at nucleotide position 2258 in ORF30. As this is within the allelic
discrimination assay probe-binding site, it introduces a base-pairing mismatch that
prevents either of the assay-specific probes from annealing under the amplification
conditions used in the assay. Although obviously important for the diagnosis EHV-1
infections, this finding may have considerable implications for our understanding of the
genetic basis of neuropathogenicity. Since A2258→C2258 transposition is non-synonymous,
it is predicted to result in the replacement of tyrosine (Y) with serine (S) at amino acid
position 753 in the viral polymerase (Y753→S753). Since the transposition is located
within the “palm domain” of the polymerase protein and is directly adjacent to the critical
aspartic acid 752 residue implicated in neuropathogenicity, it may have a significant
effect on the activity of this enzyme. Furthermore, while both amino acids contain
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hydroxyl residues, the R group in serine is significantly smaller and more hydrophilic
than that in tyrosine, suggesting that this substitution would affect the folding of the palm
domain.  Interestingly, the RAC-H modified live vaccine strain of EHV-1, used
extensively in both Europe and the United States during the 1970s and 1980s, also
contains both A2254→G2254 and A2258→C2258 substitutions.220-222 Although this vaccine
has been implicated in several equine abortions, there have been no reports of neurologic
disease associated with its use.97 As suggested previously, the presence of serine rather
than tyrosine at amino acid position 753 in the viral polymerase might counteract the
neuropathogenic effects of an aspartic acid residue at position 752.97 This possibility will
be the focus of future investigations in this laboratory. Additionally, the design of the
allelic discrimination real-time PCR assay used in this study should be examined to
ascertain if the occurrence of false negatives can be reduced.
Publication: The findings of the thesis study discussed in this chapter were published
the following article: Kathryn L. Smith, George P. Allen, Adam J. Branscum, R. Frank
Cook, Mary L. Vickers, Peter J. Timoney and U. B. Balasuriya (2010); The increased
prevalence of neuropathogenic strains of EHV-1 in equine abortions, Veterinary
Microbiology, 141, 5-11.
Copyright© Kathryn Laura Smith 2013
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CHAPTER THREE
New Real-Time PCR Assay using Allelic Discrimination for Detection and
Differentiation of Equine Herpesvirus-1 Strains with A2254 and G2254 Polymorphisms
3.1 Introduction
Equine herpesvirus-1 (EHV-1) is a double-stranded DNA virus that infects the
vast majority of the world’s equine populations.12 Almost all domesticated horses are
repeatedly exposed to this virus and as a result may experience significant morbidity and
even mortality.60 Depending on host and/or viral factors, exposure to EHV-1 can result
in respiratory disease, abortion, neonatal deaths and neurologic disease (EHM).223,224 In a
high percentage of infected animals, EHV-1 establishes life-long latent infections in long-
lived cells including the neurons within the trigeminal ganglia and/or lymphocytes in
lympho-reticular tissues associated with the respiratory tract.12 Reactivation of latent
virus can lead to recrudescence of disease with associated viral shedding that may result
in transmission of EHV-1 to susceptible in-contact horses.12,224
Since 2000 there has been a disturbing increase in the number of EHM
outbreaks in Europe and North America.45,70,104,120,225,226 Within the United States alone,
the case-fatality rate associated with some of these neurological outbreaks has been
reported to be as high as 50%.45 Although it appears that all EHV-1 strains can induce
respiratory disease and abortion in pregnant mares, only certain strains (neuropathogenic)
have the potential to cause wide scale outbreaks of EHM.97,156 Within the past decade, a
single nucleotide polymorphism has been identified that appears to be associated with the
neuropathogenic or non-neuropathogenic phenotype of EHV-1.97,227 This potential
genetic marker is found within ORF30, encoding the viral DNA polymerase, and consists
of a single non-synonymous nucleotide (nt) A to G substitution at position 2254
(A→G2254), resulting in a change from neutral asparagine to negatively charged aspartic
acid at amino acid position 752 (N→D752).97,102,105 EHV-1 isolates with the A2254
genotype have been linked principally with non-neuropathogenic infections, while
viruses possessing the G2254 genotype are frequently but not invariably associated with
neurologic disease.84,105 The discovery of this single nt polymorphism in ORF30 led to
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the development of an allelic discrimination, real-time PCR (rPCR) assay for detection
and differentiation of potential neuropathogenic and non-neuropathogenic EHV-1
strains.106,116
The clinical signs of EHV-1 related respiratory disease can mimic those caused
by other equine viral respiratory pathogens such as EHV-4, equine influenza virus,
equine arteritis virus (EAV), equine rhinitis virus A, and equine adenovirus 1.132,133
Similarly, EHV-1 induced abortions and neurologic disease must be differentiated from
those caused by other infectious (EAV, EHV-4, West Nile virus and equine protozoal
myeloencephalitis) and non-infectious causes.133 When confronted with a disease
outbreak, confirmation of a provisional clinical diagnosis with a rapid, sensitive and
specific laboratory diagnostic test(s) is vital to ensure that appropriate biosecurity and
quarantine measures are implemented without unnecessary delay. Several reports have
documented the use of PCR-based assays, both standard and real-time, for the detection
of EHV-1 in clinical specimens.116,159,164,228-231 However, the allelic discrimination rPCR
assay described by Allen 106 has a distinct advantage because it can simultaneously detect
and genotype EHV-1 strains. This assay was originally validated using 234 clinical
samples (nasal swab and blood samples) and was found to have a specificity of 100%
along with a sensitivity of 96.3% for the detection of EHV-1 nucleic acids.106 Subsequent
evaluation of clinical samples using the original rPCR assay in several diagnostic
laboratories demonstrated this assay lacks adequate sensitivity for routine diagnostic
applications and is prone to generating false dual positive (A2254+G2254) results, seriously
compromising its usefulness for A2254/G2254 genotype differentiation. (U. B. R. Balasuriya
and K. L. Smith, unpublished data; S. Sells and B. Crossley, unpublished data)
Additionally, false negative results are produced in this assay by the presence of a single
additional nt substitution within ORF30, at position 2258.70 Although numerous studies
have examined the validity and efficiency of EHV-1 rPCR-based assays as diagnostic and
research tools, there remains an urgent need for an assay that will enable reliable
detection of EHV-1 coupled with simultaneous A/G2254 genotyping directly from clinical
material.109,230-234 Therefore, the primary objective of this study was to develop a new
allelic discrimination EHV-1 rPCR assay, compare its sensitivity and specificity with the
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assay described by Allen 106, and thereby determine which assay is the more reliable for
detection of EHV-1 nucleic acid in a diagnostic setting.
3.2 Materials and Methods
3.2.1 Cells
KyED cells were maintained as confluent monolayers in 150-cm2 culture flasks
using Eagle’s Minimal Essential Medium (EMEM; Invitrogen), supplemented with 10%
fetal bovine serum and gentamicin (50µg/ml; Invitrogen) as previously described.216 In
this study, the KyED cells were used between passages 9 and 12. A low passage rabbit
kidney-13 cell line (RK-13, passage level 194-204; ATCC CCL-37; American Type
Culture Collection, Manassas, VA, USA) was maintained in EMEM (Mediatech, Inc.,
Herndon, VA, USA), supplemented with 10% ferritin-supplemented bovine calf serum
(Hyclone Laboratories, Inc., Logan, UT, USA), 1% penicillin and streptomycin (10,000
IU/ml and 10,000 µg/ml; Mediatech) and 0.1% amphotericin B (1,000 μg/ml;Sigma-
Aldrich, St. Louis, MO, USA).
3.2.2 Archived viruses
Viral nucleic acids were extracted from archived, cell culture isolated EHV-1
and EHV-4 strains from the USA (1941-2006) and Europe (United Kingdom 1981,
France 2004-2006) that had been stored either as lyophilized or frozen (-70°C) TCF
stocks (n=76). Working virus stocks of EHV-1 strains from the USA and United
Kingdom were generated in confluent monolayers of KyED cells as previously described
70, and were confirmed as either EHV-1 (n=38) or EHV-4 (n=16) by DNA sequencing
(G. P. Allen, unpublished data). EHV-1 strains from France were isolated in RK-13 cells
and identified as EHV-1 (n=22) by sequencing ORF30 at the Gluck Equine Research
Center, Lexington, KY (Y. Li and U.B. R. Balasuriya, unpublished data).
3.2.3 Clinical samples
A total of 433 clinical specimens, comprising 260 nasal swabs and 173 buffy
coat samples, were included in this study. Of these, 168 were samples from EHV
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outbreaks or single cases of infection that occurred in Kentucky between 2001 and 2006.
These samples were initially identified as positive for EHV-1 or EHV-4 by nested PCR,
using reaction conditions and primers from a previously published study.235 In addition,
the genotype (A2254 or G2254) of each EHV-1 isolate was determined by sequencing
ORF30 (G. P. Allen, unpublished data). The remaining clinical samples (n=265) were
collected from outbreaks submitted between 2008 and 2011 to the University of
Kentucky Veterinary Diagnostic Laboratory (UKVDL) or to the Gluck Equine Research
Center (GERC) for routine diagnostic investigation.
3.2.4 Viral nucleic acid purification
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient
centrifugation over Ficoll-Plaque Plus (Amersham Biosciences, Piscataway, NJ) from
buffy coats of heparinized blood collected from horses.156 The PBMC layer was collected
and washed twice with PBS (pH 7.4) by centrifugation and the final cell pellet was
resuspended at 1x106 cells/ml in PBS (pH 7.4).  These cells were used for virus isolation
and DNA extraction.
DNA extraction from archived and clinical materials was performed using four
different methods. All purified archived viruses from the USA and United Kingdom
(1941-2006) were treated with Proteinase-K (20mg/ml in TE buffer containing 50%
glycerol (pH 8.0); Invitrogen) prior to deproteination with phenol/chloroform and DNA
extraction.216 For the 2001-2006 clinical specimens, a High Pure PCR template
preparation kit (Roche, Indianapolis, IN, USA) was used to extract DNA from nasal
swabs, while the Wizard® genomic DNA purification system (Promega, Madison, WI,
USA) was employed on all buffy coat samples. In both cases, nucleic acids were
extracted according to the manufacturer’s instructions and stored at -20°C.
In addition to the techniques outlined above, clinical materials collected
between 2008 and 2011, along with cell culture EHV-1 isolates from France (2004-
2006), were processed utilizing a KingFisher® 96 automatic nucleic acid extraction
machine (Thermo Fischer Scientific, Inc., Waltham, MA, USA) in conjunction with the
Mag MaxTM -96 Viral RNA Isolation Kit (Applied Biosystems). This nucleic acid
extraction kit is recommended for both DNA and RNA isolation from clinical specimens
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by the manufacturer.  Starting material for the automated extraction procedure consisted
of 50l of clarified supernatant (13,800 g for 2 min). The DNA was eluted in 50µl of
elution buffer, divided into 25µl aliquots, and stored at -20°C.
3.2.5 PCR amplification and sequencing of ORF30
ORF30 and the flanking sequences (forward primer: 5′-
GACATGGATATACCAACGGTTAGT-3′ (nt # 51,401-51,424) and reverse primer:
5′-TTTAAAGCTAAATCTAAACACGCCC-3′;(55,206-55,230) sequences are
numbered according to GenBank accession number AY464052; 3830 bp) of all
archived specimens and 168 of the clinical samples were amplified with EHV-1
specific primers using Phusion Hot Start DNA polymerase enzyme (New England
Biolabs, Ipswich, MA, USA). The 50µl PCR mixture for each reaction contained 10µl
of 5× Phusion HF buffer, 1µl of 10mM dNTP mix, 0.5µl of Phusion Hot Start DNA
polymerase enzyme, 34µl of RNase free water, 1.0µl of the forward primer, 1.0µl of the
reverse primer (final concentration of each primer: 400nM), and 2.5µl of the template
DNA. The PCR amplification was performed in an Eppendorf thermal cycler using the
following amplification parameters: 98°C for 30s, followed by 35 cycles at 98°C for
10s, 55.7ºC for 30s, and 72°C for 2min with a final extension of 72°C for 10min. The
PCR products were analyzed on a 1% agarose gel and purified using a QIAquick gel
extraction kit (Qiagen). Both sense and anti-sense strands were sequenced with the
PRISM Ready Reaction DyeDeoxy Terminator cycle sequencing kit (MWG Operon,
Huntsville, AL, USA). Sequence data were analyzed with CodonCode (Codon Code
Corp., Dedham, MA, USA) and VectorNTI software (Invitrogen). PCR products
exhibiting sequence ambiguities at position 2254 were cloned into a pDrive cloning
vector using a Qiagen PCR cloning kit (Qiagen), according to the manufacturer’s
instructions. A minimum of six molecular clones were sequenced from each PCR
amplicon using both sense and antisense primers specific for EHV-1 ORF30.
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3.2.6 Duplex rPCR assays, E1 and E2
A new set of EHV-1 ORF30 specific primers and probes were designed to the
conserved regions of ORF30 using the Primer Express® software v3.0 (Applied
Biosystems) (Table 3.1). The relative positions of the primers and probes within
ORF30 utilized in each assay are shown in Figure 3. For a 25µl reaction, 5µl of viral
DNA was combined with 20µl of master mix, composed of the following: 1.25µl of the
A2254 primer/probe mix (400nM of each primer and 200nM of the probe), 1.25µl of the
G2254 primer/probe mix (400nM of each primer and 175nM of the probe), 12.5µl of
QuantiTect Multiplex PCR Master Mix (Qiagen), and 5µl of nuclease-free water. Using
an ABI 7500 Fast Real-Time PCR System (Applied Biosystems), the following
thermocycling conditions were used with the Fast 7500 mode: initial denaturation at
95°C for 15min, followed by 40 cycles at 95°C for 15s and 58°C for 1min. The
previously published E2 allelic discrimination rPCR assay was performed as originally
reported with the exception that the cycle number was reduced from 55 to 40.106.
Each rPCR assay included a control without DNA (20µl of master mix plus 5µl
of nuclease free water), along with EHV-1 DNA samples containing known G2254 and
A2254 genotypes. Results were represented as a plot of PCR cycle number versus the
accumulated level of fluorescence (Rn) from each of the reporter probes. If the plot line
of a given test sample did not enter the exponential phase by cycle threshold (CT) 39,
the sample was considered negative. The specificity of both assays for EHV-1 was
confirmed by using nucleic acid extracted from TCFs containing either EHV-2, EHV-3,
EHV-4 or EHV-5.
3.2.7 Determination of the analytical sensitivity of E1 and E2
Viral DNA purified from serial 10-fold dilutions (10-1 -10-8) of TCF, containing
either EHV-1 A183 (G2254 neuropathogenic genotype
236) or T220 (A2254 non-
neuropathogenic genotype 156) strains, were used to ascertain the analytical sensitivity
of each rPCR assay. The TCF was clarified by microcentrifugation at 13,800 g for 2min
with 50µl of the resultant supernatant being used for DNA extraction, utilizing a Mag
Max™ -96 viral RNA Isolation Kit (Applied Biosystems) in conjunction with a Mag
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Max™ Express Particle Processor (Applied Biosystems), according to the
manufacturer’s instructions.
Viral DNA from each of the serial dilutions was eluted in 50µl of elution buffer
and 5µl tested in triplicate with the E1 and E2 assays.  This determination was repeated
independently two times on different days. The plaque number in the highest dilution
was used to calculate the number of infectious particles that can be detected by each
assay.
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Table 3.1 EHV-1 ORF30 specific primers/probe sets used in E1 and E2 allelic
discrimination rPCR assays.
Assay
Primer/Probe ID
(Sense)
Probe
Specificity
Nucleotide
Location
Sequence (5'-3')
E1
E1Fwd
(positive)
N/A 2,229-2,245 TCT GGC CGG GCT TCA AC
E1Rev
(negative)
N/A 2,276-2,294 TTT GGT CAC CCA CCT CGA A
E1PrA2254
(positive)
A2254 2,247-2,262
5HEX-ATC CGT CAA CTA CTC
G-BHQ2a
E1PrG2254
(positive)
G2254 2,247-2,262
6~FAM-ATC CGT CGA CTA
CTC G-BHQ1
E2
E2Fwd
(positive)
N/A 2,204-2,218 CCA CCC TGG CGC TCG
E2Rev
(negative)
N/A 2,328-2,348
AGC CAG TCG CGC AGC AAG
ATG
E2PrA2254
(positive)
A2254 2,246-2,261
VIC-CAT CCG TCA ACT ACT C-
MGB
E2PrG2254
(positive)
G2254 2,248-2,261
6-FAM-TCG GTC GAC TAC TC-
MGB
The allelic-discrimination, rPCR primers/probe sets for EHV-1 ORF30. The
nucleotide sequences are listed for the primers and probes, along with their positions
within the ORF30 gene. Nucleotide positions are based on GenBank accession
numbers AY464052 and AY665713.
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3.2.8 Statistical analysis
The samples that were verified by sequencing were used as a gold standard in
the calculations of sensitivity and specificity. Confidence intervals (CI) were
calculated using the Clopper-Pearson approach. All confidence intervals reported in this
study were at the 95% level. Hypothesis tests regarding equal sensitivity between
assays were conducted using Fisher's exact test.
3.3 Results
3.3.1 Development of E1 allelic discrimination rPCR assay
The new primer and probe sets (Figure 3.1) designed in this study were highly
specific for EHV-1 and did not cross-react with any of the other equine herpesviruses
(EHV-2, EHV-3, EHV-4 and EHV-5) under same assay conditions.  Two primers
(E1Fwd and E1Rev) designed to a highly conserved region of the ORF30 of EHV-1
yielded a significantly smaller PCR product (66bp) as compared to the PCR product
generated by the E2 assay (145bp). The new probes specific for the non-
neuropathogenic and neuropathogenic genotypes (E1 PrA2254 and E1 PrG2254,
respectively) are different from the probes described for the E2 assay, although there is
significant overlap since they are directed against the same region of ORF30 (Fig 3.1).
The E1 PCR assay was optimized using DNA extracted from TCF containing EHV-1
A183 and T220 with different primer and probe combinations tested over a range of
concentrations using QuantiTect Multiplex PCR Master Mix reagents (Qiagen) in a
series of checkerboard assays.  The optimal primer and probe concentrations producing
the highest specificity and sensitivity for detection and discrimination of A2254 and
G2254 genotypes were selected for the final assay described in the Material and Methods
sections.
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Figure 3.1 Positions of the E1 and E2 primers and probes. The relative positions of both
primer/probe sets within ORF30. The binding area of the E1 assay is smaller than E2’s
and the resulting amplicon is also considerably smaller.
3.3.2 Analytical sensitivities of E1 and E2
The analytical sensitivities of the E1 and E2 assays were determined using DNA
purified from 10-fold dilutions of TCF containing EHV-1 A183 (titer 1.5 x 105 pfu/mL)
and T220 (5 x 106 pfu/mL) strains. The two viruses were titrated in equine endothelial
cells and 50µl from each dilution was used for DNA extraction. Detection of A183
(G2254) and T220 (A2254) EHV-1 DNA was linear from 10
0–10-6 TCF dilutions with
intra- and inter-assay variability of less than 1%. The detection limit of the E2 assay
was 100 infectious virus particles (average CT = 37.87) for A183 and 10 infectious
virus particles (average CT = 38.10) for T220.  By comparison, the E1 assay was
capable of detecting 10 infectious virus particles of each strain (A183 CT = 38.42; T220
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CT = 36.71). The coefficients of determination (R
2) and amplification efficiencies ((10(-
1/slope) -1) X 100) were calculated for each data set. For A183, E1 yielded an
amplification efficiency of 90% and an R2 value of 0.9972. For E2, the amplification
efficiency was 70% and R2 was 0.9952. With the T220 dilutions, E1 produced an
amplification efficiency of 83% and R2 equaled 0.9926. The amplification efficiency
for E2, however, was only 68% with an R
2 value of 0.9965 (Figure 3.2 & 3.3).
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Figure 3.2 Regression analysis of the A183 serial dilutions with E1 & E2.
Regression analysis of the PCR data derived from the A183 serial dilutions. Average CT
values were determined for each dilution, which were then used to plot a linear trend-line.
The coefficients of determination (R2) and amplification efficiencies ((10(-1/slope) -1) x
100) were calculated for each data set.
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Figure  3.3 Regression analysis of the T220 serial dilutions with E1 & E2. Results of
the regression analysis of the PCR data produced by the T220 serial dilutions. rPCR
assays and the regression analysis were performed in an identical manner to those
used with the A183 dilutions.
3.3.3 Evaluation of E1 and E2 rPCR assays using archived TCF and clinical
samples
The performance of the two rPCR assays was compared initially using DNA
extracted from archived TCF (n=76), containing either EHV-1 or EHV-4 nucleic acid.
Of the fifty-four US/United Kingdom specimens, all EHV-1 positive samples were
detected in the E1 assay with no cross reactivity with EHV-4 samples (Table 3.2).
Furthermore, the E1 assay accurately distinguished between the A2254 (17/17) and G2254
(21/21) polymorphisms present in ORF30.  In contrast, the E2 assay failed to detect
viral nucleic acid in two of the EHV-1 positive samples.
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With the archived French TCF, E1 successfully detected all twenty-two EHV-1
strains, while E2 failed to detect one of these isolates (Table 3.2). Overall, the specificity
for both assays in terms of the archived cell isolated specimen group was 100% (CI:
79%-100%). E1 demonstrated a greater diagnostic sensitivity than E2 (E1=100%, CI:
94%-100%; E2= 95%, CI: 86%-99%), although the difference was not statistically
significant (p=0.49).
Secondly, we used viral DNA extracted from 168 EHV positive clinical samples
(2001-2006) that had been sequenced to determine the specificity and sensitivity of the
E1 and E2 assays. Previous direct sequencing of ORF30 demonstrated that of the 168
clinical samples, 125 were EHV-1 (60 (48%) A2254, 65 (52%) G2254) while the
remaining forty-three samples were EHV-4. Neither of the rPCR assays produced false
positive results in the presence of EHV-4 DNA (specificity 100%, CI: 92%-100%). The
E1 assay successfully detected 110 of the 125 EHV-1 positive clinical samples (54
A2254, 56 G2254) (88%; CI: 81%-93%). In contrast, the sensitivity of E2 was significantly
lower (p <0.001) with only seventy-two of the 125 EHV-1 samples identified correctly
(33 A2254, 39 G2254) (58%; CI: 48%-66%).  The genotype of all PCR positive samples
for both assays agreed perfectly with the direct sequencing results. The comparative
sensitivities of the two assays are displayed in Figure 3.4. In the case of both rPCR
assays, the overall sensitivity scores for the 168 sequenced clinical samples were
significantly reduced by the inclusion of 109 buffy coat samples.  These buffy coats
were shown to contain EHV-1 DNA via ultrasensitive, sequence capture nested PCR
assay.116 However, 94/109 of these samples were positive for EHV-1 DNA in the E1
assay, whereas only 56/109 gave positive reactions with E2.
The PCR results of all 433 clinical samples (2001-2006 (168 samples) and
2008-2011 (265 samples)) tested by both E1 and E2 are given in Table 3.2. Of these,
204 (43%) were identified as EHV-1 positive by the E1 assay, with 107 A2254 (58%)
and 94 G2254 (41%) genotypes. Interestingly, three samples (2%) tested positive for
both A2254 and G2254 genotypes (A2254+G2254 (dual genotype)) using the E1 assay (Fig
3.5). In contrast, the E2 assay identified only 144 (35%) of these samples as EHV-1:
seventy (53%) A2254, fifty-three (34%) G2254, and twenty-one (14%) as A2254+G2254 dual
positives. Only one (F55-R4, see below) of the twenty-one E2 dual positive samples
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gave the same results as the E1 assay. Comparison of the CT values of the sequenced
clinical samples and the archived viral specimens are given in Table 3.3.
Figure 3.4 Sensitivity of E1 & E2 to EHV-1. The sensitivities of both rPCR assays (E1
and E2) using the clinical and archived samples. Also shown are their overall and allele-
specific sensitivities. The lines indicate 95% confidence intervals, and the dots point
estimates. The displayed p values test the hypothesis that E1 and E2 have equal sensitivity
for a given sample.
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Figure 3.5 Amplification plot for F35-R3. An example of a dual positive produced by E1.
The graph lines with slight arches are the reaction results for F35-R3 and the graph lines
which remain in the baseline phase are water controls. The CT values for this specimen
were A2254 =38.75 and G2254= 36.99.
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Table 3.3 CT values and genotypes of select EHV archived strains and clinical specimens.
rPCR results for both assays along with the sequencing data for a select number of
archived and clinical samples. *Indicates a false negative generated by the E2 assay. This
select sample set demonstrates the improved efficiency of E1 compared to E2, as well as
E1’s overall accuracy in identifying viral genotype.
3.3.4 Sequence confirmation of dual ORF30 genotypes and resolution of
discrepancies between the E1 and E2 assays
Direct sequence analysis of the PCR products from three clinical samples (F14-
R2, F35-R3, F55-R4) that were positive for both genotypes in the E1 assay
demonstrated sequence ambiguity at nt 2254, consistent with the presence of both virus
genotypes. This finding was further confirmed by sequencing individual molecular
clones derived from the PCR products (Table 3.4). Interestingly, molecular clones from
all three samples showed another variable site at nt 2258 within the probe binding
region of ORF30.  Of the three E1 dual positive samples, only one sample (F55-R4)
Specimen E1: Genotype, CT E2: Genotype, CT
Sequencing
Data
Archived
A2 G2254: 28.90 G2254: 31.06 G2254
A9 A2254: 24.02 A2254: 25.30 A2254
A32 A2254: 18.34 A2254: 24.57 A2254
Clinical
X1 A2254: 36.99 Negative* A2254
X15 G2254: 35.80 G2254: 38.06 G2254
X38 G2254: 31.73 G2254: 34.31 G2254
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produced similar results in the E2 assay. Additional direct sequencing of ORF30 PCR
products from a limited number of samples that gave dual positive results in the E2
assay failed to identify any ambiguities in the probe binding region.
Table 3.4 Sequence results for the molecular clones of EHV-1 strains.
The results of sequencing ORF30 nt 2254 and 2258 of the molecular clones generated
from the dual positive 2010 samples.
3.4 Discussion
The results from this study demonstrate the newly developed E1 assay provides
at least a 10-fold higher sensitivity compared to the E2 assay and, therefore, is more
appropriate for the detection of EHV-1 viral nucleic acid in clinical specimens. This
increased sensitivity probably results from the fact the E1 assay involves a shorter
amplicon length compared to E2, leading to increased efficiency and/or less
susceptibility to secondary DNA structural effects (Fig 3.1).
During these experiments, both rPCR assays were evaluated using a range of
sample types and nucleic acid extraction techniques. The archived samples from the
USA and United Kingdom were isolated in cell-culture prior to nucleic acid extraction
Sample Number of Clones
ORF30 nt 2254
Sequence
ORF30 nt 2258
Sequence
F14-R2 7 5 G/2 A 5 C/2 A
F35-R3 6 5 G/1 A 3 C/3 A
F55-R4 17 16 G/1 A 14 C/3 T
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with phenol/chloroform to remove protein contaminants. As these viruses were
amplified by propagation in mammalian cells they are predicted to contain greater
quantities of viral DNA than that found in nasal swabs or blood samples. Therefore, it
is not surprising that while a slightly higher number of EHV-1 positive reactions were
observed in the E1 assay (100%) compared to E2 (95%), these did not result in
statistically significant differences between the two tests.  Although both rPCR tests
performed well using archived TCF samples, EHV-1 isolation in cell-culture is time-
consuming and may only be possible for relatively short periods following exposure.12
For example, it has been demonstrated that certain strains of virus can only be isolated
from nasal swabs up to five days post infection as compared to rPCR, which can detect
viral nucleic acid in nasal swabs up to twenty-one days or more.103 While important for
viral characterization and molecular epidemiological studies, virus isolation is not
suited for the often urgent need for rapid diagnosis of EHV-1 infections. To meet this
requirement during EHM and/or EHV abortion outbreaks, diagnostic assays must be
capable of rapidly detecting EHV-1 nucleic acid directly from clinical specimens.
The data presented in this study suggest that E2, with an overall success rate of
just 58% when tested using nasal swab or buffy coat samples, is ill-suited for the
routine diagnosis of EHV-1 infections. Alternatively, the E1 assay is significantly more
sensitive (88%), although it too was unable to detect EHV-1 in fifteen whole blood
samples shown to contain EHV-1 DNA by a magnetic bead-based, sequence capture,
nested PCR methodology described by Allen et al.116 This technique was specifically
designed to detect EHV-1 DNA that is in low abundance in lymph nodes and buffy coat
cells during clinically quiescent periods, and relies upon oligonucleotide hybridization
coupled with biotin-streptavidin magnetic-bead capture technology. As a result, this
very powerful technology has a detection threshold limit well above conventional
nested PCR and rPCR.116 Therefore, it is possible the E1 assay was unable to detect
EHV-1 DNA in the fifteen buffy coat samples simply because of the low copy number
present, which is not too surprising considering that the amount of virus present in the
blood is highly dependent on what stage of infection the virus is in when the sample is
taken (e.g. latent or cell associated viremia).12 Alternatively, blood is known to contain
inhibitors including heme, lactoferrin and immunoglobulins that when combined with
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low nucleic acid copy numbers can prevent detection by PCR-based methods.
Furthermore, recent studies have demonstrated that at least some PCR inhibitors
present in whole blood are not completely removed by common nucleic extraction
techniques including the Mag Max™ -96 viral RNA Isolation Kit.237 Studies are
underway to determine if, as shown by Das et al. 237, improvements in detection of low-
levels of EHV-1 DNA in blood can be achieved by modification of the Mag Max™ -96
viral RNA isolation protocol by including additional high salt washes.
The detection of both A2254 and G2254 genotypes in the same clinical specimen
confirms previous findings and raises many questions about the impact that at least two
simultaneously replicating virus strains can have on viral pathogenesis, latency and
reactivation.230 While the ability to identify multiple genotypes within clinical samples
represents a significant step in our understanding of the dynamics associated with in
vivo EHV-1 replication events, dual false positive results are very detrimental in any
diagnostic situation.  Clearly, the E1 assay, with no evidence of false dual positive
results coupled with the accurate detection of actual A2254+G2254 infections, performed
significantly better than the E2 assay where there were twenty false dual positive results
among the samples tested (Table 3.2). This result confirms observations by
diagnosticians in the field.  However, the false dual positive results generated by E2
only occurred with clinical samples processed using the Mag MaxTM -96 viral RNA
isolation kit, suggesting a possible correlation between these aberrant reactions and the
method employed for nucleic acid extraction.  Although further studies are required to
confirm this observation, it should be noted the accuracy of ORF30 genotyping in the
E1 assay was completely independent of the sample preparation technique.
Overall, this study has demonstrated that E1 is significantly more sensitive than
E2 for the detection of EHV-1 in clinical samples. Furthermore, it produced fewer false
dual positives, regardless of the DNA extraction procedure employed and, as such, is
better suited than E2 for use in a routine diagnostic setting.  In such an environment, an
allelic discrimination rPCR assay directed against ORF30 has the advantage over rPCR
assays targeting other EHV-1 genes (e.g. gB and gD genes;156,159,230,232,238) because it
can both detect and discriminate between the A2254 and G2254 genotypes present in
clinical samples.  Although recent studies have suggested that possession of G2254 is not
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always associated with a neuropathogenic phenotype,104 additional data from field cases
of EHM is required before this issue can be fully clarified. The widespread use of a
more sensitive and more specific ORF30-based allelic discrimination assay, coupled
with thoroughly documented clinical histories, will play an important role in generating
this essential information. However, regardless of the genotype detected, stringent
quarantine and biosecurity practices should be implemented immediately to curtail the
spread of EHV-1.
Publication: The findings reported in this chapter have been published in the following
article: Kathryn L. Smith, Yanqiu Li, Patrick Breheny, R. Frank Cook, Pamela J.
Henney, Stephen Sells, Stéphane Pronost, Zhengchun Lu, Beate M. Crossley, Peter J.
Timoney, and Udeni B. R. Balasuriya (2012); New Real-Time PCR Assay using Allelic
Discrimination for Detection and Differentiation of Equine Herpesvirus-1 Strains with
A2254 and G2254 Polymorphisms, Journal of Clinical Microbiology, 50 (6), 1981-1988.
Note added in proof: The 1974D and 1974E isolates were both tested with E1 to
determine if the new assay would yield different results than the E2 assay (E2 failed to
detect either sample). As can be seen in Figure 3.6, E1 successfully detected both
isolates as G2254 positive samples, producing a CT value of 27.67 with 1974D (T186)
and 27.29 with 1974E (T188).
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Figure 3.6 Amplification plots for 1974D and 1974E. The 1974 isolates were tested with
both E1 and E2. Both isolates still tested negative with the E2 assay. However, E1
successfully detected both isolates as G2254 positive samples, producing a CT value of
27.67 with 1974D and 27.29 with 1974E.
Copyright© Kathryn Laura Smith 2013
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CHAPTER FOUR
Characterization of Responses of Four Mouse Strains to EHV-1 Neuropathogenic
Strain T953
4.1 Introduction
Experimental infection studies with EHV-1 typically use horses as test
subjects since equines are the virus’s natural host. However, there are limitations to
using horses as they are expensive to acquire and maintain. Mice provide an attractive
alternative since they require less space, food and water than their larger equine
counterparts. Mice were first utilized in EHV-1 experimental infection studies by
Hatziolos and Reagan (1960) and Plummer et al. (1973), both of which demonstrated
neurovirulence of the virus in mice.239,240 Awan et al.’s 1990 study described the
replication of EHV-1 neuropathogenic strain Ab4 in the nasal mucosa, trachea, and
lungs of mice, along with the detection of EHV-1 viremia in murine blood.241 Inazu et
al. confirmed these findings in 1993, along with observing the occurrence of ruffled
fur, hunched posture and weight loss after inoculation with EHV-1.242 In 2004,
Frampton et al. revealed intranasal inoculation of CBA mice with neuropathogenic
EHV-1 produced meningoencephalitis with lymphocytic cuffing of small blood
vessels in the brain.243 Furthermore, Mori et al.’s 2012 study observed the same
clinical signs as the Inazu et al. 1993 study, along with the occurrence of recumbency,
ocular and nasal discharges.244 The results of the Mori et al. study also indicated mice
were a viable option for comparing the virulence between neuropathogenic EHV-1
strains.244
These studies support the validity of using mice as an experimental host for
EHV-1. However, concerns have been raised about variations in the cellular tropism
of the virus in mice versus the horse and the impact such differences could have on
the feasibility of mice using for studying neuropathogenic EHV-1. Patel and Edington
in their 1983 study observed EHV-1 infected mice developed meningoencephalitis,
but the mice lacked vasculitis, thrombosis, and infection of the endothelial cells
associated with the central nervous system (CNS), lesions which are characteristic
with EHM in horses. 245 Hasebe et al.’s 2002 study also revealed a lack of vasculitis
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and endotheliotropism in the CNS of EHV-1 infected mice.246 In 2009, Gosztonyi et
al. conducted a study which demonstrated that EHV-1 does impact the CNS and lungs
in mice, but again variations were reported between the lesions in the mice and in
horses. The Ab4 strain of EHV-1 had a dual affinity in mice: exhibiting neurotropism
in the CNS, which does not occur in horses, and endotheliotropism in the lungs, which
was more severe than the viral induced effects in horses.247
Additionally, the severity and onset of clinical signs varies depending on the
strain of the inoculating virus. Certain strains, such as Ab4 and A4/72, produce more
severe signs (limb paralysis, recumbency) even death in mice as demonstrated by a
number of research groups.244,247-250 Moreover, Azmi and Field’s 1993 study and
Smith et al.’s 1998 study concluded the virus dosage level also impacted the intensity
of clinical signs in mice.251,252
In light of the findings of these previous studies, this dissertation research
project investigated four different mouse strains to determine which one might be the
most susceptible to infection with EHV-1 neuropathogenic strain T953. The Ab4
strain has previously been used to study the neurovirulence of EHV-1 in mice.244, 247
As a result, the Ab4 strain was selected as the positive control.211 Two strains of
EHV-1, both of which were readily available from the Gluck Equine Research
Center’s stock, were considered for possible vaccine development: T953, which is
neuropathogenic, and T262, which is non-neuropathogenic. T953 was selected
because an attenuated virus derived from this neuropathogenic strain is a more likely
candidate for an EHM vaccine. In this pilot study, four mouse strains were inoculated
with T953: CBA/CaJ, C57BL/6, B6.129S7-Interferon Gamma Knockout, and
BALB/c. Each group of mice was weighed and monitored for clinical signs for a
period of fourteen to thirty-three days. At the end of the observational period, the
mice were euthanized, their tissues collected and analyzed by virus isolation (VI) and
real-time PCR (rPCR) for the detection of virus or virus nucleic acid, respectively.
The tissues were also subjected to histopathological examination.
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4.2 Materials and Methods
4.2.1 Mice Strains
Four different strains of mice were acquired for experimental inoculation with
T953: CBA/CaJ, C57BL/6, B6.129S7-Interferon Gamma Knockout, and BALB/c. The
CBA/CaJ and C57BL/6 are both inbred strains known for their longevity, resistance to
tumors and robust body condition.253,254 B6.129S7-Interferon Gamma Knockout strain,
derived from C57BL/6, is engineered to have reduced expression of MHC II and
interferon gamma production.255 BALB/c is an in-bred strain developed in 1913, known
for its longevity and is used primarily in infectious disease studies.256
Forty-two young adult female CBA/CaJ mice, three weeks of age upon arrival,
were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). Their initial
weight ranged from 8g to 11g. The C57BL/6 mice, acquired from the Division of
Laboratory Animal Resources (DLAR), University of Kentucky, consisted of six adult
female mice. These animals were four weeks old upon arrival and their starting weight
was either 16g or 17g. DLAR also provided twelve adult male B6.129S7-Interferon
Gamma Knockout (B6Intf-γKnO) mice, aged twelve weeks upon arrival. The initial
weight of these mice ranged between 26g and 34g. Seven female BALB/c mice were
obtained from Charles River Laboratories International (Wilmington, MA, USA).The
animals were three weeks old upon arrival and weighed between 8g to 16g.
4.2.2 EHV-1 Strains
The viral stocks of EHV-1 T953 and Ab4 were archived at the Gluck Equine
Research Center at the University of Kentucky. These were stored as frozen tissue
culture fluid (TCF) stocks at -70°C. The first of these, T953, is a neuropathogenic strain
of EHV-1 isolated from a nasopharyngeal swab during an EHV-1 outbreak at the
University of Findlay’s English riding center in January 2003.107 This strain was
originally named “Findlay strain” of EHV-1. Ab4, also a neuropathogenic EHV-1
strain, was isolated in England in 1980 from a mare exhibiting signs of paresis.67,257
Each virus was propagated in 75cm2 flasks to generate viral stocks for inoculation of
each of the mouse strains. The Ab4 strain was used as a positive control since its
pathogenesis and outcome in mice are well documented.211,247,248
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4.2.3 Cells
A low passage RK-13 cell line (passage level 194-204; ATCC CCL-37;
American Type Culture Collection) was maintained in EMEM (Mediatech) with 10%
ferritin-supplemented bovine calf serum (Hyclone), 1% penicillin and streptomycin
(10,000 IU/ml and 10,000 µg/ml; Mediatech) and 0.1% amphotericin B (1,000
μg/ml;Sigma-Aldrich). Equine endothelial cells (EEC; passage level 12-20) were
maintained as confluent monolayers in 150-cm2 and 75-cm2 culture flasks using
Dulbecco’s Modified Eagle’s Essential Medium (DMEM; Gibco, Grand Island, NY,
USA), supplemented with 10% fetal bovine serum, penicillin (100 U/mL; Gibco), and
streptomycin (100 ug/mL; Gibco). L-glutamine (200nM; Gibco) and 0.1 mM
nonessential amino acids (10mM (100x); Gibco) were also added to the medium.258
4.2.4 EHV-1 gB Plasmid
A 349 bp region of ORF33 (nt # 61,666-62,015) from the T953 strain of EHV-1
was PCR amplified and cloned into a pDrive cloning vector using the Qiagen PCR
cloning kit (Qiagen, Valencia, CA), as per the manufacturer’s instructions. The
authenticity of the cloned insert was confirmed by sequencing both strands of DNA and
designated as T953gB61666. This plasmid was used to transform 100µl of DH5α cells.
A large stock of plasmid was generated using multiple DNA miniprep columns
(QIAprep spin miniprep kit (Qiagen)) according to manufacturer’s instructions. The
plasmid was linearized with XbaI, and the DNA was purified with a QIAquick PCR
purification kit (Qiagen). The final linearized plasmid was re-suspended in 120µl of
nuclease free water and the final concentration determined with a NanoDrop ND 1000
(Thermo Fischer Scientific Inc., Waltham, MA), which was 81.91 ng/µl.
4.2.5 Experimental Inoculation and Observation of Mice
Upon arrival, each group of mice was individually weighed and observed twice
a day prior to inoculation. Food and water were freely available to the mice throughout
each experiment. The average pre-inoculation weight for each group was used to
calculate the correct dosage of Ketamine (100mg/ml) and Xylazine (100mg/ml) to
anesthetize each mouse. To prepare a 2.75ml anesthesia mixture, 2.5ml of Ketamine
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was added to 0.25 ml of Xylazine, for a final concentration of 90mg/ml Ketamine and
9mg/ml of Xylazine. An anesthesia dilution (1:3) was then prepared by combining the
appropriate amounts of anesthesia mixture with PBS (pH 7.4; Gibco). The exact
amounts used to anesthetize the mice are in Table 4.1. Anesthesia was administered via
peritoneal injection. Inoculation of EHV-1 was performed intranasally with 10µl of
TCF containing the virus, or pathogen-free MEM, administered into each nostril. Table
4.2 contains the EHV-1 strain and amount of virus given.
Following inoculation, the mice were weighed and observed twice a day
(morning and evening) until the conclusion of the observation period. The CBA/CaJ
mice were observed for thirty days, C57BL/6 mice for fourteen days, the B6Intf-γKnO
mice for thirty-three days, and the BALB/c mice for fourteen days. The mice were
observed for the development of clinical signs (weight loss, ruffled coat, depression,
nasal discharge, lethargy, arching of the back and neurologic signs including
hypersensitivity, circling, limb paddling and paralysis) twice daily. Table 4.3 displays
the scoring system assigned to record severity of clinical signs. Signs of extreme pain,
total paralysis, or any animals receiving a clinical score of 5 were immediately
euthanized.
Table 4.1 Preparation of anesthesia solution.
The average weights of each mouse strain used to accurately calculate the amount of the
Ketamine/Xylazine mixture and the amount of PBS as a dilute in preparing an
anesthesia dilution (100µl final volume) for viral inoculation. The fifth column
indicates the amount of anesthesia administered to each mouse strain.
Mouse Strain Average Weight (g)
Ketamine
/Xylazine
PBS Anesthesia
CBA/CaJ 16.4 27µl 73µl 300µl
C57BL/6 16.8 27.72µl 72.28µl 300µl
B6Intf-γKnO 28.7 47.36µl 52.64 µl 500µl
BALB/c 14.1 23µl 77µl 200µl
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4.2.6 Euthanasia and Tissue Collection of Mice
At the end of the observation period, all mice were weighed prior to euthanasia.
For euthanasia of the mice, a single cage (containing one to three mice) was placed in a
CO2 chamber and firmly sealed. The gas was introduced into the chamber at a rate of
1.5L/min for five to ten minutes. The exposure time to the CO2 was increased or
decreased based on the weight of the animals. After the confirmation of the cessation of
respiration, a thoracotomy was performed on each mouse to complete euthanasia.
Dissection of each mouse involved the removal of the lungs, spleen and brain,
which were then divided for both tissue homogenization and histopathological
examination. The remaining organs were preserved in buffered formalin for
histopathologic examination. Tissue homogenization was performed using a Power Gen
125 Homogenizer with sterile tips (Fisher Scientific, Waltham, MA, USA) and 500µl
of MEM. The lung, spleen, and brain were each homogenized for 2-3min at 8,000-
9,000rpm. The resulting tissue homogenate was aliquoted into ten, 1ml microtubes,
50µl per tube, and stored at -80ºC.
4.2.7 Extraction of Viral Nucleic Acid
A KingFisher® 96 automatic nucleic acid extraction machine (Thermo Fischer
Scientific) with the Mag MaxTM -96 Viral RNA Isolation Kit (Applied Biosystems) was
used to extract DNA from 50l of each homogenized tissue suspension, according to
the manufacturer’s instructions. The resulting DNA was eluted in 50µl of elution buffer
and stored at -20°C.
4.2.8 gB Plasmid Dilutions
The molecular weight of the T953gB61666 plasmid was calculated and used to
compute the copy number in accordance with the following equation259,260:
Avogadro’s number × Plasmid concentration (g/µl)
Molecular weight of Plasmid (g/mol)
The T953gB61666 plasmid copy number in the stock solution was 1.90x108 mol./µl.
Serial 10-fold dilutions of the plasmid were prepared for the generation of a standard
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curve for absolute quantification of viral DNA copy number in a gB rPCR assay. Table
4.3 lists the number of molecules present in the working stock and in each of the
dilutions.
Table 4.2 EHV-1 inoculation of mice.
Mice Strain Mouse Id EHV-1 Strain Dosage*
M1-M6 Control 20ul of MEM
M7-M12 T953 20ul of 5x100
M13-M18 T953 20ul of 5x101
CBA/CaJ M19-M24 T953 20ul of 5x102
M25-M30 T953 20ul of 5x103
M31-M36 T953 20ul of 5x104
M37-M42 T953 20ul of 5x105
C57BL/6
M43-M45 Ab4 20ul of 5x105
M46-M48 T953 20ul of 5x105
B6Intf-γKnO
M49-M54 T953 20ul of 5x105
M55-M60 Ab4 20ul of 5x105
BALB/c M61-M67 T953 30ul of 1.8x108
The EHV-1 strains and dosages administered intranasally to the four groups of mice.
Both of the EHV-1 strains used were neuropathogenic, based on case history and
genotype (G2254). *Pfu per mouse.
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Table 4.3 Clinical scoring system for mice.
Clinical Score Clinical signs
0 Normal behavior
1 No weight loss, ruffled coat, less active, altered breathing
2
Mild weight loss (less than or equal to .5g within 24hrs),
ruffled coat, lethargic, labored breathing
3
Moderate weight loss (.5 – 1g within 24hrs), ruffled coat,
depression, nasal discharge, lethargy, arching of the back,
labored breathing
4
Rapid weight loss (greater than or equal to 1.5g within
24hrs), ruffled coat, depression, nasal discharge, lethargy,
arching of the back, labored breathing
5
Rapid weight loss (greater than or equal to 1.5g within
24hrs), ruffled coat, depression, nasal discharge, lethargy,
arching of the back and neurologic signs- limb paddling,
recumbent, loss of muscle control on one or both sides of
the body, dragging of the hind quarters and/or paralysis.
Animals in this category will be terminated due to severe
clinical signs.
The scoring system used during the observation period of all three groups of mice. Any
animals receiving a score of 5 were euthanized immediately to prevent any further
suffering of the animal in question.
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Table 4.4 T953gB61666 plasmid working stock and serial dilutions.
Stock/Dilution Number of Molecules
Original 1.90 x1010
Working 1.90 x109
Dilution #1 1.90 x108
Dilution #2 1.90 x107
Dilution #3 1.90 x106
Dilution #4 1.90 x105
Dilution #5 1.90 x104
Dilution #6 1.90 x103
Dilution #7 1.90 x102
Dilution #8 1.90 x101
Dilution #9 1.90 x100
The number of DNA molecules present in both the stock and dilutions used in
generating a standard curve for the gB rPCR assay.
4.2.9 Absolute Quantification Real-Time PCR
A gB rPCR assay, developed by Pusterla et al., was employed to quantify the
amount of EHV-1 DNA present in the various mice tissues.109 The primers and probe
are specific for EHV-1’s gB gene (ORF33; GenBank accession number NC_001491).
Table 4.4 lists their position and sequences. For a 12µl reaction, 1µl of DNA was
combined with 11µl of master mix, composed of the following: 0.044µl forward primer
(400nM), 0.044µl reverse primer (400nM), 0.01 gB TaqMan probe (80nM), 8.25µl of
Universal TaqMan Mastermix with no AmpErase UNG (Applied Biosystems), and
2.66µl of nuclease-free water. Using an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems), the following thermocycling conditions were used with the 9600
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emulation mode: 2min at 50ºC, 15min at 95°C, followed by 40 cycles at 95°C for 15s
and 60°C for 1min.109
Each rPCR plate for the gB assay included four controls without DNA (11µl of
master mix plus 1µl of nuclease free water), along with two EHV-1 DNA samples
(positive controls) and two EHV-5 samples (negative controls). Additionally, nine
wells were designated for the EHV-1 gB plasmid dilutions (#1-9), which established a
standard curve for determining the amount of EHV-1 DNA present in each test sample.
All test samples were run in duplicate wells. Results were represented as a plot of PCR
cycle number versus the accumulated level of fluorescence (Rn) from the reporter
probe.
Table 4.5 EHV-1 gB rPCR primers and probe.109
Primer/ Probe Sequence (5' to 3')
Nucleotide
Position
Amplification primers
Forward TATACTCGCTGAGGATGGAGACTTT
61,818-
61,842
Reverse TTGGGGCAAGTTCTAGGTGGTT
61,886-
61,907
Taq-Man® probe
EHV-1 gB
6-FAM-ACACCTGCCCACCGCCTACCG-MGB†-
NFQ‡
61,844-
61,864
The nucleotide sequences are listed for each primer/probe along with their positions
within the ORF33 gene. MGB† designates the minor groove binder and NFQ‡
designates the nonfluorescent quencher.
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4.2.10 Virus Isolation
Confluent monolayers of RK-13 cells were established in 6-well cell culture
plates. Serial dilutions (10-1-10-3) were prepared of each EHV-1 positive mouse tissue
homogenate by diluting 200µl of the selected tissue with 1800µl of MEM. Two wells
were assigned for each dilution and inoculated with 400µl of the designated dilution.
The plates were incubated for 1hr at 37ºC, swirling the inoculum every 15min. The
cells were then overlaid with 5ml of complete cell culture medium containing 0.75%
carboxymethylcellulose (CMC) (Sigma-Aldrich, St. Louis, MO). Both cultures were
incubated for four days at 37ºC. If plaques were seen in culture or if 100% CPE was
achieved, then the supernatant from the 10-1 wells would be pooled and divided
between five 2ml microtubes (1.5ml per tube) and stored at -70°C. The presence of
EHV-1 DNA was confirmed with rPCR. The plates were then stained with 1ml of 1%
crystal violet containing 1% formaldehyde. If the cultures exhibited no evidence of
infection after four days, then a second blind passage was performed.
For the second passage, two wells were selected for each 10-1 supernatant
aliquot for each cell line and 500µl of the supernatant used to inoculate the designated
wells. Two milliliters of the EMEM/CMC was then added to the plates, which were
incubated at 37ºC for four days. If the cultures were infected, then the supernatant was
pooled for rPCR analysis and the plates stained with 1% crystal violet. If the cultures
remained unchanged following incubation, then the supernatant was subjected to a third
blind passage. If CPE was not present in the third passage, the supernatant was pooled
and then used for a fourth blind passage.
4.3 Results
4.3.1 Experimental Inoculation of CBA/CaJ Mice with T953 Strain of EHV-1
The CBA/CaJ mice were monitored for nine days prior to inoculation with
EHV-1. The mice were divided into six inoculation groups (each group received 10-
serial dilutions of virus 5x100 to 5x105pfu/mouse) and one control group, six animals
per group. The final average pre-inoculation weight for each group ranged from 15g
to 17g. The mice were inoculated on the tenth day following arrival, and were
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observed for thirty days. All animals, including the control mice, were lethargic for
the first three days post-inoculation (DPI) due to the side-effects of the anesthetic
drugs. The observed weight for the control group during this three day period
increased by 0.5g (Table 4.6). For the infected mice, their weight increased by 0.5g or
remained unchanged by 3DPI. By day 30DPI, the average weight for the control mice
was 3.5g higher than their pre-inoculation weight. The EHV-1 infected mice exhibited
a similar pattern in terms of weight gain (Table 4.6). Blood was collected from all
mice on day 11DPI and two mice (M22 & M41) died from shock during the
procedure. None of the infected mice, regardless of dosage received, exhibited signs
of respiratory distress or paralysis during the thirty day observation period.
Examination of the tissues from the mice at the time of necropsy revealed no
abnormalities. Histopathological examination of the tissues revealed no significant
lesions. In regards to the rPCR results, specimens (brain, lung, and spleen) from the
control cages were all negative for EHV-1 DNA, as well as the tissues collected from
the two mice (M22 & M41) that died on day 11DPI. A total of forty-one specimens
tested positive for EHV-1 in the gB rPCR assay. The DNA quantities for the rPCR
positive specimens are presented in Figures 4.1 and 4.2. The concentrations of EHV-1
DNA were low even with the mice which received the highest dosages of the virus
(5x104 and 5x105). However, viral DNA was detected in the tissues from all six
inoculation groups. The VI results for the rPCR positive specimens, along with the
brain tissues from the remaining mice, were all negative. Figure 4.3 presents the
results of passage 4 of the brain tissues in RK-13 cell culture.
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Table 4.6 Body weight changes of the CBA/CaJ mice.
Dose
Initial
Weight
(g) Days Post Inoculation
Final
Weight
(g)
2 4 6 8 10 12 14 20 24 28
5x105 15 0 0 +1 0 +1 -.5 -.5 +1 0 +1 18
5x100 17 +.5 +.5 0 0 -.5 +.5 +.5 +1.5 0 0 20
Control 17 -.5 +.5 0 +.5 +.5 -.5 +.5 0 +.5 +2 20.5
The initial and final weights, along with the changes in body weight, are the averages for
each group.
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Figure 4.1 Quantity of EHV-1 DNA in the brain, lung, and spleen tissues of the
CBA/CaJ mice. The molecules/µl of DNA present in the EHV-1 positive specimens. The
mouse id and tissue type are given along the X-axis. The dosage for each mouse was as
follows: M7 5x100, M14 and M18 5x101; M20, M23 and M24 5x102; M25 and M29
5x103; M31 and M32 5x104.
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Figure 4.2 Quantity of EHV-1 DNA in the brain, lung, and spleen tissues of the
CBA/CaJ mice continued. The mouse identification and tissue type are given along the
X-axis. M33-M36 all received 5x104 pfu/ml of T953. M37-M40 and M42 were
inoculated with 5x105 pfu/ml of T953.
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Figure 4.3 Attempted virus isolation in RK-13 cells of homogenized CBA/CaJ mouse
brain tissue. This was passage 4 and the cell cultures did not exhibit any cytopathic
effect.
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4.3.2 Experimental Inoculation of C57BL/6 Mice with T953 and Ab4
Neuropathogenic Strains of EHV-1
The C57BL/6 mice were observed for two days prior to virus inoculation. The
weight of each mouse prior to inoculation was 16g or 17g. M43-M46 were inoculated
with 5x105 pfu/ml of EHV-1 strain Ab4 and M47-M48 with 5x105 pfu/ml of T953. One
mouse, M43, died during inoculation and its tissues became part of the control group.
The remaining mice were observed for fourteen days and euthanized on day 15DPI.
The behavior of both groups of mice was normal for the first four days following
inoculation, although their weight decreased by 1.5g within the same time period
(Table 4.7). On day 4DPI, their weight increased by 1g, which continued or stabilized
over the remaining ten days (Table 4.7). The final weight of the Ab4 infected mice was
18g and for the T953 infected mice, 17g.
Upon dissection, the tissues of all the mice appeared normal. Histopathological
examination of the lung tissues revealed edema in M43 (died during inoculation). Mild
multifocal lymphocytic meningoencephalitis was observed in the brain tissue of M44
(infected with Ab4) and M46 (infected with T953). No significant lesions occurred in
the remaining three mice (Table 4.8). The brain, lung, and spleen tissues of all six mice
underwent rPCR analysis. Figure 4.4 presents the DNA quantities of all PCR positive
specimens. The highest level of DNA reported in the gB assay was with the lung tissue
from M43 (Ab4) and the lowest level was reported with M47’s (T953) lung tissue.
Virus was not isolated from the rPCR positive specimens following the first
attempt of VI in RK-13 cells. However, on passage 2 100% CPE was observed in the
wells infected with M43 lung tissue P1 TCF (Figure 4.5). PCR analysis of the RK-13
supernatant produced a CT value of 15.10 and the quantity of DNA was 5.03 x
108molecules/µl. Cell culture passage (passages 3 and 4) of the brain tissues of all
remaining mice from both the T953 and Ab4 inoculation groups in RK-13 cultures
were negative.
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Table 4.7 Body weight changes of the C57BL/6 mice.
Viruses
Initial
Weight (g) Days Post Inoculation Final Weight
2 4 6 8 10 12 14
Ab4 17 -1.5 +1 +1 0 0 0 +0.5 18
T953 16.5 -1.5 +1 +0.5 0 +0.5 0 0 17
The initial and final weights, along with the changes in body weight, are the averages for
each group.
Table 4.8 Lesions observed in the C57BL/6 mice.
Mouse ID Brain Lung Heart
Ab4 M43 - +:Edema -
M44 ++: Meningoencephalitis - -
M45 - - -
T953 M46 ++: Meningoencephalitis - -
M47 - - -
M48 - - -
+: Minimal    ++: Mild -: No lesion
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Figure 4.4 Quantity of EHV-1 DNA in the C57BL/6 tissue specimens. Illustrated are the
DNA quantities as determined by the gB rPCR assay. The highest quantity of DNA was
detected in the lung tissue of M43, the mouse which died at the time of inoculation. The
red bars designate the mice infected with Ab4 and the green bars represent those infected
with T953.
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Figure 4.5 C57BL/6 inoculated cell culture plates. RK-13 cell culture plates inoculated
with C57BL/6 lung (M43 & M44) and brain tissue (M44) after a five day incubation
period (passage 2). As seen in this image, only the wells inoculated with M43 lung tissue
developed signs of CPE.
4.3.3 Experimental Inoculation of B6Intf-γKnO Mice with T953 and Ab4
strains of EHV-1
The twelve B6Intf-γKnO mice were observed and weighed for five days prior to
inoculation. The final average pre-inoculation weights were 29g and 32g. Two of the
mice, M51 and M59, were separated from the other mice due to the aggressive behavior
of their cage mates. Both mice suffered from hair loss and lacerations prior to
inoculation. The lacerations had healed completely by day 2DPI. All mice were
inoculated six days after their arrival (0DPI); they were monitored and weighed twice a
day for thirty-three days. M49-M54 were inoculated with 5x105 pfu/ml of T953 and
M55-M60 with 5x105 pfu/ml of Ab4. Lethargy was present in all mice on day 1DPI,
followed by labored breathing on day 2DPI. The Ab4 infected mice lost 1.5g per day
and the T953 mice lost 1g per day by 2DPI (Table 4.9). On 5DPI, their weight
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stabilized, but remained lower than their pre-inoculation weight (Table 4.9). By day
33DPI, the average weight for the Ab4 mice was 29g, where as the T953 infected mice
had an average weight of 32g (Table 4.9). None of the animals developed any
neurological signs or paralysis. Arching of the back was first apparent on day 7DPI in
the mice from both the Ab4 and T953 inoculation groups. Also on day 7DPI, two from
each inoculation group (M53 and M54 from the T953 group; M55 and M56 from the
Ab4 group) were euthanized and their tissues collected for analysis.
Dissection of the mice euthanized on 7DPI revealed no abnormalities. However,
when the remainder of the mice were dissected, spinal curvature was present in most of
the mice. Histopathological examination revealed mild interstitial pneumonia in the
lungs of M54 (T953 infected) and minimal interstitial pneumonia was observed with
M56 (Ab4). Mild lymphocytic meningitis was observed in M55’s (Ab4) brain tissue
(Table 4.10).
Only eight of the twelve mice produced PCR positive results. As seen in
Figure 4.6, M55’s brain tissue had the highest concentration of EHV-1 DNA.
Interestingly, more of the T953 infected tissues tested positive for EHV-1 and had
consistently higher quantities of viral DNA than the Ab4 infected mice. The first and
second cell passages of the PCR positive tissues for both strains of EHV-1 were
negative. Inoculation of RK-13 cultures with brain tissues from the Ab4 and T953
inoculation groups, passages 3 and 4, also lacked evidence of CPE.
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Table 4.9 Body weight changes of the Ab4 and T953 infected B6Intf-γKnO mice.
Virus
Initial
Weight
(g) Days Post Inoculation
Final
Weight
(g)
2 4 6 8 10 12 14 18 20 24 28
Ab4 29 -3 0 0 +1 +1 0 0 0 0 +1 0 29
T953 30 -2 0 0 +2 +1 0 0 0 +.5 0 +.5 32
Initial and final weights, along with the changes in body weight, are the averages for each
group.
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Table 4.10 Lesions observed in B6Intf-γKnO mice.
Mouse ID Brain Lung Heart
Ab4 M55 ++: Lymphocytic
meningitis
- -
M56 - +: Interstitial
pneumonia
-
M57 - - -
M58 - - -
M59 - - -
M60 - - -
T953 M49 - - -
M50 - - -
M51 - - -
M52 - - -
M53 - - -
M54 - ++: Interstitial
pneumonia
-
+: Minimal    ++: Mild -: No lesion
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Figure 4.6 Quantity of EHV-1 DNA in the B6Intf-γKnO tissue specimens. The DNA
quantities as determined by the gB rPCR assay. The highest quantity of DNA was
detected in the brain tissue of M53, one of the four mice euthanized on day 7DPI. The red
bars designate the mice infected with Ab4 and the green bars represent those infected
with T953.
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4.3.4 Experimental Inoculation of BALB/c Mice with EHV-1 Strain T953
M61-M67 weighed between 8g to 16g upon arrival and their final pre-
inoculation weight was between 10g to 18g. Excellent body condition and high activity
levels were noted in all mice prior to inoculation. All mice received 1.8x108 PFU/ml of
T953. All animals were lethargic, exhibiting signs of labored breathing, ruffled fur and
weight loss (0.5g to 2g), along with a lack of nesting behavior by the end of day 1DPI.
Ocular discharge was also observed in some of the mice. By the end of day 2DPI, five
mice were dead. Of the remaining two mice, M66 and M67, M66 had the best overall
condition: no ruffled fur, body weight above 10g (Table 4.11). However, M66 died
mid-morning on day 3DPI. M67 lived the longest out of all the mice, dying early on
day 5DPI, despite a massive loss in weight (13g pre-inoculation weight, 9g by day
4DPI; Table 4.11). None of the animals exhibited neurological signs. Table 4.12 lists
the clinical scores assigned to M61-M67 following inoculation.
Table 4.11 Body weight changes of the BALB/c mice.
Mouse
Initial
Weight (g) Days Post Inoculation
Final
Weight (g)
1 2 3 4 5
M66 16 -.5 -1 -1.5 - - 13
M67 13 -.5 -1.5 -1.5 -.5 0 9
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Table 4.12 Daily clinical scores of BALB/c mice inoculated with 1.8x108 pfu/µl of T953.
Mouse ID Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
M61
M62
M63
M64
M65
M66
M67
Clinical
Score
Color
Key
0
1
2
3
4
5
Dead
The clinical scores listed in this table are defined in Table 4.3.
Upon dissection, the lungs of all animals were dark red in color (Figure 4.7) and
some congestion was also noted in the brain of M67. Curvature of the spine was also
observed in the animals, with the exception of M67 (Figure 4.7). The histopathology
reports were consistent with the physical changes noted during dissection. While there
were no lesions found in the brains of any of the mice, numerous morphologic changes
were observed in the lungs of all of the mice. Multifocal necrotizing bronchiolitis was
observed in the lungs of M61-M63 and M65. The bronchiolar epithelium of M61-M63
was also degenerative and necrotic. Multifocal perivascular and peribronchiolar cuffs of
lymphocytes were observed in M61-M63 and M65. These lesions were also in the
lungs of M66 and M67, but the cuffing was occasional to minimal. Cuffing was also
observed in M64.  Multifocal interstitial pneumonia was present in all animals, except
M61. Table 4.13 displays the comparison of the lung lesions for M61-M67. Multifocal
disruption of the blood vessels walls with low levels of lymphocytes in the lungs was
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seen in all mice with the exception of M66 and M67. No lesions were detected in the
spleen or spine of any of the animals.
Table 4.13 Lung lesions observed in the 1.8x108 pfu/µl BALB/c mice.
Mouse ID
Necrotizing
bronchiolitis
Interstitial
pneumonia
Perivascular &
Peribronchiolar Cuffing
M61 + - ++
M62 + ++ ++
M63 + ++ ++
M64 - + +
M65 + + ++
M66 - ++ +
M67 - + +
+: Minimal    ++: Mild -: No lesion
PCR analysis of the tissues from this group revealed extremely high levels of
viral DNA (>50,000 mol/µl) in the lungs of M61-M67. EHV-1 nucleic acid was
detected in the brain tissues of only M62, M65 and M67. Viral DNA in low to
moderate levels (20-900 mol/µl) was detected in the spleens of all of mice, except M66.
The exact quantities of DNA for each of the specimens for M61-M67 are in Figures 4.8
and 4.9. The virus isolation results were consistent with the PCR data. The cell
passages of all lung specimens were positive with high virus titers. The highest titer,
1.57x106 pfu/ml, reported was with M64. Virus titers for all lung specimens appear in
Figure 4.10. No virus was isolated from the brain and spleen of any of the mice. Table
4.14 presents a summary of the rPCR and the histopathologic results for all four groups
of mice.
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Figure 4.7 Dissection of M65. These images were taken during the dissection of M65.
Image A illustrates the spinal curvature noted with this mouse, which was also seen with
M61-M64 and M66. The dark red coloring of lungs as seen in image B was observed in
all animals receiving 1.8x108PFU/µl dose of EHV-1 T953 P0.
A
B
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Figure 4.8 Quantity of EHV-1 DNA in the brain and spleen specimens of M61-M65
and M67.
Illustrated are the DNA quantities, molecules per µl, as determined by the gB rPCR
assay. The results for the spleen specimens are in red and brain specimens are orange.
The highest amount of EHV-1 DNA in the spleen was reported with M61 and in the
brain, M62 had the highest amount.
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Figure 4.9 Quantity of EHV-1 DNA in the lung specimens of M61-M67. The levels of
EHV-1 DNA for the lung samples were considerably higher than the levels observed with
either the spleen or brain. The highest level was reported for M65, which was the first
mouse to die. Also of note, no EHV-1 DNA was reported in the brain or spleen samples
from M66. The virus was only present in the lungs of this animal.
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Figure 4.10 Virus titer for the lung specimens of M61-M67. The virus titers for all seven
mice inoculated with 1.8x108 of T953, based on the passage of the lung specimens in
RK-13 cells. The highest titer was observed with M64, which was fifth animal to
succumb to EHV-1 infection. The lowest titer belonged to M67, which was the last
animal to die.
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Table 4.14 Summary of rPCR results with the histopathologic results.
Summary and comparison of the rPCR and histopathologic results for all four groups of
mice. For the CBA mice, only tissues with viral DNA concentrations of 100 molecules/µl
or greater are listed along with their corresponding histopathologic results.
Murine Strain Mouse Id rPCR (Mol./µl) Histopath
CBA/CaJ
M20 58 (Brain) Neg.
M23 1,820 (Brain) Neg.
M25 122 (Brain)
180 (Spleen)
Neg.
M29
90 (Brain)
34 (Spleen)
Neg.
M33 39 (Lung) Neg.
M36 96 (Lung) Neg.
M37 132 (Brain) Neg.
M38 119 (Lung) Neg.
C57BL/6
M44 21 (Brain) Lymphocytic meningoencephalitis
M46 16 (Brain) Lymphocytic meningoencephalitis
B6Intf-γKnO
M54 Neg. Mild pneumonia
M55 29 (Brain)
Mild lymphocytic
meningitis
M56 Neg. Minimal pneumonia
BALB/c
M65
9 (Brain)
8.74x106 (Lung)
105 (Spleen)
Lungs: Minimal interstitial pneumonia
& Minimal necrotizing  pneumonia
M66 8x106 (Lung) Mild interstitial pneumonia
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4.4 Discussion
The results of this study indicate BALB/c mice are more susceptible to
infection with EHV-1 strain T953. Lesions were detected in the lung tissues of all the
BALB/c mice with accompanying high virus titers (>2x105 pfu/ml). PCR analysis
also revealed high levels (>50,000 mol./µl) of EHV-1 DNA in the lungs. These data
confirm successful infiltration of the lungs by EHV-1 strain T953.
In the case of the remaining three mouse strains, the results were not as
definitive as with the BALB/c mice, suggesting these mice strains are not susceptible
to infection with T953. No lesions were present in any of the CBA mouse tissues and
VI attempts were unsuccessful. The low levels (<200mol./µl) of viral DNA indicate
inoculation of the CBA mice was successful, but the virus apparently failed to
establish an active infection in the brain, spleen, or lungs of any mice. It is possible
T953 infected only the peripheral blood, which would account for the positive PCR
results. EHV-1 was present in the blood circulating through the organs, but the
pathogen did not infect those organs directly. Another possibility is T953 latently
infected the CBA mice. Latent infection of mice by neuropathogenic EHV-1 has been
studied by Field et al. (1992), Baxi et al. (1996) and Iqbal and Edington
(2002).248,249,261 In those three studies, Ab4 was used to inoculate BALB/c, not CBA
mice. Only two of those studies, Baxi et al. (1996) and Iqbal and Edington (2002),
utilized PCR, specifically nested reverse transcriptase PCR (RT-PCR), to detect the
virus.248,261 However, Iqbal and Edington reported detecting only low levels of viral
DNA even with the RT-PCR and they were not able to isolate EHV-1 in culture.261
The trigeminal ganglia, olfactory bulb, and peripheral blood of the CBA mice would
need to be re-analyzed using RT-PCR to confirm the presence of latent EHV-1.
Because of the limited data generated with the CBA mice, positive control
groups were established for the C57BL/6 and B6Intf-γKno mice. The positive
controls were inoculated with Ab4. The response of various mouse strains, including
CBA and C57BL/6, to inoculation with Ab4 has been documented by Awan et al.
(1990 & 1991), Gosztonyi et al. (2009), and Kasem et al. (2010).48,241,247,262 The
Awan et al. 1990 study, in which C57BL/6 mice were inoculated with Ab4, did not
report any lesions in mice.241 Their findings did include virus isolation from lung
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tissues of this mouse strain. In this dissertation study, VI from any of the C57BL/6
tissues was unsuccessful, along with extremely low levels (<200mol./µl) of PCR
detected EHV-1 DNA. The difference between the Awan et al. 1990 study and this
study is most probably due to the amount of the Ab4 strain administered to the mice.
In the Awan study, C57BL/6 mice were intranasaly inoculated with 40µl of 1x106
pfu/ml of Ab4.241 In the current study, 20µl of 5x105pfu/ml was intranasaly
administered to the same murine strain, a fourth of the amount used in the Awan
study.
VI from the B6Intf-γKno mice tissues was also ineffective and the levels of
viral DNA were similar to those found in the C57BL/6 mice (<200mol./µl). The
lesions present in both of these murine strains were also similar. In the case of the
C57BL/6 mice, mild meningoencephalitis was present in one of the Ab4 infected
mice and one of the T953 mice. Mild lymphocytic meningitis was detected in one of
the Ab4 inoculated B6Intf-γKno mice. Interstitial pneumonia was identified in one
T953 and one Ab4 infected B6Intf-γKno mouse. In 2009, Gosztonyi et al. reported
meningoencephalitis in the brains of at least 15 mice inoculated with Ab4, along with
perivascular cuffing in the lungs.247 However, these mice received 7.5x107 pfu/ml of
the virus (volume was not reported).247 Based on the findings published by Gosztonyi
et al. 2009 and Awan et al. 1990, the data obtained from the C57BL/6 and B6Intf-
γKno mice may have been improved if the challenge dose of EHV-1 was
increased.241,247
VI was unsuccessful and only low levels (<3,000mol/µl) of EHV-1 DNA
were reported with three of the inoculated mouse strains: CBA/CaJ, C57BL/6 and
B6Intf-γKno. With the BALB/c mice, virus titers of >2x105 pfu/ml were observed
and the quantity of viral DNA was >50,000 mol./µl. This marked difference in virus
titers and EHV-1 DNA copy numbers between the BALB/c strain and the other
mouse strains used in this study most likely results from an increased dosage of T953.
The BALB/c mice received the highest dose of T953 out of the four mouse strains
challenged in this study: 30µl of 1.8x108 pfu/ml. This increase in concentration and
volume would allow the virus to infect the mice before immune clearance occurred.
However, it is still likely that the BALB/c would produce the same titers and viral
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DNA copies with a lower dose, but additional testing is needed to verify this
possibility.
The high virus titers, high viral DNA levels and histopathologic lesions in the
BALB/c mice were all reported with the lungs. Such data indicates the lungs were the
main site of infection for T953. Gosztonyi et al. 2009 reported lung lesions in
BALB/c mice infected with 7.5x107 pfu/ml of a neuropathogenic EHV-1 strain, along
with meningoencephalitis in the brain.247 As mentioned previously, this particular
study involved the Ab4 strain as the challenge virus.247 Comparison of the Gosztonyi
et al. 2009 data with the BALB/c results of this study would indicate the Ab4 strain is
more neurovirulent in this mouse strain than the T953 strain.
The main objective for this study was to determine the appropriate alternative
host to study the pathogenicity T953 and subsequently use this new host to study the
phenotype of various cell culture adapted strains of the same virus. Since T953 causes
EHM in horses, the expectation was the virus would cause neurological signs and
lesions in some of the mouse strains included in this study. While the BALB/c mice
did not exhibit any neurologic signs, a high dose of T953 was able to cause
pneumonia. The occurrence of cuffing (perivascular and peribronchiolar) and
bronchiolitis in the lungs of the BALB/c mice is consistent with EHV-1 induced lung
lesions in the horse.3,65 Furthermore, the high titers, high viral DNA levels, and
significant histopathologic lesions observed in from the BALB/c strain provides a
basis for comparing the original T953 strain and cell culture adapted strains of this
virus. In summary, the data generated in this chapter of the dissertation research
revealed the BALB/c mice could be a suitable host for future experimental
inoculation studies with the T953 strain. Accordingly, the BALB/c strain was the
selected for the comparative T953 inoculation study discussed in Chapter 5.
Copyright© Kathryn Laura Smith 2013
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CHAPTER FIVE
Experimental Inoculation of BALB/c Mice with Parental and Cell Culture Passaged
T953 Neuropathogenic Strain of EHV-1
5.1 Introduction
Equine herpesvirus myeloencephalopathy (EHM) poses a serious threat to the
horse industry because disease can occur on a widespread scale and result in severe
economic losses. As mentioned in Chapter 1, in the spring of 2011 EHM outbreak
began at a single equestrian event in Utah, spread to twelve additional states with an
overall 39% fatality rate.121 A more recent EHM outbreak at the Hawthorne
Racetrack in Illinois in November 2012, canceled racing for seven days and this
racecourse remains under quarantine.124 Such occurrences highlight the need for
effective preventive measures against the virus.124 One of the key aspects to
prevention of EHV-1 infection is vaccination.
Currently, sixteen EHV-1 vaccines are commercially available in North
America and Europe, including inactivated vaccines such as Prodigy from Intervet
and the modified live virus (MLV) vaccine Rhinoimmune from Boehringer Ingelheim
Vetmedica, Inc.203,208 While none of the presently available EHV-1 vaccines can
completely prevent infection by the virus, their administration is still beneficial.
Heldens et al. 2001 demonstrated prevention of respiratory disease in foals with an
inactivated EHV-1 vaccine.263 Two studies initiated by Patel et al. (2003 & 2004)
involving the vaccination of pregnant mares with a EHV-1 MLV vaccine, recorded
reduced nasal shedding, nasal discharge and pyrexia  in the vaccinated mares.264,265 In
2010, Goehring et al. reported administration of an EHV-1 MLV vaccine reduces
pyrexia, nasal shedding and the duration of viremia.208 Not with standing these
findings, at the present time no commercially available vaccine can prevent
EHM.203,208
In an effort to develop an effective EHM vaccine, studies have focused on
DNA and recombinant vaccines. In 2006, Soboll et al. investigated the immunity
induced by DNA vaccines against inoculation with EHV-1 neuropathogenic strain
Army 183.266 Cytotoxic T-lymphocyte (CTL) responses, along with a reduction in
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nasal discharge, were observed in the challenged horses.266 The virus neutralizing
antibody and CTL levels did not increase significantly after vaccination, indicating
the immunity afforded by these DNA vaccines was limited.266 Also in 2006, Minke et
al. engineered four vaccines using EHV-1 DNA plasmids and a canarypox virus as a
vector.211 The vaccines were administered to Welsh ponies, which were then
challenged with the neuropathogenic Ab4 strain of the virus. The result was a
suppression of virus replication in the upper respiratory tract, along with stimulation
CTL responses.211 However, none of these recombinant vaccines reduced cell-
associated viremia.211
O’Neill et al. 1999 states effective EHV-1 vaccines should stimulate strong
mucosal and serum virus neutralizing antibody activity with high CTL responses.267
Goehring et al. 2010, Minke et al. and Soboll et al. 2006 have revealed MLV, DNA,
and recombinant vaccines are capable of producing at least a portion of this required
immune response.208,211,268 Still, the duration of immunity is limited and none of them
prevents the development of EHM. An inactivated vaccine based on cell-passaged
Kentucky A (KyA) strain can induce class I MHC-restricted CTL responses and
twelve month long immunity against EHV-1.269,270 However, the efficiency of the
KyA vaccine has primarily been demonstrated against non-neuropathogenic EHV-1
strains, such as RacL11.269,270
In view of the effectiveness of the KyA vaccine, an EHM vaccine could
possibly be developed from a cell-passaged EHV-1 neuropathogenic strain.
Therefore, the first objective of this current study was to serially passage EHV-1
neuropathogenic strain T953 in equine endothelial cell cultures. Observation of
plaque size in cell culture and sequence analysis (nucleotide and amino acid) of the
parental T953 (T953 P0) strain and cell adapted strains determined if any variations
had occurred as result of sequential passage in cell culture. The second objective of
this study was the comparison of one of the cell adapted T953 (T953 P135) strain’s
phenotype with the virulent phenotype of its parental strain in BALB/c mice. The
mice were divided into two separate inoculation groups. One group received serial
dilutions of T953 P0 and the second serial dilutions of T953 P135. The animals were
monitored for clinical signs and weighed for fourteen days. They were then
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euthanized and their tissues collected for analysis. The presence of EHV-1 in the
murine tissues was determined with virus isolation (VI), histopathology, and real-time
PCR (rPCR).
5.2 Materials and Methods
5.2.1 Cells
Equine endothelial cells (EEC; passage level 12-20) were maintained as
confluent monolayers in 150-cm2 and 75-cm2 culture flasks using Dulbecco’s Modified
Eagle’s Essential Medium (DMEM; Gibco, Grand Island, NY, USA), supplemented
with 10% fetal bovine serum, penicillin (100 U/mL; Gibco), and streptomycin (100
ug/mL; Gibco). L-glutamine (200nM; Gibco) and 0.1 mM nonessential amino acids
(10mM (100x); Gibco) were also added to the medium.
A RK-13 continuous cell line (passage level 194-204; ATCC CCL-37;
American Type Culture Collection) was grown in EMEM (Mediatech Inc., Herndon, VA,
USA) with 10% ferritin-supplemented bovine calf serum (Hyclone), 1% penicillin and
streptomycin (10,000 IU/ml and 10,000 µg/ml; Mediatech) and 0.1% amphotericin B
(1,000 μg/ml;Sigma-Aldrich,St. Louis, MO).
Confluent monolayers of fetal equine dermis (KyED) cells, passages 7-10, were
maintained in 850-cm2 tissue culture roller bottles in Eagle’s Minimal Essential Medium
(EMEM; Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (10%
FBS) and gentamicin reagent solution (50-µg/ml; Invitrogen) as previously described.216-
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5.2.2 EHV-1 Strain
The origin and isolation of EHV-1 neuropathogenic strain T953 was described
in Chapter 4, section 4.2.2.
5.2.3 Sequential Cell Culture Passage of EHV-1 Neuropathogenic Strain T953
The original stock of T953 (T953 P0) was sequentially passaged in EECs. Cell
culture flasks (25cm2 flasks) of EECs were infected with T953 P0 at a multiplicity of
infection of 5. Supernatants from the infected cells were passaged every three to four
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days up to passage 210. The flasks were freeze thawed, the cellular debris removed by
centrifugation and the tissue culture fluids (TCFs) were stored at -80°C.
5.2.4 Mice Strains
Seventy-one female BALB/c mice were obtained from Charles River
Laboratories International (Wilmington, MA, USA). The BALB/c mouse is an in-bred
strain developed in 1913, known for its longevity and is used primarily in infectious
disease studies.256 The mice were three weeks old upon arrival and were kept three or
four per cage. Their initial weight ranged from 8g to 16 g.
5.2.5 Experimental Inoculation and Observation of Mice
The mice were divided into two separate groups. Thirty-five BALB/c mice
determined the potency of T953 P0 at different dosages. Twenty-eight mice were
inoculated with serial dilutions of T953 P135. Eight mice were inoculated with
pathogen-free MEM and used a control group.
Chapter 4, section 4.2.5 describes the method of monitoring, inoculation and
care of the BALB/c mice. Table 5.1 displays the specific amounts used of the
anesthesia mixture and dilute per cage for this group of test subjects. Because of the
lack of reaction in the first test groups, the volume of the inoculation solution was
increased from 20µl to 30µl of the virus. Table 5.2 contains the EHV-1 strain and the
dosage of the virus used to inoculate each group of mice.
Following inoculation, the mice were weighed and observed twice a day
(morning and evening) until the conclusion of the observation period. All BALB/c mice
were observed for fourteen days and examined daily for the development of clinical
signs (weight loss, ruffled coat, depression, nasal discharge, lethargy, arching of the
back and neurologic signs including hypersensitivity, circling, limb paddling and
paralysis). For the scoring system assigned to record severity of clinical signs, see
Table 4.3. Signs of extreme pain, total paralysis, or any animals receiving a clinical
score of 5 resulted in immediate euthanasia.
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Table 5.1 Preparation of anesthesia solution.
The amount of Ketamine/Xylazine mixture, along with the amount of PBS as a diluent, used in
preparing the anesthesia solution (100µl final volume) was based on the average weight of the
mice as listed above. The fifth column indicates the amount of anesthesia solution administered
to each group.
Mouse IDs Average Weight (g) Ketamine /Xylazine PBS Anesthesia
M68-M110 14.8 24µl 76µl 200µl
M139-M167 14.2 23.4µl 76.6µl 200µl
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Table 5.2 Inoculation of BALB/c mice with EHV-1 strains T953 P0 and T953 P135.
Virus Strain Mouse Ids Dosage
T953 P0 M68-M74 30ul of 1x108
M75-M81 30ul of 1x107
M82-M88 30ul of 1x106
M89-M95 30ul of 1x105
M96-M102 30ul of 1x104
Control M103-M110 30µl of MEM
T953 P135 M139-M145 30ul of 1x108
M146-M152 30ul of 1x107
M153-M159 30ul of 1x106
M160-M166 30ul of 1x105
Five groups of BALB/c mice (M68-M102; seven mice per group) were intranasally
inoculated with EHV-1 T953 P0 strain (15µl to each nostril). Four groups of mice
(M139-M166; seven mice per group) were administered EHV-1 T953 P135 strain (15µl
per nostril). M103-M110 were used as a control group for this experiment.
5.2.6 Euthanasia and Tissue Collection
Euthanasia, dissection of and tissue collection from the BALB/c mice was
performed according to the methods described in Chapter 4, section 4.2.6.
5.2.7 Extraction of Viral Nucleic Acid
DNA extraction was performed on the homogenized tissue specimens using the
method described in Chapter 4, section 4.2.7.
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5.2.8 EHV-1 gB Plasmid
The T953gB61666 plasmid containing a 349 bp region of ORF33 (nt # 61,666-
62,015) from the T953 strain of EHV-1 was assembled with the methods and materials
described in Chapter 4, section 4.2.4.
5.2.9 gB Plasmid Dilutions
The serial dilutions of the T953gB61666 plasmid were prepare in the manner
described in Chapter 4, section 4.2.8 and Table 4.3 lists the amount of molecules
present in the each of the dilutions.
5.2.10 Absolute Quantification Real-Time PCR
A gB rPCR assay, reported by Pusterla et al., was employed to quantify the
amount of EHV-1 DNA present in the mice tissues.109 The methods for assembling the
PCR reaction mixes, along with the reaction conditions and setup for each rPCR plate
are described in Chapter 4, section 4.2.9 and referenced in Table 4.4.
5.2.11 Virus Isolation
Confluent monolayers of RK-13 cells were established in 6-well cell culture
plates. Serial dilutions (Brain and Spleen: 10-1-10-3; Lung: 10-1 -10-4) were prepared
from each homogenized tissue sample by diluting 100µl of each tissue suspension with
900µl of MEM. Two wells were assigned for each dilution and inoculated with 400µl
of the designated dilution. The plates were incubated for 1hr at 37ºC, swirling the plates
every 15min. The cells were then overlaid with 5ml of complete cell culture medium
containing 0.75% carboxymethylcellulose (CMC) (Sigma-Aldrich). If plaques were
seen in culture or if 100% cytopathic effect (CPE) was achieved, then the plates were
then stained with 1ml of 1% crystal violet containing 1% formaldehyde, photographed,
and the virus titer calculated. If the cultures exhibited no signs of infection after four
days, then the plates would simply be stained and photographed.
5.2.12 Preparation of Viral Nucleic Acid for DNA Sequencing
To generate working virus stocks, confluent monolayers of KyED cells in 850-
cm2 tissue culture roller bottles were inoculated with one of the two viruses (T953 P0 or
T953 P135) and incubated at 37ºC until 100% CPE was evident. The TCF from each
roller bottle was harvested and centrifuged at 3,000 g for 30 min at 4ºC. The supernatant
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was then filtered using a 0.45 µm membrane filter to remove any remaining cellular
debris. The filtered supernatant underwent ultracentrifugation for one hour at 120,000 g
at 4ºC through a 30% sucrose cushion to pellet the virus. Supernatants were decanted,
and the viral pellets were resuspended in 700µl of Tris-EDTA buffer (TE; 1.0 M Tris-
HCl, (pH 8.0), 0.1 M EDTA: Sigma-Aldrich) and stored at -80ºC. The purified viruses
were treated with Proteinase-K (20 mg/ml in TE buffer containing 50% glycerol (pH
8.0): Invitrogen), and the viral DNA was isolated by phenol chloroform extraction as
previously described.216 The isolated viral DNA was resuspended in 700µl of TE buffer
(pH 8.0) and stored at -20°C.
5.2.13 DNA Sequencing
Specific ORFs (7, 16, 18, 30, 31, 37, 54, 72) of EHV-1 strains T953 P0 and
T953 P135 were sequenced using a standard laboratory protocol. PCR amplification of
viral DNA was performed with a high fidelity Pfu Turbo DNA polymerase (Stratagene,
Santa Clara, CA, USA) and the PCR products were gel-purified. Sense and antisense
strands were sequenced using the PRISM Ready DyeDeoxy Terminator cycle
sequencing kit (Applied Biosystems, CarlsBad, CA, USA). Sequencing was performed
at MWG Biotech Inc., 2211 Seminole Drive, Huntsville, AL 35805-4191.
5.3 Results
5.3.1 Serial Cell Culture Passage of EHV-1 Neuropathogenic Strain T953
EHV-1 strain T953 was sequentially cell passaged in EECs. The result was a
significant reduction in plaque size from the parental strain (P0) to passage 135 of T953
(Figure 5.1). The plaques produced by T953 P0 had a diameter of 4mm, which was
reduced to 2.5mm by passage 15. By passage 135 (T953 P135), the diameter of the
plaques was extremely reduced at 1.7mm.
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Figure 5.1 Sequential cell culture passage of EHV-1 neuropathogenic strain T953. T953
was passaged in EECs up to passage 135. The parental strain (P0) had a plaque size of
4mm in diameter, passage 15 (P15) 2.5mm and by passage 135 (P135), the plaque size
had been significantly reduced to 1.7mm in diameter.
5.3.2 Nucleotide and Amino Acid Sequence Analysis
Comparative nucleotide and amino acid sequence analysis was performed to
identify the mutations in the genes encoding the viral elongation complex (genes
involved in virus replication) and envelope glycoproteins. No nucleotide substitutions
were observed in the genes associated with the viral elongation complex, including
ORF30 (the viral DNA polymerase gene). However, substitutions were reported in the
nucleotide and amino acid sequences of two glycoproteins. As seen in Table 5.3, the
differences between the T953 P0 and T953 P135 primarily occurred in ORF16
(glycoprotein C) and 72 (glycoprotein D).
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Table 5.3 Nucleotide and amino acid sequence variation between T953 P0 and P135.
ORF Gene Product Nucleotide Sequence & Amino Acid
Sequence
T953 P0 T953 P135
7 Primase/Helicase Activity No Difference (ND) ND
18 Processivity Factor ND ND
30 DNA Polymerase ND ND
31 DNA Binding/Recombinase ND ND
37 UL24 ND ND
54 Primase/Helicase Activity ND ND
A461/Gln154 G461/Arg154
16 Glycoprotein C
(gC)
T464/Leu155 C464/Pro155
T787/Phe263 G787/Val263
72
Glycoprotein D
(gD)
G857/Gly286 T857/Val286
Comparison of the nucleotide and amino sequences of T953 P0 and P135. The sequences
of the strains were similar, with the exception of ORF16 and 72. ORF16’s gene product,
gC, is required for infecting the host. ORF 72’s gene product, gD, primary functions
include infectivity, cell entry and penetration.
5.3.3 Experimental Inoculation of BALB/c Mice with EHV-1 Strain T953 P0
The mice weighed 9g to 14g upon arrival, with their final average pre-
inoculation weights between 15g to 16g. All animals were active and in excellent
condition prior to inoculation. The first day following inoculation, all animals exhibited
lethargy as a consequence of anesthesia. At 2DPI, the mice which received 1x107 and
1x108 pfu of virus had lost 2g, and exhibited the following clinical signs: huddling,
ruffled fur, labored breathing, ocular discharge, lack of energy and lack of nesting
behavior (Table 5.4). In the same time period, the BALB/c mice inoculated with 1x104
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to 1x106 pfu of virus did not exhibit significant clinical signs. They all
maintained excellent coat condition, nesting behavior, and weight loss was minimal
(<1g) (Table 5.4.). However, these animals did display rapid breathing. The daily
clinical scores of M68-M81 are in Table 5.5. The 1x105, 1x106 and 1x107 mice
eventually surpassed their pre-inoculation weights, although most retained a rough coat
condition (Table 5.4). The 1x104 mice were identical to the control mice in terms of
weight loss, appearance and behavior during the fourteen day observation period. Loss
of muscle control and/or paralysis was not observed in any of the T953 P0 infected
mice. The only fatalities occurred with the 1x108 mice, with only two survivors (M69 &
M72). However, M69 and M72 continued to exhibit labored breathing, ruffled coats
and they failed to regain their robust pre-inoculation appearance. The differences in
appearance between the mice inoculated with 1x108 and 1x104 pfu of the virus are
shown Figure 5.2. A comparison of pre- and post-inoculation appearances for M69 is
displayed Figure 5.8.
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Table 5.5 Daily clinical scores of the BALB/c mice inoculated with EHV-1 strain T953 P0.
Animals which received 1x108 or 1x107pfu/ml of the virus exhibited signs of infection the
first day following inoculation, except for M79 and M80. All deaths recorded in this table
were the result of EHV-1 infection. The definitions of each clinical score are in Table 4.3.
Day
Dosage
(Pfu/ml)
Mouse
ID 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
M68
M69
M70
1x108 M71
M72
M73
M74
M75
M76
M77
1x107 M78
M79
M80
M81
Clinical
Score
Color
Key
0
1
2
3
4
5
Dead
135
Figure 5.2 Comparison of mice inoculated with 1x108 and 1x104 pfu of the virus at
3DPI. Both images A and B were taken on 3DPI. The 1x108 animals are very gaunt with
ruffled coats, whereas the 1x104 mice are more robust with smooth coats.
Following euthanasia, the dissection of the control and 1x104 mice revealed
normal lung and brain tissues. The mice which received 1x106 and 1x105 pfu of the
virus had dark red lungs with mild to moderate congestion of the brain tissues. The
A
B
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1x107 mice had moderate to severe hemorrhaging in the lungs and mild to moderate
congestion in the brain. M69 and M72 both had moderate hemorrhaging in the lungs
and moderate congestion in the brain. M68, M70, M71, M73, and M74 all had severe
hemorrhaging in the lungs with mild congestion in the brain.
Histopathogical examination of the tissues from the control mice and the mice
inoculated with 1x104 pfu of T953 P0 revealed an absence of significant lesions. The
lung tissues of the mice which received 1x105 pfu of the virus showed only mild
congestion. In contrast, the mice inoculated with 1x106 pfu of the virus had minimal
multifocal lymphocytic interstitial pneumonia with low levels of lymphocytes
infiltration in the lungs (Table 5.6). Mild multifocal histiocytic pneumonia was present
in the lungs of the mice infected with 1x107 pfu of the virus. Low levels of lymphocyte
and macrophage infiltration was also evident in the lungs of these animals (Table 5.6).
The BALB/c mice which received 1x108 pfu of T953 P0 demonstrated minimal
neutrophil and eosinophil infiltration of the lungs, along with low numbers of
macrophage and lymphocyte infiltrations. Multifocal degenerative and necrotic changes
were present in the bronchiolar epithelium. The histopathological diagnosis of the lung
tissue for the 1x108 mice was mild multifocal necrotizing bronchiolitis with mild
lymphocytic interstitial pneumonia (Table 5.6).
Table 5.6 Lung lesions observed in the 1x104 to 1x108 pfu/µl inoculated BALB/c mice.
Dose
Histiocytic
Pneumonia
Interstitial
pneumonia
Necrotizing
bronchiolitis
Control - - -
1x104 - - -
1x105 - - -
1x106 - + -
1x107 ++ - -
1x108 - ++ ++
+: Minimal    ++: Mild -: No lesion
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VI of T953 P0 was successful with the lung tissues of the mice which received
1x108 pfu of the virus. Specifically, M68, M70, M71, M73 and M74 all produced high
virus titers, >4x105 pfu/ml (Figure 5.3). All other tissues (brain, lung, spleen) for the
remaining twenty-nine mice, regardless of virus dosage, were negative for the presence
of T953 P0.
The PCR results were consistent with the VI results. The tissue specimens from
six of the mice inoculated with 1x108 pfu of T953 P0 tested positive for EHV-1 DNA.
The lung specimens of M68, M70, M71, M73 and M74 all had high quantities (>3x106
mol./µl) of viral DNA. The CT values for the lung samples were: M68=19.74, M70=
21.51, M71=22.23, M73=21.73, and M74=20.87. The brain specimens from M68
(CT.:39.30) and M70 (CT.:37.01) also tested positive for EHV-1 DNA. However, the
DNA quantities were significantly lower with the brain tissues (<100mol./µl).
Additionally, the spleen samples from M70 (CT.:33.76), M71 (CT.:37.11), M73
(CT.:34.08) and M74 (CT.:32.09) were positive for viral DNA (>400mol./µl). The exact
quantities of viral DNA for each of these specimens are given in Figures 5.4 and 5.5.
The tissues specimens from the remaining twenty-nine mice were negative for EHV-1
DNA.
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Figure 5.3 Virus titers for the lung specimens of mice inoculated with 1x108 pfu of
T953 P0. The virus titers based on the passage of the lung specimens in RK-13 cells.
The highest titer was observed with M68, which was the first animal to succumb to
EHV-1 infection.
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Figure 5.4 Quantity of DNA in the brain and spleen specimens of the mice inoculated
with 1x108 pfu of T953 P0.
The DNA quantities, molecules per µl, were determined by the gB rPCR assay. The
results for the spleen specimens are in red and brain specimens in orange. The highest
amount of EHV-1 DNA in the spleen was reported with M74.
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Figure 5.5 Quantity of EHV-1 DNA in the lung specimens of the mice inoculated with
1x108 pfu of T953 P0. The DNA quantities, molecules per µl, were determined by the gB
rPCR assay. The highest amount of EHV-1 DNA copy number was reported with M68
and the lowest with M71.
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5.3.4 Experimental Inoculation of BALB/c Mice with EHV-1 Strain T953 P135
The mice weighed between 8g to 12g upon arrival, were observed for seven
days and their final average pre-inoculation weights were between 14g to15g (Table
5.7). All mice were active and in excellent condition prior to inoculation. The mice
were divided into four inoculation groups (seven mice per group) and inoculated with
various doses of EHV-1 strain T953 P135 (Table 5.3). Following inoculation, the mice
inoculated with 1x108 and 1x107 pfu of the virus were lethargic with ruffled fur, ocular
discharge, labored breathing and lacked nesting behavior. No change in appearance or
behavior was noted in the control, 1x105 or 1x106 pfu inoculated mice. These animals
maintained robust, healthy appearances for the entire fourteen day observation period
following experimental inoculation. On day 2DPI, nesting behavior was observed in the
1x107 mice. By 3DPI, these mice had improved coat condition, increased energy, and a
decrease in ocular discharge. These same animals were normal by 5DPI. With the
1x108 mice, lethargy, ruffled coats, ocular discharge, labored breathing and lack of
nesting behavior were observed for the first five days following inoculation. By 6DPI,
nesting behavior resumed and all animals were fully recovered by 9DPI. No deaths or
neurological signs were observed in any of the cages. The daily clinical scores for
1x107 and 1x108 mice are in Table 5.8. The variations in body condition in the mice can
be seen in Figures 5.6 and 5.7.
In terms of weight loss, the 1x108 and 1x107 mice had the severest decrease in
weight, losing between 2g by the end of 2DPI. No change in weight was observed in
the 1x106 and 1x105 mice by the end of 2DPI (Table 5.7). By 4DPI, weight gains were
observed in all inoculation groups (1g to 2g), except for the 1x108 mice. By 8DPI,
1x108 had gained 2g and the remaining groups were maintaining their weight. The final
average post-inoculation weights for the mice ranged from 15g to 17g (Table 5.7).
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Table 5.7 Body weight changes in the BALB/c mice inoculated with EHV-1 strain T953
P135.
Initial and final weights, along with the changes in body weight, are the averages for
each group. Each of the inoculation groups consisted of seven mice.
Viruses
Initial
Weight
(g) Days Post Inoculation
Final
Weight
(g)
2 4 6 8 10 12 14
Control 16 0 +1 0 0 +0.5 -0.5 0 17
1x105 15 0 +1 0 0 +1 0 0 17
1x106 15 0 +1 0 0 0 0 +1 17
1x107 14 -2 +2 +1 0 0 +1 0 16
1x108 15 -2 -1 +1 +1 +1 0 0 15
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Table 5.8 Daily clinical scores of BALB/c mice inoculated with EHV-1 strain T953
P135.
No neurological signs were observed in any of the mice. The mice inoculated with 1x107
pfu of T953 P135 appeared normal by 5DPI. The mice which received 1x108 pfu of the
virus appeared fully recovered by 9DPI. No deaths occurred in any of the inoculation
groups. The definitions of each clinical score are in Table 4.3.
Day
Dose
(Pfu/ml)
Mouse
ID 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
M139
M140
M141
1x108 M142
M143
M144
M145
M146
M147
M148
1x107 M149
M150
M151
M152
Clinical
Score
Color
Key
0
1
2
3
4
5
Dead
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Figure 5.6 Pre- and post-inoculation comparison of BALB/c mice infected with 1x108
pfu of T953 P135.
Image A was taken one day prior to inoculation. Image B was taken on 7DPI. While
labored breathing and a gaunt appearance still persisted, the energy levels and coat
conditions of the mice by 7DPI were almost identical to their pre-inoculation conditions.
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Figure 5.7 Comparison of pre- and post-inoculation body conditions of BALB/c mice
inoculated with EHV-1 strains T953 P0 & T953 P135. Image A is M69 (T953 P0, 1x108
pfu/ml) prior to inoculation and Image B was taken at 14DPI. Image C is M139 (T953
P135, 1x108 pfu/ml) one day prior to inoculation and Image D was taken on 14DPI.
M139 regained its robust appearance (Image D), while M69 still had a rough appearance
by day 14DPI (Image B).
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Gross examination of the brain and lung tissues of all mice appeared normal.
Figure 5.8 depicts the typical appearance of the brain and lungs of the mice infected
with T953 P135. Histopathological examination further revealed no lesions in any of
the tissues from any of the mice, except the 1x108 mice. Mild histiocytic and interstitial
pneumonia was diagnosed in the lungs of the 1x108 mice (Table 5.11). No other lesions
were observed.
Table 5.9 Lung lesions observed in the control and T953 P135 BALB/c mice.
Dose
Histiocytic
pneumonia
Interstitial
pneumonia
Necrotizing
bronchiolitis
Control - - -
1x105 - - -
1x106 - - -
1x107 - - -
1x108 ++ ++ -
+: Minimal    ++: Mild -: No lesion
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Figure 5.8 Brain and lungs of M139. These images show the brain and lungs of M139 at
14DPI. Both organs have healthy pink coloring with no congestion.
Attempted VI from all tissue specimens from all inoculation groups was
negative. The PCR results were also negative, except for the lung samples from M139-
M142, M144, and M147 (Figure 5.9). The highest DNA copy number (163 mol./µl)
was recorded with M139, which was also the mouse with the severest clinical signs.
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The CT values for these lung specimens were as follows: M139=36.47, M140=37.51,
M141=38.59, M142=39.34, M144=38.98 and M147=39.56.
Figure 5.9 Viral DNA copy number in the lung specimens of the mice inoculated with
1x107 & 1x108 pfu of T953 P135. The lung tissues of only six mice from the T953 P135
inoculated group tested positive for EHV-1 DNA. The highest amount of DNA was
reported with M139, which also had the most severe clinical signs for the greatest
duration. The mice which received the 1x108 dose of T953 P135 are represented by the
dark blue columns and the purple column represents the mouse which received the 1x107
dose of the same virus.
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Table 5.10 Survival rates for T953 P0 and T953 P135 BALB/c mice.
Dose (N= No. of Mice) T953 P0
Survivors
T953 P135
Survivors
1x105(N=7) 7 7
1x106(N=7) 7 7
1x107(N=7) 7 7
1x108(N=7) 2 7
Survival Rate 29% (2/7) 100% (7/7)
5.4 Discussion
The data from this study demonstrates T953 P135 has an attenuated phenotype
in BALB/c mice. Virus isolation from any of the T953 P135 inoculated mice was
unsuccessful. Detection of EHV-1 DNA by rPCR only occurred with the lung tissues
from six mice and the amount of viral DNA was low (<100mol./µl) in all specimens.
Mild lesions were present only in the lungs of the 1x108 infected mice. The
histopathologic findings of the remaining three T953 P135 inoculated groups were
identical to the control mice. These results indicate EHV-1 respiratory disease in the
T953 P135 mice was mild.
In the case of the T953 P0 mice, virus isolation was successful only from the
lungs of the 1x108 mice and titers were high (>2x105pfu/ml). These data, combined
with high levels of viral DNA (>50,000mol./µl) and the presence of lung lesions, all
confirm severe EHV-1 infection of the lungs. The low amounts (<2,000mol./µl) of viral
DNA in the brains and spleens of these same mice indicate the establishment of viremia
and dissemination of the virus throughout the body. The lack of viral DNA and the
presence of fewer lung lesions with the 1x107 mice demonstrate respiratory disease was
less severe in this inoculated group. Similar findings were observed in the 1x106 mice.
The lack of EHV-1 DNA in the brains and spleens of both 1x107 and 1x106 mice
possibly indicates viremia was never established in these animals, or the virus was
eliminated from the bloodstream prior to euthanasia. Data from the 1x105 and 1x104
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inoculated mice (virus titer, histopathologic findings, clinical observations, viral DNA
levels) were identical to the control group.
Only four inoculation groups (1x105 to 1x108) were established for the T953
P135 mice since the control and T953 P0 1x104 groups were identical in clinical
presentation: no weight loss and no signs of respiratory distress. Comparison of the
final weights of the T953 P0 and T953 P135 mice did not reveal a significant difference
between the two viruses: T953 P0 1x108’s final weight was 1.5g higher than the final
weight of the T953 P135 mice inoculated with the same dose (Tables 5.4 & 5.7). The
survival rates of the two virus strains were more dramatic (Table 5.10). T953 P0 had a
survival rate of only 29%, whereas the T953 P135 strain had a 100% survival rate.
While the overall findings between the parental and attenuated T953 strains has
been established in this study (T953 P135 causes fewer fatalities than P0), the
differences between the two viruses in the earlier stages of infection still needs to be
investigated. The EHV-1 positive specimens (both in virus isolation and rPCR) from
the T953 P0 mice were collected from animals which died during the first five days
following inoculation. The six EHV-1 positive lung specimens from the T953 P135
mice were all obtained fourteen days after inoculation. To ascertain the exact
differences in early pathogenesis between the two viruses, alternations to the
experimental design of a future study would need to be made. Specifically, two mice
should be euthanized every two days for the first eight days following the inoculation
of the challenge groups for both viruses. The collected tissues should be analyzed with
VI, histopathology, and rPCR. Serologic testing should also be employed to gauge the
intensity of the immune response to each virus. Analysis of the resulting data should
indicate the following for both T953 P0 and P135: establishment of EHV-1 infection in
the lungs, the nature of early EHV-1 respiratory disease, the establishment and duration
of viremia.
The findings of this study indicate T953 P135 is a likely candidate for a vaccine
strain of EHV-1. However, further investigation of this virus is required to fully
evaluate its effectiveness as a vaccine in the horse. Colle et al. 1996 examined the
possibility of cell-passaged EHV-1 Kentucky A (KyA) strain as a vaccine candidate by
inoculating BALB/c mice.271 Subsequent studies (Matsumura et al. 1996 & 1998, Smith
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et al. 1998 & 2000, Zhang et al. 2003) focusing on Ky A’s capabilities as a vaccine
involved either the inoculation of mice or horses.49,269,270,272,273 The experimental design
of all six Ky A vaccine studies employed the following: inoculation of a live host with
the candidate strain, subsequent challenge with a non-neuropathogenic EHV-1 strain
(RacL11, Kentucky D, or 89c25) and then analysis of the host immune response (post-
inoculation and post-challenge).49,269,270,272,273 The data derived from these studies
proved Ky A can provoke CTL responses in the horse, induce immunity against non-
neuropathogenic strains, which may last as long as twelve months post-
immunization.49,269,270,272,273
Validation of T953 P135 as a vaccine candidate requires undertaking similar
studies. The immune response of mice to T953 P135 should be evaluated with serologic
assays, such as virus neutralization and ELISPOT. Inoculation of horses with T953
P135 is crucial since it is uncertain if this virus can cause EHM or not in the equine
host. Challenge of both T953 P135 inoculated mice and horses with a neuropathogenic
EHV-1 strain, such as Ab4, should also be undertaken. Evaluation of the immune
response prior to and after infection with neuropathogenic EHV-1 is necessary to gauge
the type and duration of the immunity afforded to the host by T953 P135. Ideally, the
immunity should last more than six months (results similar to those observed with the
Ky A vaccine) and infection with a field strain of EHV-1 should elicit no or only mild
clinical signs (nasal discharge, low pyrexia).
Development of T953 P135 as a vaccine candidate could pursue different
routes. This attenuated strain could be incorporated into an inactivated vaccine with a
suitable adjuvant, as with the KyA strain.274 Another option would be to utilize the
P135 strain as the basis of a MLV vaccine. Besides these, a third possibility might be to
use T953 P135 as the basis for a recombinant vaccine. Mutations have been established
in two of the ORFs of this virus through cell culture passage. Additional nucleotide
substitutions could be engineered into the virus’s genome to enhance the host’s immune
response, without increasing the pathogenicity of P135. Regardless of which route is
taken, further research is required to determine the viability of T953 P135 as a vaccine
candidate for horses.
Copyright© Kathryn Laura Smith 2013
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CHAPTER SIX
Summary and Conclusions
The first of objective of this research was to design an allelic discrimination
real-time (rPCR) assay, which could distinguish between the two known genotypes of
EHV-1 with greater sensitivity and specificity than the original allelic discrimination
rPCR assay developed by the late Dr. George Allen in 2007.106 The resulting assay,
designated as E1, had a 10-fold higher sensitivity compared to the original assay.
Furthermore, it produced fewer false dual positives, regardless of the DNA extraction
procedure employed and, as such, was considered more reliable for routine screening of
EHV-1 in clinical specimens.
The second objective of this dissertation research was the in vivo
characterization of a cell culture adapted strain of T953 to determine if this virus’s
phenotype was attenuated and could possibly serve as a vaccine candidate to against
EHM. To determine this, four mouse strains were experimentally inoculated with
unaltered T953 to assess their respective susceptibilities to the virus. The BALB/c strain
was the most susceptible to infection and was used in a comparative inoculation study
using two T953 strains: T953 P0 and T953 P135. The resulting data demonstrated T953
P135 produced only mild respiratory disease in mice and therefore, had a less virulent
phenotype than T953 P0.
In the course of investigating objective one, certain findings had unexpected
implications. Two isolates from the 1970s produced negative results when tested with the
Allen assay, but were positive with the E1 assay. Sequencing analysis determined these
isolates were in fact EHV-1, along with revealing an additional point mutation (C2258)
within the probe binding region. These isolates were eventually identified as the EHV-1
RAC-H strain. This viral strain possess the G2254 genotype, but is only associated with
EHV-1 abortion. It is possible the C2258 substitution masks the presence of G2254, altering
the resulting phenotype.
The C2258 substitution implies additional genetic factors may influence the
occurrence of EHV-1’s neuropathogenic genotype. Additional nucleotide substitutions
within ORF30 could enhance or inhibit EHV-1’s neuropathogencity. Besides, ORF30,
B
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other genes are involved with EHV-1 replication, such as ORF18 and 57. The effect of
polymorphisms within these ORFs on EHV-1’s neuropathogenic phenotype also merits
investigation. A possible method for elucidating the impact of such substitutions would
be the use of BAC clones. Point mutations could be introduced into the replicative
machinery of a sequenced neuropathogenic strain, such as Ab4, through the use of BAC
clones. Inoculation of cell cultures and animal hosts with the recombinant viruses would
determine the effect the mutations have on the viruses’ replication rates and ability to
induce neurological signs.
Besides the possible influence of additional polymorphisms on EHV-1’s
phenotype, another area which warrants further study is the occurrence of the A2254+G2254
genotype. The detection of this genotype has been reported previously by Pusterla et al.
2011, but the characterization of the A2254+G2254 genotype is incomplete.
16 The exact
clinical signs which accompany the dual genotype are not known. At the very least, upper
respiratory tract disease would occur, but the progression of infection beyond this is
difficult to predict. The two genotypes could compete for dominance within the host,
with either neurological disease or rhinopneumonitis as the outcome. Another scenario is
co-dominance could occur between these two genotypes, resulting in lower respiratory
tract disease. Additionally, it is unknown if the host is actively infected with both
genotypes, or if reactivation has occurred. The animal may have been latently infected
with one genotype and recent infection with the second could have reactivated the latent
genotype. Dual latent infection has been reported, but whether reactivation causes the
expression of one or both genotypes is uncertain.116
To characterize A2254+G2254’s exact phenotype, an inoculation study should be
performed. Dual positive specimens, possibly nasal swabs, should be used to infect
horses and then the animals monitored for clinical signs. Clinical samples (blood and
nasal swabs) should be collected during the course of the observation period and
analyzed with rPCR. The E1 assay could be modified for the absolute quantification of
EHV-1 DNA by preparing serial dilutions of two ORF30 plasmids, an A2254 plasmid and
G2254 plasmid. The resulting data would establish if both genotypes are being equally
expressed throughout the course of infection, or if one of the two has become dominant
over the other. Horses of different ages and immune histories (naïve versus previously
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exposed to EHV-1) should be included in the study to ascertain the impact of host factors,
such as age and previous exposure, on the phenotype of A2254+G2254. Infection of cell
cultures with dual positive samples should be undertaken as well to examine if both
genotypes are expressed in culture, or only one. RK-13 or equine endothelial cell cultures
could be inoculated with a dual positive specimen, incubated, and the resulting
supernatant from the cultures would be analyzed for the genotypes, again, using the E1
assay.
In regard to objective two, the main focus for future studies should be on the
effects of T953 P135 on the horse. Based on the results reported in Chapter 5, P135 only
causes mild respiratory disease in BALB/c mice, but it is uncertain if the same clinical
signs will occur in horses. An inoculation study should be performed, this time using
horses as the experimental host. Monitoring of the infected animals will determine the
nature and intensity of the clinical signs associated with P135. Also, the level of viremia
in the horse should be determined, along with nasal shedding. Whole blood should be
collected and analyzed throughout the observation period to determine when viremia is
established and its duration. Virus isolation and rPCR can be used to obtain this data.
Also, nasopharyngeal swabs should also be obtained from the infected animals. Analysis
with virus isolation and rPCR of the swabs would gauge the level of nasal shedding
occurring in these animals. The impact of age and immune exposure on the host’s
reaction to P135 should also be examined by including horses of various ages and prior
exposures. The immune response to P135 should be measured using the serum
neutralization assay to specify the horse’s immune response to the virus. Additionally, the
frequency of cytotoxic-T lymphocytes should be elucidated through split-well limiting
dilution analysis, as described by O’Neill et al. 1999.267
The sequencing data of T953 P135 so far indicates the mutations primarily
occurred within ORF16 and ORF72. It is uncertain if the decrease in plaque size and
attenuated phenotype in mice resulted from the polymorphisms in both or just one of
these ORFs. To examine the genetic basis for T953 P135’s altered phenotype, a series of
BAC clone studies could be performed. Clones of T953 P135’s ORF 16 and 72 would be
generated. The ORF16 clone would be inserted into T953 P0 to generate a recombinant
virus and then used to inoculate BALB/c mice. The ORF72 clone would undergo the
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same procedure. A third recombinant virus would also be generated, containing clones of
both ORFs and used to inoculate a third group of mice. The animals would be monitored
for clinical signs, their tissues collected and analyzed. The subsequent data would be
compared to the T953 P135 results and determine if the mutations in one or both ORFs
cause the attenuated phenotype.
The T953 P135 strain was generated through serial passages in equine
endothelial cells.  Baumann et al. 1984 and 1987 demonstrated serial passage of
undiluted EHV-1 can produce defective particles, whose genomes have unique
characteristics.275,276 Specifically, these genomes are mainly composed of the repeat
sequences of the US region and the terminal repeat sequence of the UL region.
275 Based
on the preliminary sequence data analysis, there was no evidence of major sequence
differences between P0 and P135. These results are consistent with the findings reported
by Locker and Frenkel 1979, which demonstrated the US’s repeat sequences are stable
between passages 6 and 15.277 The cell passage data of T953 P15 and P135 is also
consistent with the findings of Allen et al. 1983, which confirmed a lack of changes in the
genome of EHV-1 after 100 sequential passages in equine cell cultures.278
These studies suggest the appearance of the “defective” EHV-1 genome occurs
approximately at passage 200. It is also possible passages 100-200 serve as a transition
stage between EHV-1’s standard genome (characterized by a limited number of repeat
sequences) and the “defective” genome (dominated by repeat sequences). It would be
interesting to sequence the full-length genome of passage 210 of T953 to determine
whether any defective particles appear following extensive cell culture passage.
Furthermore, a probable method for deducing when these changes in EHV-1’s genome
occur would be the sequential cell passage of T953 in equine cells, up to passage 400.
Sequence analysis would be performed on the virus at the conclusion of each passage to
reveal when the defective genome manifests.
Baumann et al. 1987 also determined EHV-1’s transcriptional regulator genes
remain intact and are the main genes present in the defective genome, i.e. US’s repeat
sequences are transcriptional regulators.276 This particular study did not any changes in
the virus’s replication genes. Examining changes in EHV-1’s genome up to and beyond
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passage 400 could reveal if and when any of the genes associated with EHV-1’s
replication are deleted from the virus’s genome.
In summary, this dissertation described the design and validation of a new rPCR
assay, which can be a valuable diagnostic asset during EHV-1 outbreaks. Also, the
BALB/c mouse strain proved to be a suitable alternative host for T953 and the
inoculation of this murine strain with T953 P135 revealed this virus’s phenotype is
attenuated in comparison to the parental strain. However, there are still many aspects to
EHV-1 which are not completely understood. More research is still needed to elucidate
the unique genetic characteristics of this virus and to utilize them in reducing the disease
threat EHV-1 poses to the horse population.
Copyright© Kathryn Laura Smith 2013
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